cancer incidence report 2004 - nhic.gov.sa report 2004.pdf · ** source: census 2004, central...

$: Cancer Incidence Report 2004 - nhic.gov.sa Report 2004.pdf · ** Source: Census 2004, Central Department for Statistics (CDS) data, Ministry of Planning,(web site http:\\). Figure$
Kingdom of Saudi ArabiaMinistry of Health

Saudi Cancer Registry

Cancer Incidence ReportSaudi Arabia

2004

Part001.indd 1 30-04-2008 5:00:05 PM

Report prepared by: Haya S. Al-Eid, BDS, DFE, CTR

Suad Omer Arteh, MA

Reviewed by: Shouki Bazarbashi, MD Ali Al-Zahrani, MD, PhD

Part001.indd 2 30-04-2008 5:00:05 PM

3

AcknowledgmentForewordThis annual report presents the cancer incidence data for the start of the second decade of the Saudi Cancer Registry operation. Analysis of the last 10 years trends in cancer incidence will be presented in a separate report in the near future.

The Saudi Cancer Registry (SCR) is in continuous evolution. Starting with the name, we have personalized our name to be more descriptive of our identity (from National to Saudi Cancer Registry). We are fortunate in being now overseen by the Higher counsel for health services which will hopefully help in overcoming many of the obstacle that we face in our operation. We are in the process of changing software from the International Agency Against Cancer (IARC) supported CanReg program to a custom-made web-based program that will hopefully connect all our regional offices instantaneously and willfacilitate data cleaning and filtering of duplication.We are also working toward registering mortality data so that both cancer incidence and mortality can be presented, and projection of incidence and prevalence based on current data.

In an effort to disseminate the data the Saudi Cancer Registry makes every effort to participate in any major cancer conference or symposium. More and more people are becoming aware of the valuable data collected by the registry. Over the past 12 months we have responded to data request. The SCR is committed to provide all requesters with the required available data and believe that our data is much underutilized. Epidemiological studies using our data need to be encouraged and is one way this data should be used for.

In addition we are looking forward to a starting fruitful collaboration with several nongovernmental agencies in the country to include but not restricted to the Saudi Cancer Society and the Saudi Oncology Society as well as others.

Shouki Bazarbashi, MDChairmanRiyadh, April 2008

The Saudi Cancer Registry is funded by The Ministry of Health. The work of the Saudi Cancer Registry including the production of this report is the result of teamwork by our valuable cancer registrars, main office staff and members of theboard of directors.

Special thanks to the support provided by the Ministry of Health represented by his Excellency the Minister of Health Dr. Hamad Al Manea and the deputy Minister of Health Dr. Mansour Al Hawasi. In addition we continue to be in debt for the support of King Faisal Specialist Hospital and Research Center leadership represented by Dr. Qasem Al Qasabi and Dr. Adnan Ezzat.

We also would like to record our thanks to the support from The Saudi Cancer Society represented by Dr. Abdullah Al Amro in their effort to support the registry in many aspects.

Many thanks to several pharmaceutical companies who have supported us with unrestricted grants. In particular we would like to thank Roche Oncology, Merck AG and Sanofi-Aventis for their support

Part001.indd 3 30-04-2008 5:00:05 PM

4

Part001.indd 4 30-04-2008 5:00:05 PM

5

IntroductionPart IV Cancer Incidence among Non-Saudis

This part presents the incidence of cancer cases among Non-Saudis including the most common types of cancer. The analysis of the Non-Saudis is performed separately due to the nature of the expatriate population in Saudi Arabia in which a large part of the population, particularly among males, falls in the 25- 44 age group.

Part V Incidence Tables

Part V contains the following detailed tables for all newly diagnosed cancer types among Saudis and Non-Saudis for 2004:

• Distribution of cancer cases among Saudis by age group and sex

• Distribution of cancer cases among Non-Saudis by age group and sex

• Cancer Incidence (per 100,000 population) among Saudis by age group and sex

• Cancer Incidence (per 100,000 population) among Non-Saudis by age group and sex

• Age-standardized incidence rate and relative frequencies among Saudis by cancer site, sex and administrative regions

Part VI Appendices

Appendix A: Regional listing of all health care facilities from which cancer cases have been reported. The objective is to receive feedback from facilities that have not been included in order to improve our case-finding and reportingprocesses.

Appendix B: Names of the members of the Board of Directors.

Appendix C: Data request form which may be copied, filled and submitted to the SCR MainOffice.

Appendix D: Copy of the cancer registration abstract form which is completed by cancer registrars for each cancer case.

This is the eighth incidence report published by the Saudi Cancer Registry of Saudi Arabia. Previous publications include the 1994 Summary Report, 1994-1996 Incidence Report, 1997-1998 Incidence Report, 1999-2000 Incidence Report, 2001 Incidence Report, 2002 and 2003 Incidence Report.

The structure of this report can be outlined as follows:

Part I Materials and Methods

This part of the report contains information about the background of the Saudi Cancer Registry and methods used in collecting and analyzing the data. We present the basics of coding and classificationof tumor topography, morphology and extent of disease at the time of diagnosis. Also we describe the software programs we have used to analyze the data.

Part II Overview of Cancer Incidence

Part II contains figures and tables that show overallcancer incidence in Saudi Arabia for the year 2004. We present these figures and tables mainly by sexand in certain areas we have it analyzed by different age groups. There are bar charts representing the age distribution of cancer incidence for the year 2004 among Saudis by sex and age groups. We present incidence and morphology tables for the most common types of cancers among adults and children. In addition, tables list the total number of cases, the Age-Standardized Incidence Rate (ASR) per 100,000 population, Crude Incidence Rate (CIR) and Cumulative rates by primary site and sex. Separate bar charts depict the most common types of cancer, by sex, in each of the 13 administrative regions of Saudi Arabia.

Part III Incidence of Selected-Sites

In this part the incidence of the most common cancers among Saudi males and females are outlined. A standardized layout presents data for all patients and for both sexes where applicable. For each selected site the number and the percentage of all newly diagnosed cases for the year 2004, the ASR for each sex, and the specific cancer rank for bothsexes. In addition, ASR for the specified canceramong Saudis is compared with ASR among other populations from selected countries.

Part001.indd 5 30-04-2008 5:00:05 PM

Table of Contents

Acknowledgment ......................................................................................................................................................... 3Foreword ....................................................................................................................................................................... 3Introduction .................................................................................................................................................................. 5

PART I ................................................................................................................................................... 9

Background on Saudi Arabia .................................................................................................................................... 10Saudi Cancer Registry ............................................................................................................................................... 10Definitions of Statistical Terms ................................................................................................................................ 13

PART II ................................................................................................................... 15

Cancer in Saudi Arabia 2004 ................................................................................................................................... 16Adult Cancers in Saudi Arabia, 2004 (above 14 years) ...................................................................................... 22Childhood Cancers in Saudi Arabia 2004 (14 years and below) ..................................................................... 24Cancer in the 13 Administrative Regions of the Kingdom ............................................................................... 26International Comparison of Age-Standardized Incidence Rates .................................................................. 31

PART III .................................................................................................................. 33

Cancer Incidence for Specific Sites, 2004 ............................................................................................................. 35Female Breast (C 50) ................................................................................................................................................ 36Colo-rectal (C18-C20) ............................................................................................................................................. 38Non-Hodgkin Lymphoma (C82-C85; C96) .......................................................................................................... 40Leukemia (C91-C95) ................................................................................................................................................. 42Thyroid (C 73) ............................................................................................................................................................ 44Liver (C 22) ................................................................................................................................................................. 46Lung (C33-C34) ......................................................................................................................................................... 48Hodgkins disease (C 81) .......................................................................................................................................... 50Skin (Non-Melanoma) (C 44) ................................................................................................................................. 52Brain, Nervous System ( ........................................................................................................................................... 54Prostate (C 61) ........................................................................................................................................................... 56Stomach (C 16) .......................................................................................................................................................... 58Bladder (C 67) ............................................................................................................................................................ 60Corpus Uteri (C 55) ................................................................................................................................................. 62Ovary Cancer (C 56) ................................................................................................................................................ 64

PART IV .................................................................................................................. 67

Cancer Among Non-Saudi Population 2004 ........................................................................................................ 69

Part001.indd 6 30-04-2008 5:00:06 PM

PART V .................................................................................................................... 71

Table 5.1.1 Age Distribution of Cancer Cases among Saudi Males, 2004 ..................................................... 72Table 5.1.2 Age Distribution of Cancer Cases among Saudi Females, 2004 ................................................. 73Table 5.1.3 Cancer Incidence Cases among Saudi Males by Age Group (per 100,000), 2004 .................. 74Table 5.1.4 Cancer Incidence Cases among Saudi Females by Age Group (per 100,000), 2004 ............. 75Table 5.2.1 Age Standardized Rates and Relative Frequencies among Saudi Males by Cancer Site and Administrative Region, 2004 .............................................................................................................. 76-79Table 5.2.2 Age Standardized Rates and Relative Frequencies among Saudi Females by Cancer Site and Administrative Region, 2004 .............................................................................................................. 80-83Table 5.3.1 Age Distribution of Cancer Cases among non-Saudi Males, 2004 ............................................. 84Table 5.3.2 Age Distribution of Cancer Cases among non-Saudi Females, 2004 ........................................ 85Table 5.3.3 Incidence Rates for Cancer Cases among non-Saudi Males by Age Group (per 100,000), 2004 ............................................................................................................................. 86Table 5.3.4 Incidence Rates for Cancer Cases among non-Saudi Females by Age Group (per 100,000), 2004 ............................................................................................................................. 87

PART VI .................................................................................................................. 89

APPENDIX A: Reporting Health Care Facilities .................................................................................. 90-93APPENDIX B: Members of SCR Board of Directors ......................................................................... 94-95APPENDIX C: SCR Data Request Form ...................................................................................................... 96APPENDIX D: Cancer Registration Abstract Form ................................................................................... 97

Part001.indd 7 30-04-2008 5:00:06 PM

8

Part001.indd 8 30-04-2008 5:00:06 PM

PART IMATERIALS AND METHODS

Part001.indd 9 30-04-2008 5:00:06 PM

10

Saudi Arabia is a vast country extending over four-fifths of the Arabian Peninsula. It stretchesfrom the Arabian Gulf in the east to the Red Sea in the west. It is approximately 2,149,700* square kilometers in area and is divided into 13 administrative regions (Figure 1.1).

Figure 1.1 Administrative Regions of Saudi Arabia

Figure 1.2 Population Pyramid of Saudis (%) by Sex and Age Group, 2004

Saudi Cancer Registry

The Saudi Cancer Registry (SCR) of Saudi Arabia is a population-based registry established in 1992 under the jurisdiction of the Ministry of Health (MOH) by the order of His Excellency the Minister of Health. The SCR commenced reporting cancer cases from 01 January 1994.

Objectives:

The primary goal of the SCR is to define thepopulation-based incidence of cancer in Saudi Arabia. Additional objectives include programs for early detection and cancer screening, as well as cancer research projects.

Organizational Structure:

A Board of Directors was appointed to include representatives from the MOH, King Faisal Specialist Hospital and Research Center (KFSH&RC), and the Medical Services Departments of the Ministry of Defense and Aviation, Ministry of Interior, the National Guard, King Saud University, King Faisal University, King Abdul-Aziz University and King Khalid University. The Board is charged with the responsibility of overseeing the SCR’s establishment, defining demographic and cancer-related data to becollected, approving research requests, and reporting findings, as well as disseminating informationcollected while ensuring the confidentiality of alldata reported to the SCR.

* Source: Demographic and Health Indicators for Countries of the East Mediterranean, WHO, Regional Office for the EM, 1999** Source: Census 2004, Central Department for Statistics (CDS) data, Ministry of Planning,(web site http:\\www.planning.gov.sa).

Figure 1.3 Population Pyramid of non-Saudis (%) by Sex and Age Group, 2004

Background on Saudi Arabia

The Saudi national population for year 2004 was 16,527,340**. Of these, 8,287,370 were males and 8,239,970 were females. The Non-Saudi population in 2004 was 6,150,922**; of these 4,269,870 were males and 1,881,052 females.

Figures 1.2 and 1.3 show the Saudi and Non-Saudi population pyramids by sex and age group respectively.

6.46.86.55.7

4.64.43.43.02.51.91.30.90.80.60.50.7

0246810

FemalesMale

1.2

1.72.3

3.03.5

4.24.8

5.77.06.7

6.4

0.90.8

0.60.50.6

0 2 4 6 8 10

0-4 5-9

10-1415-1920-2425-2930-3435-3940-4445-4950-5455-5960-6465-6970-7475+ 93,419

84,898101,213134,390153,194199,415277,511372,981498,170575,126701,326786,510938,9821,155,7281,112,5821,054,525

115,67177,277103,245126,594146,079222,166313,340411,890492,543569,152725,413760,146948,7071,081,8841,127,2531,066,010

8,287,370 8,239,970

11.510.2

4.82.42.93.43.6

11.0

8.35.5

3.11.40.60.30.20.1 0.2

0.20.20.40.61.21.9

3.25.1

7.26.4

4.33.84.55.35.7

024681012

7,2316,3817,84614,97321,64443,51672,775121,907190,103271,093240,156159,920142,200167,659197,901215,747

FemalesMale

0 2 4 6 8 10 12

0-4 5-9

10-1415-1920-2425-2930-3435-3940-4445-4950-5455-5960-6465-6970-7475+8,981

9,83716,67839,55584,880193,133338,148511,983674,734709,730626,706298,251150,298176,568207,007223,381

4,269,870 1,881,052

Part001.indd 10 30-04-2008 5:00:16 PM

11

Figure 1.4 Organizational Chart of the Saudi Cancer Registry of Saudi Arabia

Ministry of HealthSaudi Arabia

Saudi Cancer RegistryMain Office

Central Region (Riyadh, Qassim & Hail)

King Faisal Specialist Hospital& Research Centre (Riyadh)

National Guard Hospitals

Armed Forces Hospitals

Security Forces Hospitals

Madinah Region (Madinah, Tabuk, Jouf & Northern Region)

Southern Region (Asir, Baha, Jazan & Najran)

Western Region (Jeddah, Makkah, Taif & Qunfudah)

Eastern Region (Dammam, Ahsa & Hafr Al Batin)

Format

The format of the current report is similar to the previous reports.

The SCR Main Office, including administrative and technical staff, is located in the premises of the KFSH&RC in Riyadh. Additionally, five regionalbranches and four hospital-based offices were setup to ensure comprehensive data collection from all over the Kingdom (Figure 1.4).

Regional Offices:

1 Central Region: King Khalid University Hospital in Riyadh, covering Riyadh, Qassim, and Hail Health Regions.

2 Eastern Region: King Fahad Hospital of the University, Al Khobar, covering Dammam, Al Ahsa, and Hafr Al-Batin Health Regions.

3 Western Region: King Abdulaziz Hospital and Cancer Center, Jeddah, covering Jeddah, Makkah, Taif and Qunfudah Health Regions.

4 Southern Region: King Khalid University, Abha, covering Asir, Baha, Najran, Jazan and Bisha Health Regions.

5 Madinah/Northern Region: King Fahad Hospital, Madinah, covering Madinah, Tabuk, Jouf and Northern Health Regions.

Offices at the Medical Service Division or OncologyDepartment of the following establishment

1 Ministry of Defense and Aviation, Armed Forces Hospital, Riyadh

2 King Abdulaziz Medical City.3 Ministry of Interior, Security Forces Hospital,

Riyadh.4 King Faisal Specialist Hospital and Research

Centre, Riyadh.5 King Abdul Aziz University Hospital, Jeddah

Each of the SCR offices operates under thesupervision of a member of the Board of Directors who is responsible for the daily management of that office. Staffing consists of tumor registrars andsecretarial staff.

The SCR Main Office indirectly supervises the regionaloffices and is responsible for ensuring the accuracyand quality of data collected in all of the regions. Quality control processes include verification ofsite, morphology, and staging information as well as case linkage (tumor and patient), and consolidation of data. The Main Office also prepares periodicreports for dissemination of information to the medical community, government establishments, international organizations and the media.

Part001.indd 11 30-04-2008 5:00:19 PM

12

A ministerial decree has categorized cancer as a mandatory notifiable disease. This ensures theopportunity for comprehensive data collection. The SCR strives for full access to cancer data from all Ministry of Health, governmental and private hospitals, as well as clinics and laboratories throughout the Kingdom. Cancer data are abstracted from patients’ medical records, based on clinical and/or histopathological diagnosis, by SCR-trained cancer registrars.

The data abstract (see appendix D) includes personal identification (name, ID Number, sex,age), demographic information (address, telephone number, nationality), and tumor details (diagnosis date, primary site, histology, behavior, grade, stage, basis of diagnosis). The primary site (topography) and histology (morphology) of the malignancies are identified and coded according to the International Classification of Diseases for Oncology 3rd Edition (ICD-O-3), published by the World Health Organization (WHO), 2000.

Effective from year 2001, changes were made in coding of cancer types and behaviors as well as staging according to International guidelines. The new SEER Summary Stage 2000 guidelines should result in increased accuracy and consistency in the coding of stage. There are some differences in the staging according to different time period and some sites are coded differently using the new staging guidelines. However, the new criteria and guidelines should improve the usefulness of staging as a predictor of prognosis and survival as the changes reflect a new understanding ofthe natural history of cancer. The new guidelines, SEER Summary Stage Manual 2000, is available on the web at: http:/seer.cancer.gov/tools/ssm/. Cases diagnosed on or after 01 January 2004 are classifiedaccording to the updated ICD-O-3. Improvements in the understanding of cancer pathology over the last decade are reflected in the changes to ICD-O-3. While there have not been any changes in the primary site codes, there are significant changesregarding histology (cell types). Leukemias and lymphomas, particularly are affected. Some cases that were previously considered benign are now

The computer software programs used for data entry and incidence tables output are CanReg 4.31, developed by the International Agency for Research on Cancer, (IARC) Lyon, France.

The second part of the report includes the overall cancer incidence in Saudi Arabia and the relevant epidemiological and clinicopathological details for the 14 most common cancers among Saudi nationals for the year 2004. For each cancer site, the number and the percentage of all newly diagnosed cases for the year 2004, the age-standardized incidence rate (ASR) per 100,000 population for each sex, and the specific cancer rank in comparison to all cancersfor both sexes are presented. Useful international statistics for the specified cancer include theranking of the cancer worldwide. The source for this information is summarized on page 66.

counted as malignant. Also small number of cancers that were previously coded as borderline tumors are now considered benign. Counts of ovarian cancers, lymphomas and leukemias as well as some hematopoietic diseases will change due to changes in either reportability or definition. However,as with the new staging guidelines, the ICD-O changes reflect advances in the understanding ofthe pathology and behavior of cancers.

It should be noted that ICD-O-3 codes are converted to ICD-10 for analysis purposes. Since the WHO has not yet converted the ICD-10 hematopoietic disease behavior changes, our software, CanReg 4.31, cannot include these cases for analysis and they have been excluded. Every effort is made to accurately code patient and tumor information, to ensure that all data can be reviewed, linked, and consolidated, as appropriate. This way each malignancy is counted only once for statistical analysis.

Data management

Part001.indd 12 30-04-2008 5:00:19 PM

13

* Doll R. Payne P. Waterhouse J. Cancer incidence in Five Continents Vol. I. International Union Against Cancer. 1966

1. An arithmetic line graph represents the age-specific incidence rate (AIR) for all agegroups at five-year intervals. The graph isplotted by sex, where applicable.

2. A table lists the percentages of the most common histology sub-types for each specific cancer.

3. A pie chart shows the distribution of the clinical stages of each cancer such as localized, regional, distant metastasis and unknown.

4. A bar chart shows regional distribution of ASR for particular cancer across the admin-istrative regions by males and females.

5. A bar chart shows comparison of age-standardized incidence rate (ASR) for each cancer type in Saudi Arabia with ASR in selected countries.

In reviewing the data, its collection and analysis, two qualifying statements can be made:

Definitions ofTerms

Age-Specific Incidence Rate (AIR)

The number of cancer cases occurring during a specific period in a population of a specific ageand sex group, divided by the number of midyear population of that age and sex group.

Age-Standardized Rate (ASR)

The Age-standardized rate is a summary measure of a rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age structure. The most frequently used standard population is the World Standard Population (see below). The calculated incidence is known as the World Standardized Incidence Rate. The rate is expressed per 100,000 populations.

Notification

The data included in this report were abstracted up to June 2005. 2004 incident cases which are identified after this date (late reporting) will benoted in subsequent incidence reports. It is anticipated that the number of late-reported cases will decrease as case ascertainment processes are improved.

The relevant data incorporate details for all patients presented over the year 2004. For each cancer there are five figures:

a. The number of patients presenting with malignant disease from Riyadh region exceeds the anticipated number per population. The reason for this is that Riyadh has many referral centers providing patients from outside the region with cancer-related care. Many of these patients fail to provide their permanent address, but instead, provide a temporary Riyadh address. This situation is partially resolved through tumor and patient linkage of cases from all regions based on identifiers suchas national ID.

b. As previously noted, the software used in analyzing this report, CanReg 4.31, does not include in situ cases in the incidence tables. These cases were added to the total cancer cases in the overview.

Age Class Population

0-4 12,0005-9 10,00010-14 9,00015-19 9,00020-24 8,00025-29 8,00030-34 6,00035-39 6,00040-44 6,00045-49 6,00050-54 5,00055-59 4,00060-64 4,00065-69 3,00070-74 2,00075+ 2,000

Total 100,000

Part001.indd 13 30-04-2008 5:00:20 PM

14

An incidence rate is defined as the rate at which anew event occurs in a population. It is calculated as the number of new cases of disease arising in a population over a defined time period, divided bythe population at risk of developing that disease.

Mean

The simple mathematical average of two or more numbers.

Median

The midpoint of the range numbers that are arranged in order of value.

Metastasis

Metastasis is the distant spread of cancer from its original site to other organs of the body, including lymph nodes, skeletal and or visceral organs.

Range

Is the difference between the maximum and minimum values in a set of observations.

Rank

This measure reflects the importance of a specificcancer site relative to other sites, in terms of the number of registrations. Ranking illustrates the most and least frequent cancer sites in a population according to their frequency.

Ratio

The relation between two quantities. The first quantity as numerator and the second asdenominator

Relative Frequency

This statistic is defined as the number of specificcancer cases registered relative to the total number of all cancer. It is expressed as a percentage.

Summary Stage

Staging is the grouping of cancer cases into broad categories based on the extent of disease.

The crude incidence rate for a cancer site is the total number of cases registered as a proportion of the total population. It denotes the approximate number of cases occurring in each 100,000 individuals. All rates are thus, expressed as per 100,000 population.

Cancer rates vary greatly with age and the crude rate is strongly influenced by the demo-graphic structure of the population. Hence, if the population structure changes over time the crude rate over that period may be artificially altered. Itis not appropriate to compare crude rates across geographical areas of cancer registries with different population age structures. Therefore, in order to assess time trends in registration data or compare incidence across geographical areas or between registries it is necessary to first standarize the rateswith respect to age.

Cumulative Incidence rate

Cumulative incidence is the probability or risk of individuals developing the disease during a specifiedperiod. For cancer, it is expressed as the number of new born children (out of 100, or 1000) who would be expected to develop a particular cancer before the age of 65 (or 70, or 75) if they had the rates of cancers currently observed. Like the age standardized rate, it permits comparison between populations of different age structures. In this report the age ranges 0-64 and 0-74 years are used. The cumulative rate is the summation of the cancer age-specific rates; which are computed for five-yearage intervals. The cumulative rate is five times thesum of the age-specific rates calculated over thefive-year age groups.

ICD-10

The World Health Organization’s International Classification of Diseases, tenth edition.

ICD-O-3

The World Health Organization’s International Classification of Diseases for Oncology, 3rd Editionhas been the standard coding system for neoplasms for over 25 years. The coding system includes a four character code for primary site, a four-digit numeric code for cell type, one-digit code for behavior and a one-digit code for tumor aggressiveness (grade).

Crude Incidence Rate Incidence Rate

Part001.indd 14 30-04-2008 5:00:20 PM

PART IIOVERVIEW OF CANCER INCIDENCE

2004

Part002.indd 15 15-04-2008 10:45:35 AM

16

* ICD-10 conversion failure** Unknown nationalities, in situ cases and ICD-10 conversion failures are excluded from analysis

As shown in table 2.1, 8,913 cases were analyzed, of which 6,969 (78%) were Saudis and 1,944 (22.%) were Non-Saudis. Among the Saudis, 3,478 (49.9%) were male and 3,491 (50.1 %) were female. The male to female ratio was 99.6:100. The crude incidence rate (CIR) of all cancers among the Saudi population was 41.9/100,000 (41.6/100,000 among males and 42.1/100,000 among females). The overall age-standardized incidence rate (ASR) for all Saudis with a world standard population reference was 69.7/100,000 (70.2/100,000 in males and 69.3/100,000 in females). For all sites, the age-specific incidence rate (AIR) increased with age for both males and females. After the age of 64 years, the increase was nearly two folds for males compared to females. The median age at diagnosis was 59 years for men (Range 0-110) and 49 years for women (Range 0-100). The five geographicregions with the highest ASR were Riyadh region at 91.9/100,000, Eastern region at 89.9/100,000, Tabuk region at 74.8/100,000, Makkah region at 74.6/100,000, and Jouf region at 64.9/100,000.

Between January 01 and December 31, 2004, the total number of cancer incident cases reported to the SCR was 9381. Overall, cancer was slightly more in men than in women. Cancers affected 4,778 (50.9%) males and 4,603 (49.1%) females, with a male to female ratio of 104:100. 7,138 cases were reported among Saudis, 1,987 among Non-Saudis. The total number of cases excluded from analysis included 256 cases of unknown nationalities. Other exclusions were 191 in situ cases. The current software program CanReg-4 version 4.31, does not include in situ cases in the statistical analysis. Also, 27 were ICD-O-3 coded cases that failed to convert to ICD-10 codes as described in the Data Management (see page 12). This puts the total number of exclusions from the analysis as 468 cases. Table 2.1 illustrates the distribution of the cases by sex.

Diagnosis of malignancy was confirmed histologicallyand/or cytologically in 97.3% of the cases. Clinically confirmed cases were 0.2%; radiologically confirmedcases were 1.9%; and cases confirmed by DeathCertificate were 0.1%. The method of diagnosiswas unknown for 0.6% of the cases.

Reported Cancer Incidence Cases in Saudi Arabia, 2004

Table 2.1 Distribution of Cancer Cases in Saudi Arabia by Nationality and Sex 2004

Saudis Non-Saudis Unknown Nationality All

Male Female Total Male Female Total Male Female Total Total

Total 3551 3587 7138 1092 895 1987 135 121 256 9381

Invasive 3488 3507 6995 1066 878 1944 131 119 250 9189

In Situ 63 80 143 26 17 43 3 2 5 191

ICD 10 * 10 16 26 0 0 0 1 0 1 27

Analyzed ** 3478 3491 6969 1066 878 1944 131 119 250 8913

Part002.indd 16 15-04-2008 10:45:36 AM

17

Cancer among Saudis 2004

Figure 2.1 Percentage Distribution of Cancer Incidence among Saudis by Sex according to Age Group, 2004

The total number of cancer cases analyzed among Saudis during the year 2004 were 6,969. Of those cases 49.9 % (3,478) were reported among men and 50.1% (3,491) among women.

Figure 2.2 Percentage Distribution of Most Frequent Types of Cancer by Sex among Saudis, 2004

* 5 cases (2 male and 3 female) of unknown age are included only in the total as they may not be added to any age group.

4.6 4.7

6.2

9.9

16.1

8.3

3.8

5.2

11.5

13.112.3

4.2

0

2

4

6

8

10

12

14

16

18

0-14 15-29 30-44 45-59 60-74 75+

Perc

enta

ge

Age Group

Male

Female

5.34.83.5

3.33.3

3.12.42.32.12.0

17.9 16.31.41.41.51.71.82.83.2

4.04.7

11.2

01020304050

Female (3491)*Male (3478)*10 20 30 40 50

All agesBreast

ThyroidColo-rectal

Non-Hodgkin lymphomaLeukemia

SkinCorpus Uteri

OvaryBrain, Nervous system

Hodgkin diseaseOther sites

Colo-rectalNon-Hodgkin lymphomaLeukemia

LungLiver

ProstateHodgkin disease

BladderBrain, Nervous system

StomachOther sites

4.50.91.01.42.13.6

7.48.69.1

16.1

01020304050

Female (266)Male (318)

4.82.12.22.63.33.33.43.86.3

13.9

10 20 30 40 50

0-14 yearsLeukemia

Brain, Nervous systemKidney

Non-Hodgkin lymphomaConnective,Soft tissue

Hodgkin diseaseBone

Adrenal glandEye

Other sites

LeukemiaBrain, Nervous systemHodgkin diseaseNon-Hodgkin lymphomaBoneKidneyConnective,Soft tissueEyeLiverOther sites

8.68.27.7

5.12.62.6

2.31.91.61.3

5.8 8.21.31.61.71.9

2.94.24.85.57.4

12.7

01020304050

Female (359)Male (328)10 20 30 40 50

15-29 years

ThyroidHodgkin disease

BreastLeukemia

Non-Hodgkin lymphomaBrain, Nervous system

BoneConnective,Soft tissue

OvarySkin

Other sites

Hodgkin diseaseNon-Hodgkin lymphomaLeukemiaBoneConnective,Soft tissueTestis

ThyroidBrain, Nervous systemNasopharynxColo-rectal

Other sites

5.1

4.5

2.4

2.3

2.2

2.0

1.9

1.5

1.5

1.5

10.3 11.9

1.2

1.3

1.3

1.8

2.5

2.5

2.8

4.5

10.3

24.7

01020304050

Female (801)Male (434)10 20 30 40 50

30-44 years

Breast

Thyroid

Colo-rectal

Non-Hodgkin lymphoma

Cervix Uteri

Leukemia

Ovary

Skin

Corpus Uteri

Brain, Nervous system

Other sites


Colo-rectal

Thyroid

Hodgkin disease


Leukemia

Nasopharynx

Trachea,Bronchus,Lung

Other Skin

Kidney

Other sites

7.0

4.0

3.1

3.0

2.2

2.2

2.1

1.6

1.6

1.3

15.0 15.5

1.2

1.5

1.7

2.0

2.1

2.2

3.5

3.7

5.4

18.1

01020304050

Female (913)Male (690)10 20 30 40 50

45-59 years

Breast

Colo-rectal

Thyroid


Cervix Uteri

Corpus Uteri

Ovary

Leukemia

Liver

Lung

Other sites

Colo-rectal

Lung


Liver

Nasopharynx

Kidney

Bladder

Prostate

Stomach

Skin

Other sites

7.1

5.65.5

5.0

4.2

3.62.9

2.8

1.8

1.7

16.5 15.9

1.4

1.4

1.4

1.82.2

2.6

2.8

3.04.9

5.8

01020304050

Female (859)Male (1125)10 20 30 40 50

60-74 years

Breast

Colo-rectal


Skin

Corpus Uteri

LiverThyroid

Stomach

Kidney

Ovary

Other sites

Colo-rectal

Liver

Prostate

Lung


BladderStomach

Other Skin

Pancreas

Kidney

Other sites

8.8

6.15.65.24.9

4.8

4.44.23.0

2.12.0

15.6 10.31.11.1

1.31.31.4

1.6

1.72.82.83.9

4.0

01020304050

Female (290)Male (581)10 20 30 40 50

75+ years

Prostate

LiverColo-rectal

Lung

Bladder

Stomach

Skin


Oesophagus

LeukemiaKidney

Other sites

Colo-rectal

BreastSkin


Liver

Corpus Uteri

Stomach

Oesophagus

Thyroid

LungOvary

Other sites

Part002.indd 17 15-04-2008 10:45:46 AM

18

Table 2.2 Ten Most Common Cancers among Saudis, 2004 (All Ages)

Figure 2.3 Ten Most Common Cancers among Saudis by Sex, 2004

Cancer No. %

Breast 798 11.5

Colo-rectal 647 9.3

Non-Hodgkin lymphoma 556 8.0

Leukemia 435 6.2

Thyroid 415 6.0

Liver 324 4.6

Lung 296 4.2

Hodgkin disease 264 3.8

Skin 261 3.7

Brain, Nervous system 247 3.5

366

332

241

233

231

214

166

160

147

141

10.5%

9.5%

6.9%

6.7%

6.6%

6.2%

4.8%

4.6%

4.2%

4.1%

Colo-rectal

NHL

Leukemia

Lung

Liver

Prostate

Hodgkin disease

Bladder


Stomach

Male Female

Breast

Thyroid

Colo-rectal

NHL

Leukemia

Skin

Corpus uteri

Ovary


Hodgkin disease

783

328

281

224

194

125

117

108

100

98

22.4%

9.4%

8.0%

6.4%

5.6%

3.6%

3.4%

3.1%

2.9%

2.8%

3478 3491

Part002.indd 18 15-04-2008 10:45:53 AM

19

Figure 2.5 Age Standardized Rate (ASR) Regional Distribution (per 100,000) of All Sites of Cancer among Saudis, 2004

Figure 2.4 Age-Specific Incidence Rates (AIR) for All Cancers among Saudis, 2004

0

100

200

300

400

500

600

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

AIR

(per

100

,000

)

male female

31.2

47.6

57.1

45.8

50.1

59.9

55.9

54.4

61.0

77.0

85.0

90.5

89.5

32.4

38.3

31.6

52.0

48.5

50.3

59.9

74.5

68.9

72.2

64.6

89.3

94.2

0 20 40 60 80 100

Jazan

Hail

Najran

Baha

Asir

Qassim

Madinah

Northern

Jouf

Makkah

Tabuk

Eastern

Riyadh

Part002.indd 19 15-04-2008 10:45:55 AM

20

ICD-10 Site No. % Crude ASR No. % Crude ASR Cumulative RateRate World 0-64 0-74 Rate World 0-64 0-74

All All sites Total 3478 100 41.6 70.2 40.72 81.08 3491 100 42.1 69.3 48.405 75.21Not C44 All sites but C44 3342 96.1 40.0 67.2 39.46 77.3 3366 96.4 40.6 66.4 47.05 71.70C00 Lip 8 0.2 0.1 0.2 0.09 0.21 6 0.2 0.1 0.2 0.16 0.21C01-C02 Tongue 31 0.9 0.4 0.7 0.50 0.99 30 0.9 0.4 0.7 0.48 0.88C03-C06 Mouth 35 1.0 0.4 0.7 0.33 0.81 22 0.6 0.3 0.5 0.33 0.64C07-C08 Salivary glands 11 0.3 0.1 0.2 0.09 0.27 10 0.3 0.1 0.2 0.13 0.35C09 Tonsil 2 0.1 0 0.1 0.04 0.11 1 0.0 − − 0.03 0.03C10 Other Oropharynx 2 0.1 0 0 0.00 0.00 2 0.1 − 0.1 0.00 0.10C11 Nasopharynx 100 2.9 1.2 2 1.55 2.12 45 1.3 0.5 0.9 0.76 0.98C12-C13 Hypopharynx 6 0.2 0.1 0.1 0.15 0.15 16 0.5 0.2 0.4 0.35 0.40C14 Pharynx unspec. 4 0.1 0 0.1 0.04 0.09 3 0.1 − 0.1 0.02 0.12C15 Oesophagus 50 1.4 0.6 1.1 0.39 1.06 51 1.5 0.6 1.2 0.62 1.45C16 Stomach 141 4.1 1.7 3.2 1.89 3.60 70 2.0 0.8 1.6 0.74 1.87C17 Small intestine 21 0.6 0.3 0.4 0.34 0.49 13 0.4 0.2 0.3 0.16 0.31C18 Colon 190 5.5 2.3 4.2 2.80 5.17 173 5.0 2.1 3.9 2.67 4.60C19-C20 Rectum 176 5.1 2.1 4.1 2.76 5.23 108 3.1 1.3 2.4 1.56 2.76C21 Anus 18 0.5 0.2 0.4 0.36 0.47 4 0.1 − 0.1 0.02 0.07C22 Liver 231 6.6 2.8 5.5 2.67 7.04 93 2.7 1.1 2.2 1.43 2.76C23-C24 Gallbladder etc. 24 0.7 0.3 0.6 0.39 0.57 51 1.5 0.6 1.2 0.76 1.41C25 Pancreas 71 2.0 0.9 1.7 1.00 2.24 28 0.8 0.3 0.7 0.47 0.93C30-C31 Nose, sinuses etc. 10 0.3 0.1 0.2 0.07 0.23 6 0.2 0.1 0.1 0.09 0.09C32 Larynx 49 1.4 0.6 1.2 0.74 1.56 5 0.1 0.1 0.1 0.00 0.10C33-C34 Trachea,Bronchus,Lung 233 6.7 2.8 5.5 3.62 6.78 63 1.8 0.8 1.5 1.08 1.78C37-C38 Other Thoracic organs 12 0.3 0.1 0.2 0.16 0.21 10 0.3 0.1 0.2 0.16 0.32C40-C41 Bone 63 1.8 0.8 0.6 0.38 0.38 38 1.1 0.5 0.5 0.32 0.32C43 Melanoma of Skin 13 0.4 0.2 0.3 0.21 0.34 12 0.3 0.1 0.2 0.14 0.25C44 Other Skin 136 3.9 1.6 3 1.26 3.75 125 3.6 1.5 2.9 1.36 3.51C45 Mesothelioma 6 0.2 0.1 0.1 0.05 0.17 4 0.1 − 0.1 0.11 0.11C46 Kaposi sarcoma 25 0.7 0.3 0.5 0.28 0.73 6 0.2 0.1 0.1 0.09 0.09C47;C49 Connective,Soft tissue 57 1.6 0.7 0.8 0.58 0.78 70 2.0 0.8 1.2 0.79 1.08C50 Breast 15 0.4 0.2 0.3 0.28 0.35 783 22.4 9.5 15.4 13.24 15.73C51 Vulva − − − − − − 11 0.3 0.1 0.2 0.11 0.27C52 Vagina − − − − − − 3 0.1 − 0.1 0.01 0.06C53 Cervix Uteri − − − − − − 89 2.5 1.1 1.8 1.48 2.13C54 Corpus Uteri − − − − − − 117 3.4 1.4 2.8 1.84 3.43C55 Uterus unspec. − − − − − − 9 0.3 0.1 0.2 0.20 0.25C56 Ovary − − − − − − 108 3.1 1.3 2.2 1.57 2.37C57 Other Female Genital − − − − − − 9 0.3 0.1 0.2 0.15 0.21C58 Placenta − − − − − − 5 0.1 0.1 0.1 0.06 0.06C60 Penis 3 0.1 − 0.1 0.07 0.14 − − − − − −C61 Prostate 214 6.2 2.6 5.1 1.89 6.47 − − − − − −C62 Testis 44 1.3 0.5 0.6 0.48 0.48 − − − − − −C63 Other male genital 3 0.1 − 0.1 0.05 0.10 − − − − − −C64 Kidney 122 3.5 1.5 2.5 1.54 2.83 76 2.2 0.9 1.6 1.03 1.94C65 Renal Pelvis 8 0.2 0.1 0.2 0.12 0.24 − − − − 0.00 0.00C66 Ureter 2 0.1 0 0.1 0.02 0.07 2 0.1 − − 0.05 0.05C67 Bladder 160 4.6 1.9 3.7 1.81 4.50 41 1.2 0.5 1 0.70 1.08C68 Other Urinary organs 1 0.0 − − 0.04 0.04 1 − − − 0.00 0.00C69 Eye 19 0.5 0.2 0.3 0.21 0.37 18 0.5 0.2 0.3 0.13 0.23C70-C72 Brain, Nervous system 147 4.2 1.8 2.3 1.42 2.37 100 2.9 1.2 1.5 0.78 1.53C73 Thyroid 87 2.5 1 1.6 1.00 1.82 328 9.4 4 5.3 4.19 4.93C74 Adrenal gland 5 0.1 0.1 0.1 0.03 0.03 16 0.5 0.2 0.2 0.09 0.09C75 Other Endocrine 3 0.1 − − 0.02 0.02 2 0.1 − − 0.02 0.02C81 Hodgkin disease 166 4.8 2 2.1 1.44 1.79 98 2.8 1.2 1.2 0.74 1.01C82-C85;C96 Non-Hodgkin lymphoma 332 9.5 4 5.9 3.57 6.39 224 6.4 2.7 4.5 2.96 4.88C88 Immunoproliferative dis. 1 0.0 − − 0.04 0.04 − − − − 0.00 0.00C90 Multiple Myeloma 37 1.1 0.4 0.9 0.48 1.06 21 0.6 0.3 0.5 0.34 0.68C91 Lymphoid Leukemia 128 3.7 1.5 1.7 0.95 1.48 81 2.3 1.0 1.0 0.53 0.81C92-C94 Myeloid Leukemia 102 2.9 1.2 1.6 0.75 1.45 106 3.0 1.3 1.6 1.26 1.48C95 Leukemia unspec. 11 0.3 0.1 0.1 0.09 0.09 7 0.2 0.1 0.1 0.06 0.06Other Other & unspecified 143 4.1 1.7 3.2 1.79 3.55 171 4.9 2.1 3.9 2.19 4.53

Male FemaleCumulative Rate

Table 2.3 Number, Percentage, ASR, CIR, and Cumulative Rates (per 1000) of New Cases by Primary Site and Sex among Saudis, 2004

Part002.indd 20 15-04-2008 10:45:57 AM

21

Between January and December 2004, the total number of adult cancer incidence cases reported was 8,595. Overall cancer was slightly more in males than in females. Cancer affected 4,341 (50.5%) males and 4,254 (49.5%) females, with a ratio of

104:100. Of all cases, there were 6,549 Saudis, 1,883 of Non-Saudis and 163 of unknown nationalities. As shown on table 2.4, the total number of analysed cases were 8,220.

Adult Cancers in Saudi Arabia, 2004 (>14 years)


Male Female Total Male Female Total Male Female Total Total Total 3231 3318 6549 1026 857 1883 84 79 163 8595

Invasive 3168 3238 6406 1000 840 1840 81 77 158 8404

In-Situ 63 80 143 26 17 43 3 2 5 191

ICD 10* 10 16 26 0 0 0 0 0 0 26

Analyzed** 3158 3222 6380 1000 840 1840 81 77 158 8220

Table 2.4 Distribution of Reported Adult Cancer Cases in Saudi Arabia by Nationality and Sex 2004

Figure 2.6 Ten Most Common Cancers among Saudi Adults, 2004

366

289

231

226

214

159

146

140

136

116

11.6%

9.2%

7.3%

7.2%

6.8%

5.0%

4.6%

4.4%

4.3%

3.7%

Colo-rectal

NHL

Lung

Liver

Prostate

Bladder

Leukemia

Stomach

Other Skin

Hodgkin disease

Male Female

Breast

Thyroid

Colo-rectal

NHL

Other Skin

Corpus Uteri

Leukemia

Ovary

Liver

Cervix Uteri

783

320

281

203

123

117

113

102

89

88

24.3%

9.9%

8.7%

6.3%

3.8%

3.6%

3.5%

3.2%

2.8%

2.7%

3158 3222

Part002.indd 21 15-04-2008 10:46:00 AM

22

Primary Site Code Morphology Male % Female %

Breast 8500 Infiltrating duct carcinoma, NOS 11 73.3 616 78.78520 Lobular carcinoma, NOS 0 0.0 38 4.98523 Infiltrating duct mixed with other types of carcinoma 1 6.7 20 2.68522 Infiltrating duct and lobular carcinoma 0 0.0 20 2.68010 Carcinoma, NOS 0 0.0 18 2.38510 Medullary carcinoma, NOS 0 0.0 14 1.89020 Phyllodes tumor, malignant 0 0.0 9 1.18140 Adenocarcinoma, NOS 1 6.7 7 0.9

All Others 2 13.3 41 5.2

Colo-rectal 8140 Adenocarcinoma, NOS 264 72.1 203 72.28480 Mucinous adenocarcinoma 36 9.8 31 11.08481 Mucin-producing adenocarcinoma 15 4.1 4 1.48261 Adenocarcinoma in villous adenoma 11 3.0 5 1.88263 Adenocarcinoma in tubulovillous adenoma 9 2.5 6 2.18010 Carcinoma, NOS 6 1.6 7 2.58490 Signet ring cell carcinoma 6 1.6 5 1.88210 Adenocarcinoma in adenomatous polyp 6 1.6 2 0.78260 Papillary adenocarcinoma, NOS 4 1.1 3 1.1

All Others 9 2.5 15 5.3

NHL 9680 Malignant lymphoma, large B-cell, diffuse, NOS 148 51.2 104 51.29590 Malignant lymphoma, NOS 18 6.2 14 6.99591 Malignant lymphoma, non-Hodgkin, NOS 16 5.5 16 7.99699 Marginal zone B-cell lymphoma, NOS 14 4.8 10 4.99714 Anaplastic large cell lymphoma, T cell and Null cell type 10 3.5 7 3.49702 Mature T-cell lymphoma, NOS 11 3.8 5 2.59687 Burkitt lymphoma, NOS 9 3.1 4 2.09700 Mycosis fungoides 10 3.5 3 1.59690 Follicular lymphoma, NOS 8 2.8 4 2.09670 Malignant lymphoma, small B lymphocytic, NOS 5 1.7 6 3.09691 Follicular lymphoma, grade 2 4 1.4 6 3.0

All Others 36 12.5 24 11.8

Thyroid 8260 Papillary adenocarcinoma, NOS 58 66.7 193 60.38340 Papillary carcinoma, follicular variant 7 8.0 46 14.48341 Papillary microcarcinoma 4 4.6 28 8.88330 Follicular adenocarcinoma, NOS 3 3.4 7 2.28335 Follicular carcinoma, minimally invasive 0 0.0 9 2.88343 Papillary carcinoma, encapsulated 2 2.3 7 2.28510 Medullary carcinoma, NOS 4 4.6 4 1.3

All Others 9 10.3 26 8.1

Liver 8170 Hepatocellular carcinoma, NOS 208 92.0 69 77.58160 Cholangiocarcinoma 6 2.7 6 6.78010 Carcinoma, NOS 4 1.8 2 2.28000 Neoplasm, malignant 2 0.9 3 3.48140 Adenocarcinoma, NOS 1 0.4 4 4.5

All Others 5 2.2 5 5.6

Lung 8140 Adenocarcinoma, NOS 50 21.6 18 28.68070 Squamous cell carcinoma, NOS 57 24.7 7 11.18041 Small cell carcinoma, NOS 29 12.6 6 9.58046 Non-small cell carcinoma 26 11.3 5 7.98010 Carcinoma, NOS 13 5.6 6 9.58240 Carcinoid tumor, NOS 7 3.0 6 9.58071 Squamous cell carcinoma, keratinizing, NOS 7 3.0 1 1.68250 Bronchiolo-alveolar adenocarcinoma, NOS 5 2.2 3 4.88000 Neoplasm, malignant 5 2.2 2 3.28012 Large cell carcinoma, NOS 7 3.0 0 0.0

All Others 25 10.8 9 14.3

Skin 8090 Basal cell carcinoma, NOS 70 51.5 52 42.38070 Squamous cell carcinoma, NOS 24 17.6 33 26.88094 Basosquamous carcinoma 12 8.8 4 3.38832 Dermatofibrosarcoma, NOS 6 4.4 9 7.38071 Squamous cell carcinoma, keratinizing, NOS 6 4.4 6 4.98410 Sebaceous adenocarcinoma 7 5.1 3 2.48097 Basal cell carcinoma, nodular 3 2.2 6 4.9

All Others 8 5.9 10 8.1

Table 2.5 Number and Proportion of Morphological Types for the Most Common Types of Cancer among Saudi Adults, 2004

Part002.indd 22 15-04-2008 10:46:03 AM

23

Primary Site Code Morphology Male % Female %

Leukemia 9863 Chronic myeloid leukemia, NOS 19 13.0 28 24.89823 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma 24 16.4 11 9.79835 Precursor cell lymphoblastic leukemia, NOS 22 15.1 8 7.19861 Acute myeloid leukemia, NOS 14 9.6 12 10.69867 Acute myelomonocytic leukemia 9 6.2 9 8.09866 Acute promyelocytic leukemia, t(15;17) (q22;q11-12) 7 4.8 9 8.09874 Acute myeloid leukemia with maturation 6 4.1 9 8.09891 Acute monocytic leukemia 7 4.8 5 4.49836 Precursor B-cell lymphoblastic leukemia 8 5.5 3 2.79873 Acute myeloid leukemia without maturation 5 3.4 4 3.59837 Precursor T-cell lymphoblastic leukemia 7 4.8 1 0.99872 Acute myeloid leukemia, minimal differentiation 2 1.4 4 3.5

All Others 16 11.0 10 8.8

Prostate 8140 Adenocarcinoma, NOS 187 87.4 − −8010 Carcinoma, NOS 20 9.3 − −

All Others 7 3.3 − −

Stomach 8140 Adenocarcinoma, NOS 66 47.1 29 41.48490 Signet ring cell carcinoma 27 19.3 28 40.08144 Adenocarcinoma, intestinal type 17 12.1 4 5.78480 Mucinous adenocarcinoma 5 3.6 2 2.98010 Carcinoma, NOS 5 3.6 - 0.08145 Carcinoma, diffuse type 3 2.1 2 2.9

All Others 17 12.1 5 7.1

Bladder 8120 Transitional cell carcinoma, NOS 84 52.8 20 48.88130 Papillary transitional cell carcinoma 54 34.0 11 26.88070 Squamous cell carcinoma, NOS 11 6.9 4 9.88010 Carcinoma, NOS 3 1.9 1 2.48071 Squamous cell carcinoma, keratinizing, NOS 3 1.9 0 0.08140 Adenocarcinoma, NOS 1 0.6 2 4.9


Hodgkin Disease 9663 Hodgkin lymphoma, nodular sclerosis, NOS 51 44.0 39 49.49652 Hodgkin lymphoma, mixed cellularity, NOS 16 13.8 11 13.99665 Hodgkin lymphoma, nodular sclerosis, grade 1 8 6.9 10 12.79667 Hodgkin lymphoma, nodular sclerosis, grade 2 9 7.8 8 10.19650 Hodgkin lymphoma, NOS 11 9.5 4 5.19651 Hodgkin lymphoma, lymphocyte-rich 6 5.2 6 7.69659 Hodgkin lymphoma, nodular lymphocyte predominance 12 10.3 0 0.0


Corpus Uterine 8380 Endometrioid adenocarcinoma, NOS − − 63 53.88140 Adenocarcinoma, NOS − − 27 23.18950 Mullerian mixed tumor − − 4 3.48010 Carcinoma, NOS − − 3 2.68260 Papillary adenocarcinoma, NOS − − 2 1.78310 Clear cell adenocarcinoma, NOS − − 2 1.78441 Serous cystadenocarcinoma, NOS − − 2 1.78460 Papillary serous cystadenocarcinoma − − 2 1.78480 Mucinous adenocarcinoma − − 2 1.78933 Adenosarcoma − − 2 1.7

All Others − − 8 6.8

Ovary 8460 Papillary serous cystadenocarcinoma − − 26 25.58441 Serous cystadenocarcinoma, NOS − − 14 13.78140 Adenocarcinoma, NOS − − 7 6.98380 Endometrioid adenocarcinoma, NOS − − 7 6.98470 Mucinous cystadenocarcinoma, NOS − − 6 5.98000 Neoplasm, malignant − − 5 4.98461 Serous surface papillary carcinoma − − 5 4.98010 Carcinoma, NOS − − 4 3.98260 Papillary adenocarcinoma, NOS − − 4 3.98480 Mucinous adenocarcinoma − − 4 3.98310 Clear cell adenocarcinoma, NOS − − 3 2.98810 Fibrosarcoma, NOS − − 2 2.09071 Yolk sac tumor − − 2 2.0


Cervix Uteri 8070 Squamous cell carcinoma, NOS − − 28 31.88072 Squamous cell carcinoma, large cell, nonkeratinizing, NOS − − 24 27.38071 Squamous cell carcinoma, keratinizing, NOS − − 12 13.68140 Adenocarcinoma, NOS − − 11 12.5


Table 2.5 continued .....

Part002.indd 23 15-04-2008 10:46:05 AM

24

The total incident cases reported among children (0-14 years) between January and December 2004 were 713. This represents 7.6 % of the total number of cancers in Saudi Arabia. The reported incidents show that cancer was more common among boys than girls. 400 (56.1%) cases were reported among boys and 313 (43.9%) among girls, with a male to female ratio of 128:100. Of all the

cases reported there were 584 Saudis, 115 non-Saudis and 14 of “unknown nationality”. Based on table 2.6, the total number of cases analyzed was 685 including 584 (85.3%) Saudis and 101 (14.7%) non-Saudis. Among Saudis, 318 (54.5%) were male and 266 (45.5%) were female. The male to female ratio among Saudis was 120:100.

Childhood cancer is very important, not only because of the age of occurrence, but also because 41.7% of the Saudi population is under 15 years of age. In addition to this, recent years have shown a breakthrough for the cure of many childhood cancers. Childhood cancers accounted for 8.2% of all cancer among Saudis. The leading cancer

among Saudi children was leukemia, which accounted for 30%, followed by Brain (CNS) then Hodgkins disease and NHL. Figure 2.7 shows the top ten sites by sex and frequency, and table 2.7 shows the number and proportion of the morphological types for the most common types of cancer.

Childhood Cancers in Saudi Arabia, 2004 (≤14 years)

* ICD-10 conversion failure ** Unknown nationalities, in situ cases and ICD-10 conversion failures are excluded from analysis

Figure 2.7 Ten Most Common Cancers among Saudi Children by Sex, 2004

Table 2.6 Distribution of Reported Childhood Cancer Cases in Saudi Arabia by Nationality and Sex, 2004


Male Female Total Male Female Total Male Female Total Total Total 318 266 584 73 42 115 9 5 14 713

Invasive 0 0 0 0 0 0 0 0 0 0

In-situ 0 0 0 0 0 0 0 0 0 0

ICD 10* 0 0 0 0 0 0 1 0 0 1

Analyzed** 318 266 584 73 42 115 8 5 13 685

94

53

50

43

21

12

8

6

5

4

4

29.6%

16.7%

15.7%

13.5%

6.6%

3.8%

2.5%

1.9%

1.6%

1.3%

1.3%

Leukemia


Hodgkin disease

NHL

Bone

Kidney

Connective,Soft tissue

Eye

Liver

Nasopharynx

Testis

4 1.3%Adrenal gland

Boys Girls

Leukemia


Kidney

NHL


Hodgkin disease

Bone

Adrenal gland

Eye

Thyroid

81

37

22

20

19

19

15

13

12

8

30.5%

13.9%

8.3%

7.5%

7.1%

7.1%

5.6%

4.9%

4.5%

3.0%

318 266

Part002.indd 24 15-04-2008 10:46:09 AM

25

Table 2.7 Number and Proportion of Morphological Types for the Most Common Types of Cancer among Saudi Children, 2004

Primary Site Code Morphology Male % Female %Leukemia 9835 Precursor cell lymphoblastic leukemia, NOS 39 41.5 28 34.6

9836 Precursor B-cell lymphoblastic leukemia 19 20.2 25 30.99861 Acute myeloid leukemia, NOS 4 4.3 6 7.49874 Acute myeloid leukemia with maturation 6 6.4 2 2.59805 Acute biphenotypic leukemia 2 2.1 4 4.99837 Precursor T-cell lymphoblastic leukemia 4 4.3 2 2.59891 Acute monocytic leukemia 2 2.1 4 4.99801 Acute leukemia, NOS 4 4.3 1 1.29866 Acute promyelocytic leukemia, t(15;17)(q22;q11-12) 2 2.1 2 2.59867 Acute myelomonocytic leukemia 2 2.1 2 2.5

All Others 10 10.6 5 6.2Brain 9470 Medulloblastoma, NOS 27 50.9 11 29.7

9380 Glioma, malignant 3 5.7 8 21.69400 Astrocytoma, NOS 5 9.4 3 8.19391 Ependymoma, NOS 2 3.8 2 5.49392 Ependymoma, anaplastic 2 3.8 2 5.49440 Glioblastoma, NOS 3 5.7 1 2.79471 Desmoplastic nodular medulloblastoma 3 5.7 1 2.79401 Astrocytoma, anaplastic 1 1.9 2 5.4

All Others 7 13.2 7 18.9Hodgkin Disease 9663 Hodgkin lymphoma, nodular sclerosis, NOS 20 40.0 8 42.1

9652 Hodgkin lymphoma, mixed cellularity, NOS 13 26.0 4 21.19650 Hodgkin lymphoma, NOS 6 12.0 1 5.39665 Hodgkin lymphoma, nodular sclerosis, grade 1 4 8.0 0 0.09667 Hodgkin lymphoma, nodular sclerosis, grade 2 2 4.0 2 10.59651 Hodgkin lymphoma, lymphocyte-rich 2 4.0 1 5.39659 Hodgkin lymphoma, nodular lymphocyte predominance 1 2.0 1 5.39664 Hodgkin lymphoma, nodular sclerosis, cellular phase 1 2.0 1 5.3

All Others 1 2.0 1 5.3NHL 9687 Burkitt lymphoma, NOS 15 34.9 7 35.0

9729 Precursor T-cell lymphoblastic lymphoma 8 18.6 3 15.09680 Malignant lymphoma, large B-cell, diffuse, NOS 4 9.3 5 25.09591 Malignant lymphoma, non-Hodgkin, NOS 6 14.0 0 0.09727 Precursor cell lymphoblastic lymphoma, NOS 2 4.7 1 5.09728 Precursor B-cell lymphoblastic lymphoma 1 2.3 2 10.09590 Malignant lymphoma, NOS 1 2.3 1 5.09699 Marginal zone B-cell lymphoma, NOS 2 4.7 0 0.09700 Mycosis fungoides 2 4.7 0 0.0

All Others 5 11.6 1 5.0Bone 9260 Ewing sarcoma 11 52.4 5 33.3

9180 Osteosarcoma, NOS 5 23.8 9 60.0All Others 5 23.8 1 6.7

Kidney 8960 Nephroblastoma, NOS 11 91.7 21 95.58001 Tumor cells, malignant 1 8.3 0 0.08963 Malignant rhabdoid tumor 0 0.0 1 4.5

Connective Tissue 8900 Rhabdomyosarcoma, NOS 2 25.0 3 15.89500 Neuroblastoma, NOS 2 25.0 3 15.88910 Embryonal rhabdomyosarcoma, NOS 0 0.0 3 15.88963 Malignant rhabdoid tumor 0 0.0 2 10.59040 Synovial sarcoma, NOS 0 0.0 2 10.59364 Peripheral neuroectodermal tumor 0 0.0 2 10.59473 Primitive neuroectodermal tumor, NOS 2 25.0 0 0.0

All Others 2 25.0 4 21.1Eye 9512 Retinoblastoma, undifferentiated 4 66.7 10 83.3

9510 Retinoblastoma, NOS 2 33.3 0 0.09511 Retinoblastoma, differentiated 0 0.0 1 8.39513 Retinoblastoma, diffuse 0 0.0 1 8.3

Adrenal Gland 9500 Neuroblastoma, NOS 3 75.0 12 92.38370 Adrenal cortical carcinoma 1 25.0 1 7.7

Liver 8970 Hepatoblastoma 4 80.0 2 50.08170 Hepatocellular carcinoma, NOS 1 20.0 2 50.0

Thyroid 8260 Papillary adenocarcinoma, NOS − − 7 87.58341 Papillary microcarcinoma − − 1 12.5

Nasopharynx 8010 Carcinoma, NOS 0 0.0 1 100.08020 Carcinoma, undifferentiated, NOS 3 75.0 0 0.08910 Embryonal rhabdomyosarcoma, NOS 1 25.0 0 0.0

Testis 9061 Seminoma, NOS 1 25.0 − −9071 Yolk sac tumor 3 75.0 − −

Part002.indd 25 15-04-2008 10:46:11 AM

26

The following bar charts list the most common cancer sites in the 13 administrative regions of Saudi Arabia by sex. These sites are listed on the basis of the total number of cases reported by permanent address (region) at the time of diagnosis. In most regions breast cancer was the leading cancer among women, while among men Colo-rectal, NHL, liver and Leukemia

interchange. It is worth noting that the major regions such as Riyadh, Makkah and Eastern Province represent the majority of cases. This can be attributed to the increasing number of people seeking medical attention in these urbanized cities with modern hospital facilities where permanent addresses may not be documented in source records.

Cancer in the 13 Administrative Regions of the Kingdom

33.3

3.8

3.8

4.4

5.2

5.4

5.8

7.8

9.7

9.7

11.1

0 10 20 30 40

Other Sites

Stomach

Bladder

Hodgkin disease

Lung


Prostate

Leukemia

Colo-rectal

NHL

Liver

Males (893)

29.8

2.7

2.8

3.3

3.7

3.9

5.1

5.5

8.6

13.3

21.3

0 10 20 30 40

Other Sites

Skin

Hodgkin disease

Corpus Uteri

Ovary

Liver

Leukemia

NHL

Colo-rectal

Thyroid

Breast

Females (949)

36.5

3.0

3.0

3.6

3.7

6.4

7.4

7.5

8.3

9.2

11.3

0 10 20 30 40

Other Sites

Lung

Skin

Hodgkin disease


Leukemia

Liver

NHL

Thyroid

Colo-rectal

Breast

All (1842)

Figure 2.8.1 Riyadh Region, 2004 (Percentage Distribution)

33.9

30 40

4.0

4.6

4.8

4.8

5.1

5.5

6.7

9.2

9.9

11.4

0 10 20

Males (868)

Colo-rectal

NHL

Lung

Prostate

Leukemia

Bladder

Liver

Stomach

Kidney

Hodgkin disease

Other Sites

Breast

NHL

Thyroid

Colo-rectal

Leukemia

Skin

Ovary

Cervix Uteri

Corpus Uteri


Other Sites

Breast

Colo-rectal

NHL

Lung

Thyroid

Leukemia

Liver

Prostate

Skin

Bladder

Other Sites29.0

2.9

3.2

3.3

3.5

3.7

3.9

6.8

8.2

8.2

27.1

0 10 20 30 40

Females (837)

39.2

3.2

3.4

3.4

3.5

4.8

4.9

6.0

9.1

9.1

13.4

0 10 20 30 40

All (1705)

Figure 2.8.2 Makkah Region, 2004 (Percentage Distribution)

Part002.indd 26 15-04-2008 10:46:14 AM

27


35.0

3.9

4.1

4.1

4.2

6.0

6.0

7.6

9.5

9.5

10.1

0 10 20 30 40

Males (566)

28.9

3.0

3.1

3.3

3.5

4.1

4.3

6.1

8.1

9.3

26.3

0 10 20 30 40

Females (605)

36.1

3.2

3.4

3.7

4.7

6.1

6.1

6.6

6.8

9.4

13.9

0 10 20 30 40

All (1171)

Lung

NHL

Colo-rectal

Prostate

Leukemia

Hodgkin disease


Bladder

Liver

Thyroid

Other Sites

Breast

Colo-rectal

NHL

Lung

Leukemia

Thyroid

Hodgkin disease

Prostate


Liver

Other Sites

Breast

Colo-rectal

Thyroid

Leukemia

NHL

Corpus Uteri

Hodgkin disease

Lung

Cervix Uteri

Skin

Other Sites

Figure 2.8.3 Eastern Region, 2004 (Percentage Distribution)

26.0

5.1

5.6

5.6

6.1

6.6

6.6

7.1

8.2

10.2

12.8

0 10 20 30 40

Males (196)

31.1

4.2

4.2

4.2

4.2

4.2

5.25.2

6.6

6.6

6.6

17.0

0 10 20 30 40Females (212)

37.3

3.4

3.9

4.7

5.1

5.9

6.1

6.6

8.3

9.1

9.6

0 10 20 30 40

All (408)

Colo-rectal

NHL

Liver


Leukemia

Bladder

Lung

Hodgkin disease

Prostate

Stomach

Other Sites

Colo-rectal

Breast

NHL

Leukemia


Liver

Hodgkin disease

Stomach

Lung

Bladder

Other Sites

Breast

Leukemia

NHL

Colo-rectal

Brain, Nervous systemOesophagus

Hodgkin disease

Thyroid

Corpus Uteri

Cervix Uteri

Stomach

Other Sites

9.13.03.03.03.03.03.03.03.03.03.03.03.03.03.03.0

6.19.1

15.215.2

0 10 20 30 40

Males (33)

26.5

4.1

4.1

4.1

4.1

6.1

6.1

6.1

8.2

14.3

16.3

0 10 20 30 40

Females (49)

30.52.42.42.42.42.43.73.74.9

7.38.58.59.811.0

0 10 20 30 40All (82)

Hodgkin diseaseColo-rectalLeukemia

TongueMultiple Myeloma

NHLBrain, Nervous system

EyeBladder

Other male genitalProstate

PenisMesothelioma

SkinGall bladder etc.

AnusSmall intestine

StomachNasopharynx

Other Sites

Thyroid

Breast

Colo-rectal

Leukemia

Bladder

Cervix Uteri

Hodgkin disease

Kidney

Gall bladder etc.

Liver

Other Sites

Colo-rectalThyroid

Hodgkin diseaseBreast

LeukemiaBladder

Cervix UteriGall bladder etc.

NHLKidney

SkinLiver

TongueOther Sites

Figure 2.8.5 Northern Region, 2004 (Percentage Distribution)

Figure 2.8.4 Madinah Region, 2004 (Percentage Distribution)

Part002.indd 27 15-04-2008 10:46:18 AM

28


Figure 2.8.7 Jazan Region, 2004 (Percentage Distribution)

Figure 2.8.8 Hail Region, 2004 (Percentage Distribution)

Figure 2.8.6 Qassim Region, 2004 (Percentage Distribution)

31.3

3.7

3.7

4.3

4.3

5.5

6.1

6.7

10.4

11.7

12.3

0 10 20 30 40

Males (163)

25.4

3.0

3.0

3.0

5.2

7.5

8.2

9.0

10.4

25.4

0 10 20 30 40

Females (134)

29.0

3.03.43.73.74.44.76.1

10.110.1

10.411.4

All (297)

Colo-rectal

NHL

Leukemia

Prostate

Hodgkin disease

Stomach

Skin

Liver

Thyroid

Oesophagus

Other Sites

Breast

Leukemia

NHLColo-rectal

Thyroid

Skin

Stomach

Prostate

Hodgkin disease

Oesophagus

Nasopharynx

Other Sites

Breast

Leukemia

Thyroid

NHL

Colo-rectal

Skin

Stomach

Oesophagus

Nasopharynx

Other Sites

0 10 20 30 40

30.2

3.83.8

4.7

5.7

6.6

6.6

7.5

9.4

10.4

11.3

0 10 20 30 40

Males (106)

29.4

3.7

3.7

3.7

3.7

5.5

7.3

7.3

8.3

9.2

18.3

0 10 20 30 40 0 10 20 30 40

Females (109)

32.14.24.24.24.25.65.6

6.57.47.4

9.39.3

All (215)

Colo-rectal

NHL

Mouth

Leukemia

Prostate

Stomach

Liver

Bladder

Skin

Tongue

Other Sites

Breast

Tongue

NHL

Thyroid

Skin

Mouth

Leukemia

Bladder

Ovary

Colo-rectal

Other Sites

NHL

Breast

Colo-rectal

Mouth

Tongue

LeukemiaSkin

Thyroid

Bladder

Liver

Stomach

Other Sites

27.3

3.9

3.95.2

5.2

5.2

5.2

6.5

6.5

6.5

11.7

13.0

0 10 20 30 40Males (77)

14.93.03.03.03.03.03.04.5

7.57.59.09.09.0

20.9

0 10 20 30 40Females (67)

36.1

3.5

3.5

3.5

4.9

6.3

6.9

6.9

7.6

9.7

11.1

0 10 20 30 40

All (144)

Colo-rectal

Liver

NHL

Hodgkin disease

Thyroid


Bladder

Lung

PancreasSkin

Nasopharynx

Other Sites

BreastThyroid

Brain, Nervous systemColo-rectalLeukemia

NHLBone

Hodgkin diseaseOvary

Corpus UteriCervix Uteri

Connective, Soft tissueSkin

Other Sites

Colo-rectal

Breast

Thyroid

NHL


Liver

Hodgkin disease

Leukemia

Bladder

Skin

Other Sites

Part002.indd 28 15-04-2008 10:46:23 AM

29


Figure 2.8.11 Asir Region, 2004 (Percentage Distribution)

Figure 2.8.10 Baha Region, 2004 (Percentage Distribution)

Figure 2.8.9 Najran Region, 2004 (Percentage Distribution)

15.53.43.43.43.43.43.43.43.45.25.2

8.610.312.1

15.5

0 2010 30 40

Males (58)

35.1

5.4

5.4

5.4

5.4

8.1

8.1

10.8

16.2

0 10 20 30 40

Other Sites

Skin

Breast

Adrenal gland

Hodgkin disease

Gallbladder etc.


Thyroid

Leukemia

Females (37)

28.43.23.23.23.23.23.23.24.25.37.4

9.510.5

12.6

0 10 20 30 40

Other SitesTongue

StomachColo-rectal

Gallbladder etc.Bone

Connective,Soft tissueMultiple Myeloma

KidneyThyroid

Hodgkin diseaseSkinNHL

Leukemia

All (95)

NHLSkin

LeukemiaHodgkin disease

Multiple MyelomaKidney

BladderTestisBoneLung

Colo-rectalStomach

OesophagusTongue

Other Sites

19.03.43.43.43.43.43.45.25.25.26.98.68.610.310.3

0 10 20 30 40

Males (58)

24.72.72.72.74.14.14.14.14.14.14.1

6.811.0

20.5

0 10 20 30 40

Females (73)

36.63.13.13.13.83.83.83.84.6

6.96.98.4

12.2

0 10 20 30 40

All (131)

LeukemiaColo-rectal

ProstateLung

TongueNHL

BoneLiver

Hodgkin diseaseBrain, Nervous system

BladderKidney

SkinNasopharynx

Other Sites

BreastNHL

ThyroidLeukemia

OvaryCorpus UteriCervix Uteri

SkinColo-rectal

StomachBrain, Nervous system

OesophagusTongue

Other Sites

BreastNHL

LeukemiaColo-rectal

TongueThyroid

ProstateSkin

LungBrain, Nervous system

LiverStomach

Other Sites

31.73.53.53.54.24.65.0

8.18.58.98.99.7

0 10 20 30 40

Males (259)

31.0

2.9

3.3

4.1

4.5

4.5

5.8

7.9

10.3

11.2

14.5

0 10 20 30 40

Females (242)

34.73.23.84.04.24.45.46.06.67.48.4

12.0

0 10 20 30 40

All (501)

Colo-rectal

Leukemia

NHL

Skin

Prostate

Bladder

Liver

Stomach

Hodgkin disease

Kaposi sarcoma

Nasopharynx

Other Sites

Colo-rectal

Breast

Thyroid

NHL

Leukemia

Skin

Stomach

Corpus Uteri

Liver

Hodgkin disease

Other Sites

Colo-rectal

NHL

Leukemia

Skin

Thyroid

Breast

Stomach

Prostate

Liver

Bladder

Hodgkin diseaseOther Sites

Part002.indd 29 15-04-2008 10:46:28 AM

30


Figure 2.8.12 Tabuk Region, 2004 (Percentage Distribution)

Figure 2.8.13 Jouf Region, 2004 (Percentage Distribution)

27.2

3.5

3.5

4.4

5.3

6.1

6.1

7.0

8.8

8.8

9.6

0 10 20 30 40

Males (114)

30.3

4.0

4.0

4.0

5.1

5.1

6.1

7.1

8.1

8.1

18.2

0 10 20 30 40

Females (99)

38.0

3.8

3.8

4.7

5.2

6.1

6.1

6.6

8.5

8.5

8.9

0 10 20 30 40

All (213)

Colo-rectal9.6Bladder

Leukemia

Liver

Lung

NHL

Hodgkin disease


Skin

Kidney

Connective, Soft tissue

Other Sites

Breast

Leukemia


Colo-rectal

NHL

Stomach

Oesophagus

Thyroid

Ovary

Corpus Uteri

Other Sites

Breast

Leukemia

Colo-rectal


NHL

Bladder

Liver

Hodgkin disease

Lung

Oesophagus

Other Sites

30.9

3.6

5.5

5.5

5.5

5.5

7.3

7.3

7.3

9.1

12.7

0 10 20 30 40

Males (55)

23.6

3.6

3.6

3.6

3.6

3.6

3.6

5.5

5.5

5.5

9.1

29.1

0 10 20 30 40

Females (55)

32.7

3.6

3.6

3.6

3.6

5.5

5.5

5.5

5.5

7.3

9.1

14.5

0 10 20 30 40

All (110)

NHL

Colo-rectal

Thyroid

Bladder

Lung

Leukemia

Kidney

Skin

Nasopharynx

Pancreas

Other Sites

Breast

Leukemia

NHL

Corpus Uteri

Skin

Hodgkin disease

Thyroid


Lung

Gall bladder etc.

Salivary glandsOther Sites

Breast

NHL

Leukemia

Thyroid

Skin

Lung

Colo-rectal


Bladder

Kidney

Nasopharynx

Other Sites

Part002.indd 30 15-04-2008 10:46:32 AM

31

Worldwide, it is estimated that around 11 million people developed cancer in 2002. Of these, 53.7% were in developing countries and 46.5% were in developed countries. According to 2002 estimates, the most common cancer site among all men was lung cancer. However, in developed countries prostate was the leading cancer followed by lung, colo-rectal, and stomach.

While in developing countries, lung cancer was firstfollowed by stomach, liver, esophagus and colo-rectal cancers. Among women, breast cancer was the most common followed by colo-rectal, lung and corpus uteri cancers in developed countries. While in the developing countries breast cancer was followed by cancers of the cervix, stomach and lung.

International Comparison of Age-Standardized Incidence Rates

Figure 2.9.A Comparison of ASR* for Saudi Males with Selected Countries**

Figure 2.9.B Comparison of ASR* for Saudi Females with Selected Countries**

36.2170.170.599.1

130.3132.6157158.7179.0

252.0318340.4

537.6611.3

0 100 200 300 400 500 600 700

EnglandUnited States (All Races)

NorwaySwedenPoland

Pakistan, Karachi

BahrainQatar

KuwaitThailand, Lamphun

Oman

Saudi ArabiaUnited Arab Emirates

India, Barashi

45.02

69.3

81.9

85.4

136.7

138.9

142.3

165.2

204.1

270.6

278.3

403.1

560.5

0 100 200 300 400 500 600

England

United States (All Races)

Norway

Sweden

Pakistan, Karachi

Qatar

Bahrain

Thailand, Lamphun

Kuwait

Oman

United Arab Emirates

Saudi Arabia

India, Barashi

* ASR Per 100,000 ** Source for this information is summarized on page 66

Part002.indd 31 15-04-2008 10:46:34 AM

32

Part002.indd 32 15-04-2008 10:46:35 AM

PART IIICANCER INCIDENCE FOR MOST COMMON SITES

2004

Part003.indd 33 15-04-2008 10:43:12 AM

Part003.indd 34 15-04-2008 10:43:12 AM

35

In this section, the incidence of the most common cancers among Saudi males and females are outlined in accordance to their

relative frequencies. The relevant data incorporate details for all patients presented over the period of January through December 2004

Cancer Incidence for Most Common Sites, 2004

Table 3.1 Most Common Cancers among Saudis, 2004

Cancer Male Female All % Breast 15 783 798 11.5 Colo-rectal 366 281 647 9.3 Non-Hodgkin lymphoma 332 224 556 8.0 Leukemia 241 194 435 6.2 Thyroid 87 328 415 6.0 Liver 231 93 324 4.6 Lung 233 63 296 4.2 Hodgkin disease 166 98 264 3.8 Skin 136 125 261 3.7 Brain, Nervous system 147 100 247 3.5 Prostate 214 - 214 3.1 Stomach 141 70 211 3.0 Bladder 160 41 201 2.9 Corpus uteri - 117 117 1.7 Ovary - 108 108 1.5 Other sites 1009 866 1875 26.9 Total 3478 3491 6969 100

Part003.indd 35 15-04-2008 10:43:12 AM

36

Figure 3.1.2 Stage Distribution of Female Breast Cancer, 2004

Figure 3.1.1 Age-Specific Incidence Rate (AIR) for Female Breast Cancer in Saudi Arabia, 2004

Table 3.1.1 Morphological Distribution of Female Breast Cancer in Saudi Arabia, 2004

There were 783 female breast cancer cases analyzed for year 2004. Breast cancer ranked first amongfemales accounting for 22.4% of all newly diagnosed female cancers (3,491). The ASR was 15.4/100,000 for female population. The five regions with the highest

ASR were Eastern region at 22.6/100,000, Riyadh region at 19.4/100,000, Makkah region at 19.1/100,000, Jouf region at 17.5/100,000 and Qassim region at 12.6/100,000. The median age at diagnosis was 47 years (Range 18-96 years).

Female Breast (C 50)

0

10

20

30

40

50

60

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

Age Groups

AIR

(per

100

,000

)

female

ICD-O Code Morphology Total %

8500 Infiltrating duct carcinoma, NOS 616 78.7%

8520 Lobular carcinoma, NOS 38 4.9%

8522 Infiltrating duct and lobular carcinoma 20 2.6%

8523 Infiltrating duct mixed with other types of carcinoma 20 2.6%

8010 Carcinoma, NOS 18 2.3%

8510 Medullary carcinoma, NOS 14 1.8%

9020 Phyllodes tumor, malignant 9 1.1%

All Others 48 6.1%

13.8%

24.0%

48.5%

13.7%

Distant

Localised

Regional

Unknown

Part003.indd 36 15-04-2008 10:43:13 AM

37

Figure 3.1.4 Comparison of ASR* for Female Breast Cancer among Saudi Females with ASR in Selected Countries**

Figure 3.1.3 ASR* Regional Distribution of Female Breast Cancer in Saudi Arabia, 2004


2.2

5.7

6.3

9.0

10.6

11.3

11.5

11.7

12.6

17.5

19.1

19.4

22.6

0 5 10 15 20 25

Najran

Asir

Jazan

Hail

Madinah

Baha

Northern

Tabuk

Qassim

Jouf

Makkah

Riyadh

Eastern

15.4

15.8

20.5

40.7

44.0

47.151.3

69.1

76.189.0

117.7

119.0144.6

0 20 40 60 80 100 120 140 160

England



SwedenNorway

Pakistan, Karachi

BahrainQatar

Kuwait

Poland

Thailand, Lamphun

Oman

Saudi Arabia

Part003.indd 37 15-04-2008 10:43:13 AM

38

Figure 3.2.1 Age-Specific Incidence Rate (AIR) for Colo-rectal Cancer in Saudi Arabia, 2004

Figure 3.2.2 Stage Distribution of Colo-rectal Cancer, 2004

There were 647 cases of colo-rectal cancer accounting for 9.3% of all newly diagnosed cases in year 2004. This cancer ranked first among malepopulation and third among female population. It affected 366 (56.6%) males and 281 (43.4.%) females with a male to female ratio of 130:100. The overall ASR was 7.3/100,000. ASR for males was 8.3/100,000 and for females 6.3/100,000.

The five regions with the highest ASR wereEastern region at 9.8/100,000, Northern region at 9.6/100,000, Riyadh region at 9.6/100,000, Tabuk region at 8.2/100,000 and Makkah region at 7.4/100,000. The median age at diagnosis was 60 years among males (range 19-105 years) and 58 years among females (range 16-100 years).

Colo-rectal (C18-C20)

Table 3.2.1 Morphological Distribution of Colo-rectal Cancer in Saudi Arabia, 2004

0

10

20

30

40

50

60

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

Age Groups

male female

AIR

(per

100

,000

)

ICD-O-3 Code Morphology Male % Female %

8140 Adenocarcinoma, NOS 264 40.8% 203 31.4%

8480 Mucinous adenocarcinoma 36 5.6% 31 4.8%

8481 Mucin-producing adenocarcinoma 15 2.3% 4 0.6%

8261 Adenocarcinoma in villous adenoma 11 1.7% 5 0.8%

8263 Adenocarcinoma in tubulovillous adenoma 9 1.4% 6 0.9%

8010 Carcinoma, NOS 6 0.9% 7 1.1%

8490 Signet ring cell carcinoma 6 0.9% 5 0.8%

8210 Adenocarcinoma in adenomatous polyp 6 0.9% 2 0.3%

8260 Papillary adenocarcinoma, NOS 4 0.6% 3 0.5%

All Others 9 1.4% 15 2.3%

25.4%

26.2%

35.2%

13.1%

Male

27.5%

26.4%

34.9%

11.1%

All

30.2%

26.7%

34.5%

8.5%

Female

Part003.indd 38 15-04-2008 10:43:13 AM

39

Figure 3.2.4 Comparison of ASR* for Colo-rectal Cancer among Saudis with ASR in Selected Countries**

Figure 3.2.3 ASR* Regional Distribution of Colo-rectal Cancer in Saudi Arabia, 2004

2.9

3.3

4.9

6.1

5.9

8.2

5.8

9.7

9.3

10.2

9.6

10.8

10.8

0.7

1.2

2.0

1.5

3.6

4.77.7

4.5

5.5

6.1

9.6

8.4

9.0

0 2 4 6 8 10 12

Eastern

Northern

Riyadh

Tabuk

Makkah

Madinah

Asir

Qassim

Hail

Jouf

Baha

Jazan

Najran

4.5

5.8

7.80

8.3

8.70

14.7

15.0

31.7

27.943.50

58.2

64.4

3.8

6.3

5.2

6.3

7.4

10.0

14.5

7.7

16.8

34.9

42.7

51.0

0 10 20 30 40 50 60 70

England


Norway

Poland

Qatar

Kuwait

Bahrain

Thailand, Lamphun

Saudi Arabia

Pakistan, Karachi


Oman


Part003.indd 39 15-04-2008 10:43:14 AM

40

Figure 3.3.1 Age-Specific Incidence Rate (AIR) for NHL in Saudi Arabia, 2004

Table 3.3.1 Morphological Distribution of NHL in Saudi Arabia, 2004

There were 556 cases of Non-Hodgkin Lymphoma accounting for 8% of all newly diagnosed cancers in year 2004. This cancer ranked second among male population and fourth among female population. It affected 332(59.7%) males and 224(40.3%) females with a male to female ratio of 148:100. The overall ASR was 5.2/100,000. ASR for males was 5.9/100,000 and 4.5/100,000 for females.

The five regions with the highest ASR were Riyadh region at 6.8/100,000, Makkah region at 6.6/100,000, Eastern region at 5.5/100,000, Jouf region at 5.1/100,000 and Najran regions at 4.4/100,000 each. The median age at diagnosis was 46 years among males (range 2-103 years) and 53 years among females (range 1-94 years).

Non-Hodgkin Lymphoma (C82-C85; C96)

0

5

10

15

20

25

30

35

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

Age Groups

male female

AIR

(per

100

,000

)

ICD-O-3 Code Morphology Male % Female %

9680 Malignant lymphoma, large B-cell, diffuse, NOS 152 27.3% 109 19.6%

9591 Malignant lymphoma, non-Hodgkin, NOS 22 4.0% 16 2.9%

9687 Burkitt lymphoma, NOS 24 4.3% 11 2.0%

9590 Malignant lymphoma, NOS 19 3.4% 15 2.7%

9699 Marginal zone B-cell lymphoma, NOS 16 2.9% 10 1.8%

9714 Anaplastic large cell lymphoma, T cell and Null cell type 11 2.0% 7 1.3%

9702 Mature T-cell lymphoma, NOS 11 2.0% 6 1.1%

9729 Precursor T-cell lymphoblastic lymphoma 11 2.0% 5 0.9%

9700 Mycosis fungoides 12 2.2% 3 0.5%

9690 Follicular lymphoma, NOS 8 1.4% 4 0.7%

9670 Malignant lymphoma, small B lymphocytic, NOS 5 0.9% 6 1.1%

9691 Follicular lymphoma, grade 2 4 0.7% 6 1.1%



9675 Malignant lymphoma, mixed small and large cell, diffuse 5 0.9% 2 0.4%

9684 Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS- 3 0.5% 3 0.5%

All Others 19 3.4% 14 2.5%

Part003.indd 40 15-04-2008 10:43:14 AM

41

Figure 3.3.3 ASR* Regional Distribution of NHL Cancer in Saudi Arabia, 2004

Figure 3.3.4 Comparison of ASR* for NHL Cancer among Saudis with ASR in Selected Countries**

Figure 3.3.2 Stage Distribution of NHL Cancer, 2004

5.1

5.9

8.8

5.8

9.3

7.7

11.4

9.5

12.00

17.9

22.6

4.6

4.5

3.7

7.3

6.9

9.1

5.9

9.2

8.8

15.2

16.1

0 5 10 15 20 25


England

Norway

Kuwait

Oman

Qatar

Sweden


Bahrain

Saudi Arabia

Thailand, Lamphun

0.5

2.6

2.7

2.6

4.0

3.2

5.4

4.6

7.4

6.2

6.8

7.0

8.0

0.7

2.2

2.7

3.4

3.5

4.5

3.1

4.2

1.4

3.9

4.2

6.2

5.6

0 1 2 3 4 5 6 7 8 9

Riyadh

Makkah

Eastern

Jouf

Najran

Madinah

Qassim

Baha

Asir

Tabuk

Jazan

Hail

Northern

38.0%

16.9%18.1%

27.1%

Male

37.9%

15.8%15.8%

30.4%

All

37.9%

14.3%12.5%

35.3%

Female


Part003.indd 41 15-04-2008 10:43:14 AM

42

Figure 3.4.1 Age-Specific Incidence Rate (AIR) for Leukemia in Saudi Arabia, 2004

Table 3.4.1 Morphological Distribution of Leukemia in Saudi Arabia, 2004

There were 435 cases of leukemia accounting for 6.2% of all newly diagnosed cancers in year 2004. This cancer ranked third for males and fifthamong females and affected 241(55.4%) males and 194(44.6%) females with a male to female ratio of 124:100. The overall ASR was 3.1/100,000. ASR for males was 3.4/100,000 and 2.7/1000,000 for females.

The five regions with the highest ASR were Najranregion at 5.7/100,000, Qassim region at 4.8/100,000, Tabuk region at 4.2/100,000, Riyadh region at 4.1/100,000 and Jouf region at 3.5/100,000. The median age at diagnosis is 20 years among males (range 0-90 years) and 20 years among females (range 0-88 years).

Leukemia (C91-C95)

0

2

4

6

8

10

12

14

16

18

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

Age Groups

male female

AIR

(per

100

,000

)

ICD-O-3Code Morphology Male % Female %

9835 Precursor cell lymphoblastic leukemia, NOS 61 14.0% 36 8.3%

9836 Precursor B-cell lymphoblastic leukemia 27 6.2% 28 6.4%

9863 Chronic myeloid leukemia, NOS 20 4.6% 29 6.7%

9861 Acute myeloid leukemia, NOS 19 4.4% 18 4.1%

9823 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma 24 5.5% 11 2.5%

9874 Acute myeloid leukemia with maturation 12 2.8% 11 2.5%

9867 Acute myelomonocytic leukemia 11 2.5% 11 2.5%

9866 Acute promyelocytic leukemia, t(15;17) (q22; q11-12) 9 2.1% 11 2.5%

9891 Acute monocytic leukemia 9 2.1% 9 2.1%

9837 Precursor T-cell lymphoblastic leukemia 11 2.5% 3 0.7%

9801 Acute leukemia, NOS 8 1.8% 2 0.5%

9873 Acute myeloid leukemia without maturation 6 1.4% 4 0.9%

9805 Acute biphenotypic leukemia 2 0.5% 5 1.1%

9872 Acute myeloid leukemia, minimal differentiation 2 0.5% 5 1.1%

9910 Acute megakaryoblastic leukemia 5 1.1% 0 0.0%

All Others 15 3.4% 11 2.5%

Part003.indd 42 15-04-2008 10:43:15 AM

43

Figure 3.4.3 Comparison of ASR* for Leukemia among Saudis with ASR in Selected Countries**

Figure 3.4.2 ASR* Regional Distribution of Leukemia in Saudi Arabia, 2004


1.90.0

3.2

3.2

3.12.1

3.1

3.5

2.6

4.8

5.2

5.2

6.1

0.7

3.1

1.9

2.0

2.34.2

3.7

3.54.4

3.3

3.1

4.3

5.2

0 1 2 3 4 5 6 7

Najran

Qassim

Tabuk

Riyadh

Jouf

Eastern

Northern

Madinah

Makkah

Asir

Baha

Hail

Jazan

3.43.1

6.14.0

4.8

6.17.0

7.08.9

9.28.2

13.5

15.2

2.7

3.4

1.64.6

4.74.6

4.0

5.0

6.3

6.79.0

9.5

9.1

0 2 4 6 8 10 12 14 16


England

Oman

Norway

Sweden

Kuwait

Poland

Qatar

Pakistan, Karachi


Bahrain

Thailand, Lamphun

Saudi Arabia

Part003.indd 43 15-04-2008 10:43:15 AM

44

There were 415 cases of thyroid cancer accounting for 6% of all newly diagnosed cases in year 2004. This cancer ranked second among female population and 14th among male population. It affected 87 (21%) males and 328 (79%) females with a male to female ratio of 100:266. The overall ASR was 3.5/100,000. ASR was 1.6/100,000 for males and

Figure 3.5.2 Stage Distribution of Thyroid Cancer, 2004

5.3/100,000 for females. The five regions with thehighest ASR were Riyadh region at 6.1/100,000, Northern region at 4.5/100,000, Jouf region at 4.5/100,000, Eastern region at 4 /100,000 and Hail region at 3.4/100,000. The median age at diagnosis was 43 years among males (range 17-90 years) and 37 years among females (range 5-92 years).

Table 3.5.1 Morphological Distribution of Thyroid Cancer in Saudi Arabia, 2004

Figure 3.5.1 Age-Specific Incidence Rate (AIR) forThyroid Cancer in Saudi Arabia, 2004

Thyroid (C 73)

0

2

4

6

8

10

12

14

16

18

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

Age Groups

male female

AIR

(per

100,0

00)

ICD-O-3 Code Morphology Male

%

Female %

8260 Papillary adenocarcinoma, NOS 58 14.0% 200 48.2%

8340 Papillary carcinoma, follicular variant 7 1.7% 46 11.1%

8341 Papillary microcarcinoma 4 1.0% 29 7.0%

8330 Follicular adenocarcinoma, NOS 3 0.7% 7 1.7%

8335 Follicular carcinoma, minimally invasive 0 0.0% 9 2.2%

8343 Papillary carcinoma, encapsulated 2 0.5% 7 1.7%

8510 Medullary carcinoma, NOS 4 1.0% 4 1.0%

8021 Carcinoma, anaplastic, NOS 1 0.2% 6 1.4%

8050 Papillary carcinoma, NOS 2 0.5% 5 1.2%

8010 Carcinoma, NOS 1 0.2% 4 1.0%

8290 Oxyphilic adenocarcinoma 2 0.5% 3 0.7%

All Others 3 0.7% 8 1.9%

13.8%

31.0%

37.9%

17.2%

Male

9.2%

41.9%

29.6%

19.3%

All

7.9%

44.8%

27.4%

19.8%

Female

Part003.indd 44 15-04-2008 10:43:16 AM

45

Figure 3.5.3 ASR* Regional Distribution of Thyroid Cancer in Saudi Arabia, 2004

Figure 3.5.4 Comparison of ASR* for Thyroid Cancer among Saudis with ASR in Selected Countries**


0.0

0.2

1.0

0.0

0.9

1.0

2.4

0.9

3.72.6

6.7

0.0

2.2

1.8

2.3

2.2

3.4

2.9

4.5

3.4

4.9

3.0

5.4

2.28.9

9.9

0 2 4 6 8 10 12

Riyadh

Northern

Jouf

Eastern

Hail

Asir

Qassim

Makkah

Najran

Baha

Tabuk

Jazan

Madinah

0.91.0

1.5

1.61.3

1.51.6

1.33.0

1.6

2.4

4.6

2.8

1.8

3.3

3.9

4.0

4.9

5.1

5.3

6.9

8.5

8.3

8.7

13.8

21.1

0 5 10 15 20 25

Qatar


Bahrain

Kuwait

Oman


Saudi Arabia

Norway

Poland

Sweden

England

Pakistan, Karachi

Thailand, Lamphun

Part003.indd 45 15-04-2008 10:43:16 AM

46

Figure 3.6.1 Age-Specific Incidence Rate (AIR) for Liver Cancer in Saudi Arabia, 2004

Figure 3.6.2 Stage Distribution of Liver Cancer, 2004

Table 3.6.1 Morphological Distribution of Liver Cancer in Saudi Arabia, 2004

There were 324 cases of liver cancer accounting for 4.6% of all newly diagnosed cases in year 2004. This cancer ranked fifth in males, and eleventh in femalesand affected 231 (71.3%) males and 93 (28.7%) females with a male to female ratio of 248:100. The overall ASR was 3.9/100,000. ASR was 5.5/100,000 for males and 2.2/100,000 for females.

The five regions with the highest ASR were Riyadhregion at 8.7/100,000, Tabuk region at 5.5/100,000, Madinah region at 3.7/100,000, Eastern region at 3.6/100,000 and Hail region at 3.4/100,000. The median age at diagnosis was 66 years in males (range 1-110 years) and 63 years in female (range 1-98 years).

Liver (C 22)

0

5

10

15

20

25

30

35

40

45

50

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

Age Groups

male female

AIR

(per

100

,000

)

ICD-O-3Code Morphology Male

%

Female %

8170 Hepatocellular carcinoma, NOS 209 64.5% 71 21.9%

8160 Cholangiocarcinoma 6 1.9% 6 1.9%

8010 Carcinoma, NOS 4 1.2% 2 0.6%

8970 Hepatoblastoma 4 1.2% 2 0.6%

8000 Neoplasm, malignant 2 0.6% 3 0.9%

8140 Aden carcinoma, NOS 1 0.3% 4 1.2%

All Others 5 1.5% 5 1.5%

16.5%

23.8%

7.4%

52.4%

Male

15.7%

23.5%

7.7%

53.1%

All

14.0%

22.6%

8.6%

54.8%

Female

Part003.indd 46 15-04-2008 10:43:16 AM

47

Figure 3.6.4 Comparison of ASR* for Liver Cancer among Saudis with ASR in Selected Countries**

Figure 3.6.3 ASR* Regional Distribution of Liver Cancer in Saudi Arabia, 2004


0.5

0.6

0.0

2.0

2.5

3.2

2.7

4.3

6.7

4.0

4.8

10.1

12.4

0.0

0.0

1.2

1.0

0.6

0.5

1.8

1.6

0.0

3.1

2.6

0.9

4.9

0 2 4 6 8 10 12 14

Riyadh

Tabuk

Madinah

Eastern

Hail

Makkah

Asir

Qassim

Baha

Jazan

Northern

Jouf

Najran

1.91.1

3.0

5.5

5.8

4.74.2

5.65.3

8.7

8.8

15.3

21.6

0.9

1.8

1.7

2.2

2.2

3.7

4.33.7

4.0

3.0

3.9

5.2

5.1

0 5 10 15 20 25

Qatar

Thailand, Lamphun

Kuwait


Pakistan, Karachi

England

Bahrain

Sweden

Oman

Saudi Arabia

Poland

Norway


Part003.indd 47 15-04-2008 10:43:17 AM

48

Figure 3.7.1 Age-Specific Incidence Rate (AIR) for Lung Cancer in Saudi Arabia, 2004

Table 3.7.1 Morphological Distribution of Lung Cancer in Saudi Arabia, 2004

There were 296 cases of lung cancer accounting for 4.2% of all diagnosed cases in year 2004. Lung cancer ranked fourth among male population and 16th among female population. It affected 233 (78.7%) males and 63 (21.3%) females with a male to female ratio of 369:100. The overall ASR was 3.1/100,000. ASR was 5.5/100,000 for males and 1.5/100,000 for females.

The five regions with the highest ASR were Eastern region at 7.6/100,000, Makkah region at 5.4/100,000, Jouf region at 4.2/100,000, Tabuk region at 3.7/100,000 and Riyadh region at 3.1 /100,000. The median age at diagnosis was 63 years among males (range 0-94 years) and 61 years among females (range 17-90 years).

Lung (C33-C34)

0

5

10

15

20

25

30

35

40

45

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

Age Groups

male female

AIR

(per

100

,000

)

ICD-O-3Code Morphology Male %

Female

%


8070 Squamous cell carcinoma, NOS 57 19.3% 7 2.4%

8041 Small cell carcinoma, NOS 29 9.8% 6 2.0%

8046 Non-small cell carcinoma 26 8.8% 5 1.7%

8010 Carcinoma, NOS 13 4.4% 6 2.0%

8240 Carcinoid tumor, NOS 7 2.4% 6 2.0%

8071 Squamous cell carcinoma, keratinizing, NOS 7 2.4% 1 0.3%

8250 Bronchiolo-alveolar adenocarcinoma, NOS 5 1.7% 3 1.0%


8012 Large cell carcinoma, NOS 7 2.4% 0 0.0%

8246 Neuroendocrine carcinoma, NOS 1 0.3% 3 1.0%

8560 Adenosquamous carcinoma 3 1.0% 1 0.3%

8001 Tumor cells, malignant 1 0.3% 2 0.7%

8020 Carcinoma, undifferentiated, NOS 3 1.0% 0 0.0%

8072 Squamous cell carcinoma, large cell, nonkeratinizing, NOS 3 1.0% 0 0.0%


All Others 14 4.7% 2 0.7%

Part003.indd 48 15-04-2008 10:43:17 AM

49

Figure 3.7.2 Stage Distribution of Lung Cancer, 2004

Figure 3.7.4 Comparison of ASR* for Lung Cancer among Saudis with ASR in Selected Countries**

Figure 3.7.3 ASR* Regional Distribution of Lung Cancer in Saudi Arabia, 2004


56.2%

7.7%

14.6%

21.5%

Male

55.7%

10.8%

13.2%

20.3%

All

54.0%

22.2%

7.9%

15.9%

Female

0.0

0.4

0.6

1.7

2.1

2.9

3.7

5.6

5.3

7.4

5.3

8.2

11.2

0.0

0.4

0.5

0.0

0.4

0.0

1.4

0.0

0.9

0.0

3.0

2.5

4.0

0 2 4 6 8 10 12

Eastern

Makkah

Jouf

Tabuk

Riyadh

Baha

Madinah

Hail

Qassim

Najran

Asir

Jazan

Northern

5.5

9.4

9.1

12.9

19.5

25.5

22.1

29.9

31.9

34.6

60.0

73.7

85.7

1.5

0.5

2.62.7

6.9

4.2

16.5

10.2

19.7

21.7

13.9

48.4

54.2

0 10 20 30 40 50 60 70 80 90


England

Poland

Norway

Thailand, Lamphun

Bahrain

Sweden

Pakistan, Karachi

Kuwait

Qatar

Oman

Saudi Arabia


Part003.indd 49 15-04-2008 10:43:17 AM

50

There were 264 cases of hodgkins disease accounting for 3.8% of all newly diagnosed cases in year 2004. This cancer ranked seventh among male and tenth in female population. It affected 166 (62.9%) males and 98 (37.1%) females with a male to female ratio of 167:100. The overall ASR was 1.65/100,000. ASR was 2.1/100,000 for males

and 1.2/100,000 for females. The five regions withhighest ASR were Northern region at 3.2/100,000, Tabuk region at 2.3/100,000, Eastern region at 2.3100,000, Najran region at 2.2/100,000 and Madinah region at 1.9/100,000. The median age at diagnosis was 21 years (range 2-76 years) in males and 21 year in females (range 4-85).

Table 3.8.1 Morphological Distribution of Hodgkins disease in Saudi Arabia, 2004

Figure 3.8.2 Stage Distribution of Hodgkins disease, 2004

Figure 3.8.1 Age-Specific Incidence Rate (AIR) for Hodgkins disease in Saudi Arabia, 2004

Hodgkins disease (C 81)

0

1

2

3

4

5

6

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

Age Groups

male female

AIR

(per

100

,000

)

ICD-O-3Code Morphology Male %

Female %

9663 Hodgkin lymphoma, nodular sclerosis, NOS 71 26.9% 47 17.8%

9652 Hodgkin lymphoma, mixed cellularity, NOS 29 11.0% 15 5.7%

9650 Hodgkin lymphoma, NOS 17 6.4% 5 1.9%

9665 Hodgkin lymphoma, nodular sclerosis, grade 1 12 4.5% 10 3.8%

9667 Hodgkin lymphoma, nodular sclerosis, grade 2 11 4.2% 10 3.8%

9651 Hodgkin lymphoma, lymphocyte-rich 8 3.0% 7 2.7%

9659 Hodgkin lymphoma, nodular lymphocyte predominance 13 4.9% 1 0.4%

9653 Hodgkin lymphoma, lymphocyte depletion, NOS 3 1.1% 0 0.0%

All Others 2 0.8% 3 1.1%

31.9%

11.4%31.9%

24.7%

Male

33.7%

11.7%29.9%

24.6%

All

36.7%

12.2%26.5%

24.5%

Female

Part003.indd 50 15-04-2008 10:43:18 AM

51

Figure 3.8.3 ASR* Regional Distribution of Hodgkins disease in Saudi Arabia, 2004

Figure 3.8.4 Comparison of ASR* for Hodgkins disease among Saudis with ASR in Selected Countries**


0.7

0.4

1.1

2.0

2.5

2.2

2.6

2.0

2.1

3.3

2.6

3.8

3.8

0.2

0.9

1.0

0.4

0.3

0.9

0.6

1.7

1.7

1.1

2.0

0.8

2.5

0 1 2 3 4

Northern

Tabuk

Eastern

Najran

Madinah

Riyadh

Hail

Makkah

Qassim

Baha

Asir

Jouf

Jazan

0.8

1.11.2

2.1

1.8

2.0

4.0

3.0

2.8

3.0

3.1

6.1

0.1

0.6

1.3

1.2

1.7

1.9

0.6

1.8

2.2

2.55.9

3.5

0 1 2 3 4 5 6 7

Qatar

Oman


England

Norway

Kuwait

Poland

Sweden

Saudi Arabia

Bahrain


Thailand, Lamphun

Part003.indd 51 15-04-2008 10:43:18 AM

52

There were 261 cases of skin cancer accounting for 3.7% of all newly diagnosed cases in year 2004. This cancer ranked eleventh for males and sixth for females. It affected 136(52.1%) males and 125(47.9%) females with a male to female ratio of 109:100. The overall ASR was 2.95/100,000. ASR was 3.0/100,000 for males and 2.9/100,000 for females.

Figure 3.9.2 Stage Distribution of Skin Cancer in Saudi Arabia, 2004

The five regions with the highest ASR were Najranregion at 4.8/100,000, Jouf region at 3.7/100,000, Riyadh region at 3.4/100,000, Qassim region at 3.1/100,000 and Asir region at 3.0/100,000. The median age at diagnosis was 67 years among males (range 17-101 years) and 65 years among female (range 3-99 years).

Figure 3.9.1 Age-Specific Incidence Rate (AIR) for Skin Cancer in Saudi Arabia, 2004

Table 3.9.1 Morphological Distribution of Skin Cancer in Saudi Arabia, 2004

Skin (Non-Melanoma) (C 44)

0

5

10

15

20

25

30

35

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

Age Groups

male female

AIR

(per

100

,000

)

ICD-O-3Code Morphology Male % Female %

8090 Basal cell carcinoma, NOS 70 26.8% 53 20.3%


8094 Basosquamous carcinoma 12 4.6% 4 1.5%

8832 Dermatofibrosarcoma, NOS 6 2.3% 9 3.4%


8410 Sebaceous adenocarcinoma 7 2.7% 3 1.1%

8097 Basal cell carcinoma, nodular 3 1.1% 6 2.3%

8091 Multifocal superficial basal cell carcinoma 2 0.8% 1 0.4%

All Others 6 2.3% 10 3.8%

4.4%

50.0%

4.4%

41.2%

Male

3.4%

46.7%

7.7%

42.1%

All

2.4%

43.2%

11.2%

43.2%

Female

Distant

Localised

Regional

Unknown

Part003.indd 52 15-04-2008 10:43:19 AM

53

Figure 3.9.4 Comparison of ASR* for Skin Cancer among Saudis with ASR in Selected Countries**

Figure 3.9.3 ASR* Regional Distribution of Skin Cancer in Saudi Arabia, 2004


1.3

1.3

1.1

2.21.8

4.1

2.6

2.6

4.03.0

3.6

2.7

7.5

2.0

2.1

2.4

1.5

2.2

0.43.1

3.2

2.0

3.2

3.2

4.7

2.0

0 2 4 6 8

Najran

Jouf

Riyadh

Qassim

Asir

Makkah

Eastern

Tabuk

Northern

Hail

Jazan

Madinah

Baha

1.01.8

3.0

4.6

4.3

6.44.8

11.613.0

13.9

18.223.4

131.5

1.82.9

2.9

1.5

2.5

1.5

5.5

3.0

9.7

9.0

9.6

15.2

107.0

0 20 40 60 80 100 120 140

England


Sweden

Norway

Poland

Qatar

Pakistan. Karachi


Oman

Bahrain

Saudi Arabia

Thailand, Lamphun

Kuwait

Part003.indd 53 15-04-2008 10:43:19 AM

54

There were 247 cases of brain and nervous system cancer accounting for 3.5% of all newly diagnosed cases in year 2004. This cancer ranked ninth for both males and females. It affected 147(59.5%) males and 100(40.5%) females with a male to female ratio of 147:100. The overall ASR was 2.5/100,000. ASR was 2.3/100,000 for males and 1.5/100,000

Brain, Nervous System (C70-C72)

for females. The five regions with the highest ASRwere Tabuk region at 3.9/100,000, Eastern region at 2.9/100,000, Madinah region at 2.5/100,000, Riyadh region at 2.5/100,000 and Hail region at 1.9/100,000. The median age at diagnosis was 35 years among males (range 0-88 years) and 22 years among female (range 0-90 years).

Figure 3.10.2 Stage Distribution of Brain Cancer in Saudi Arabia, 2004

Figure 3.10.1 Age-Specific Incidence Rate (AIR) for Brain Cancer in Saudi Arabia, 2004

Table 3.10.1 Morphological Distribution of Brain Cancer in Saudi Arabia, 2004

0

2

4

6

8

10

12

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

Age Groups

male female

AIR

(per

100

,000

)

ICD-O Code Morphology FemaleMale %% 9440 Glioblastoma, NOS 29 11.7% 9470 Medulloblastoma, NOS 14 5.7% 9400 Astrocytoma, NOS 8 3.2% 9380 Glioma, malignant 12 4.9% 9391 Ependymoma, NOS 6 2.4% 9401 Astrocytoma, anaplastic 2 0.8% 9450 Oligodendroglioma, NOS 3 1.2% 9382 Mixed glioma 4 1.6% 9471 Desmoplastic nodular medulloblastoma 2 0.8% 8000 Neoplasm, malignant 1 0.4% 9392 Ependymoma, anaplastic 2 0.8% 9451 Oligodendroglioma, anaplastic 1 0.4% 9473 Primitive neuroectodermal tumor, NOS 3 1.2%

All Others 13 5.3%

42 17.0%31 12.6%17 6.9% 7 2.8% 5 2.0% 8 3.2% 7 2.8% 3 1.2% 4 1.6% 4 1.6% 3 1.2% 4 1.6% 2 0.8%

10 4.0%

6.1%

52.4%10.9%

30.6%

Male

4.9%

52.2%14.2%

28.7%

All

3.0%

52.0%19.0%

26.0%

Female

Part003.indd 54 15-04-2008 10:43:19 AM

55


Figure 3.10.3 ASR* Regional Distribution of Brain Cancer in Saudi Arabia, 2004

Figure 3.10.4 Comparison of ASR* for Brain Cancer among Saudis with ASR in Selected Countries**

0.4

0.5

1.4

2.2

1.2

1.71.8

1.8

3.5

2.6

3.93.0

0.3

0.4

0.8

0.0

1.6

1.5

1.31.8

2.0

1.4

2.4

1.8

4.8

0 1 2 3 4 5 6

Tabuk

Eastern

Madinah

Riyadh

Hail

Makkah

Baha

Asir

Jouf

Northern

Qassim

Najran

Jazan

1.91.8

2.3

3.03.03.3

5.05.4

7.0

7.7

8.810.3

10.9

0.9

1.4

1.5

0.9

2.2

2.3

1.8

3.3

5.3

5.66.0

10.6

14.2

0 2 4 6 8 10 12 14 16

Norway

Sweden

England


Poland

Kuwait

Qatar

Oman

Pakistan, Karachi

Bahrain

Saudi Arabia

Thailand, Lamphun


Part003.indd 55 15-04-2008 10:43:20 AM

56

Figure 3.11.1 Age-Specific Incidence Rate (AIR) for Prostate Cancer in Saudi Arabia, 2004

Figure 3.11.2 Stage Distribution of Prostate Cancer, 2004

Table 3.11.1 Morphological Distribution of Prostate Cancer in Saudi Arabia, 2004

There were 214 cases of prostate cancer accounting for 6.2% of all newly diagnosed cases among males in year 2004. The ASR was 5.1/100,000 among male population. This cancer ranked sixth among males. The five regions with

the highest ASR were Eastern region at 9.3/100,000, Riyadh region at 6.7/100,000, Makkah region at 5.7/100,000, Qassim region at 4.7/100,000 and Asir region at 4.1/100,000. The median age at diagnosis was 71 years (range 25-107 years).

Prostate (C 61)

0

10

20

30

40

50

60

70

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

AIR

(per

100

,000

)

ICD-O Code Morphology Total %

8140 Adenocarcinoma, NOS 187 87.4%


8000 Neoplasm, malignant 2 0.9%

8120 Transitional cell carcinoma, NOS 2 0.9%

8050 Papillary carcinoma, NOS 1 0.5%

8070 Squamous cell carcinoma, NOS 1 0.5%

8550 Acinar cell carcinoma 1 0.5%

34.1%

27.6%9.8%

28.5%

Part003.indd 56 15-04-2008 10:43:20 AM

57

Figure 3.11.4 Comparison of ASR* for Prostate Cancer among Saudi Males with ASR in Selected Countries**

Figure 3.11.3 ASR* Regional Distribution of Prostate Cancer in Saudi Arabia, 2004


0.0

0.7

1.4

2.0

2.6

2.6

3.2

3.3

4.1

4.7

5.7

6.7

9.3

0 2 4 6 8 10

Eastern

Riyadh

Makkah

Qassim

Asir

Madinah

Baha

Jazan

Tabuk

Northern

Jouf

Hail

Najran

2.4

5.16.57.99.810.211.816.0

24.598.0

115.1119.8

145.3

0 20 40 60 80 100 120 140 160


England

Sweden

Norway

Poland

Kuwait

Bahrain

Qatar

Pakistan, Karachi

Oman


Saudi Arabia

Thailand, Lamphun

Part003.indd 57 15-04-2008 10:43:20 AM

58

Stomach (C 16)

Table 3.12.1 Morphological Distribution of Stomach Cancer in Saudi Arabia, 2004

Figure 3.12.2 Stage Distribution of Stomach Cancer, 2004

There were 211 cases of stomach cancer accounting for 3% of all newly diagnosed cases in year 2004. This cancer ranked tenth among male population and 14th among female population. It affected 141(66.8%) males and 70(33.2%) females with a male to female ratio of 201:100. The overall ASR was 3.1/100,000. ASR was 4.1/100,000 for male and 2/100,000 for females.

The five regions with the highest ASR were Madinah region at 3.3/100,000, Tabuk region at 3.3/100,000, Riyadh region at 2.8/100,000, Qassim region at 2.7/100,000 and Eastern region at 2.6/100,000. The median age at diagnosis was 65 years among males (range 28-103 years) and 64 years among female (range 17-92 years).

Figure 3.12.1 Age-Specific Incidence Rate (AIR) for Stomach Cancer in Saudi Arabia, 2004

0

5

10

15

20

25

30

35

40

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

male female

AIR

(per

100

,000

)

ICD-O-3 Code Morphology Male

%

Female %


8490 Signet ring cell carcinoma 27 12.8% 28 13.3%

8144 Adenocarcinoma, intestinal type 18 8.5% 4 1.9%


8010 Carcinoma, NOS 5 2.4% 0 0.0%

8145 Carcinoma, diffuse type 3 1.4% 2 0.9%

8481 Mucin-producing adenocarcinoma 4 1.9% 0 0.0%

8936 Gastrointestinal stromal sarcoma 3 1.4% 1 0.5%



All Others 5 2.4% 3 1.4%

24.1%

12.8%

43.3%

19.9%

Male

23.7%

12.3%

46.4%

17.5%

All

22.9%

11.4%

52.9%

12.9%

Female

Part003.indd 58 15-04-2008 10:43:21 AM

59

Figure 3.12.4 Comparison of ASR* for Stomach Cancer among Saudis with ASR in Selected Countries**

Figure 3.12.3 ASR* Regional Distribution of Stomach Cancer in Saudi Arabia, 2004


0.9

1.7

2.4

2.0

1.7

2.9

3.7

4.6

4.7

4.4

6.0

2.5

8.9

1.0

0.5

0.0

0.6

1.4

0.5

0.8

0.4

0.5

1.1

0.06.5

2.0

0 2 4 6 8 10

Tabuk

Northern

Jouf

Makkah

Eastern

Madinah

Riyadh

Asir

Jazan

Hail

Najran

Qassim

Baha

3.2

3.5

5.0

5.5

6.6

6.0

7.45.8

8.1

9.2

9.7

13.8

17.1

1.6

2.0

2.9

2.7

3.4

4.0

3.9

6.14.4

4.3

4.7

5.0

9.4

0 2 4 6 8 10 12 14 16 18

England

Poland


Oman

Norway

Bahrain


Pakistan, Karachi

Sweden

Qatar

Thailand, Lamphun

Kuwait

Saudi Arabia

Part003.indd 59 15-04-2008 10:43:21 AM

60

Figure 3.13.1 Age-Specific Incidence Rate (AIR) for Bladder Cancer in Saudi Arabia, 2004

Table 3.13.1 Morphological Distribution of Bladder Cancer in Saudi Arabia, 2004

Figure 3.13.2 Stage Distribution of Bladder Cancer, 2004

There were 201cases of bladder cancer accounting for 2.9% of all newly diagnosed cases in year 2004. This cancer ranked eighth among male population and 20th among female population. It affected 160(79.6%) males and 41(20.4%) females with a male to female ratio of 390:100. The overall ASR was 2.4/100,000. ASR was 3.7/100,000 for males and 1/100,000 for females.

The five regions with the highest ASR were Tabuk region at 5.5/100,000, Northern region at 4.5/100,000, Jouf region at 3.0/100,000, Makkah region at 2.8/100,000 and Eastern region at 2.6/100,000. The median age at diagnosis was 67 among males (range 6-110 years) and 60 among females (range 16-100 years).

Bladder (C 67)

0

5

10

15

20

25

30

35

40

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

Age Groups

male female

AIR

(per

100

,000

)

ICD-O-3Code Morphology

Male

% Female %

8120 Transitional cell carcinoma, NOS 84 41.8% 20 10.0%

8130 Papillary transitional cell carcinoma 54 26.9% 11 5.5%


8010 Carcinoma, NOS 3 1.5% 1 0.5%



8910 Embryonal rhabdomyosarcoma, NOS 1 0.5% 1 0.5%

All Others 3 1.5% 2 1.0%

13.8%

51.9%

18.8%

15.6%

Male

13.9%

49.3%

19.9%

16.9%

All

14.6%

39.0%

24.4%

22.0%

Female

Part003.indd 60 15-04-2008 10:43:21 AM

61

Figure 3.13.4 Comparison of ASR* for Bladder Cancer among Saudis with ASR in Selected Countries**

Figure 3.13.3 ASR* Regional Distribution of Bladder Cancer in Saudi Arabia, 2004


0.9

1.7

2.4

2.0

1.7

2.9

3.7

4.6

4.7

4.4

6.0

2.5

8.9

1.0

0.5

0.0

0.6

1.4

0.5

0.8

0.4

0.5

1.1

0.06.5

2.0

0 2 4 6 8 10

Tabuk

Northern

Jouf

Makkah

Eastern

Madinah

Riyadh

Asir

Jazan

Hail

Najran

Qassim

Baha

3.1

3.7

4.7

6.0

6.1

9.5

9.9

11.7

16.0

22.6

23.6

37.3

0.9

1.0

1.3

2.0

2.7

0.0

2.8

1.6

3.0

5.6

9.2

9.6

0 5 10 15 20 25 30 35 40


England

Norway

Poland

Bahrain

Pakistan, Karachi

Qatar

Oman

Kuwait


Saudi Arabia

Thailand, Lamphun

Part003.indd 61 15-04-2008 10:43:22 AM

62

There were 117 cases of corpus uterine cancer among females accounting for 3.4 % of all newly diagnosed cases for females in year 2004. This cancer ranked seventh among female population. The ASR was 2.8/100,000 for female population.

The five regions with the highest ASR were Easternregion at 5/100,000, Jouf region at 4/100,000, Riyadh region at 3.9/100,000, Madinah region at 3.2/100,000 and Tabuk region at 3.1/100,000. The median age at diagnosis was 61 years (range 18-92 years).

Figure 3.14.1 Age-Specific Incidence Rate (AIR) for Corpus uterine Cancer in Saudi Arabia, 2004

Table 3.14.1 Morphological Distribution of Corpus uterine Cancer in Saudi Arabia, 2004

Figure 3.14.2 Stage Distribution of Corpus uterine Cancer, 2004

Corpus uteri (C 54)

0

2

4

6

8

10

12

14

16

18

20

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

Age Groups

AIR

(per

100

,000

)

ICD-O-3Code Morphology Total %

8380 Endometrioid adenocarcinoma, NOS 63 53.8%


8950 Mullerian mixed tumor 4 3.4%


8260 Papillary adenocarcinoma, NOS 2 1.7%

8310 Clear cell adenocarcinoma, NOS 2 1.7%

8441 Serous cystadenocarcinoma, NOS 2 1.7%

8460 Papillary serous cystadenocarcinoma 2 1.7%

8480 Mucinous adenocarcinoma 2 1.7%

8933 Adenosarcoma 2 1.7%

All Others 8 6.8%

15.4%

47.0%

25.6%

12.0%

Part003.indd 62 15-04-2008 10:43:22 AM

63

Figure 3.14.4 Comparison of ASR* for Corpus uterine Cancer among Saudi Females with ASR in Selected Countries**

Figure 3.14.3 ASR* Regional Distribution of Corpus uterine Cancer in Saudi Arabia, 2004


0.0

0.3

0.5

1.3

1.4

2.5

2.6

2.8

3.1

3.2

3.9

4.0

5.0

0 1 2 3 4 5 6

Eastern

Jouf

Riyadh

Madinah

Tabuk

Baha

Makkah

Asir

Northern

Hail

Qassim

Jazan

Najran

1.72.8

4.04.25.0

5.77.4

9.113.414.0

16.619.7

22.4

0 5 10 15 20 25


England

Norway

Sweden

Poland

Bahrain

Kuwait


Pakistan, Karachi

Thailand, Lamphun

Qatar

Saudi Arabia

Oman

Part003.indd 63 15-04-2008 10:43:23 AM

64

Figure 3.15.1 Age-Specific Incidence Rate (AIR) for Ovarian Cancer in Saudi Arabia, 2004

Figure 3.15.2 Stage Distribution of Ovarian Cancer, 2004

Table 3.15.1 Morphological Distribution of Ovarian Cancer in Saudi Arabia, 2004

There were 108 cases of ovarian cancer among females accounting for 3.1% of all newly diagnosed cases among females in year 2004. This cancer ranked eighth among female population. The ASR was 2.2/100,000 for females. The five regions

with the highest ASR were Tabuk region at 3.7/100,000, Riyadh region at 3.4/100,000, Baha region at 2.9/100,000, Eastern region at 2.7/100,000 and Makkah region at 2.4/100,000. The median age at diagnosis was 51years (range 6-93 years).

Ovary Cancer (C 56)

0

2

4

6

8

10

12

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

AIR

(per

100

,000

)

ICD-OCode Morphology Total %

8460 Papillary serous cystadenocarcinoma 26 24.1%

8441 Serous cystadenocarcinoma, NOS 14 13.0%


8380 Endometrioid adenocarcinoma, NOS 7 6.5%

8470 Mucinous cystadenocarcinoma, NOS 6 5.6%

8000 Neoplasm, malignant 5 4.6%

8461 Serous surface papillary carcinoma 5 4.6%

9071 Yolk sac tumor 5 4.6%


8260 Papillary adenocarcinoma, NOS 4 3.7%

8480 Mucinous adenocarcinoma 4 3.7%

8310 Clear cell adenocarcinoma, NOS 3 2.8%

8810 Fibrosarcoma, NOS 2 1.9%

9060 Dysgerminoma 2 1.9%

All Others 14 13.0%

46.3%

27.8%

13.0%

13.0%

Part003.indd 64 15-04-2008 10:43:23 AM

65


Figure 3.15.4 Comparison of ASR* for Ovarian Cancer among Saudi Females with ASR in Selected Countries**

Figure 3.15.3 ASR* Regional Distribution of Ovarian Cancer in Saudi Arabia, 2004

0.5

1.0

1.0

1.1

1.3

1.5

1.5

1.9

2.4

2.7

2.9

3.4

3.7

0 1 2 3 4

Tabuk

Riyadh

Baha

Eastern

Makkah

Madinah

Jouf

Hail

Jazan

Qassim

Najran

Northern

Asir

2.22.2

3.6

3.6

4.5

5.3

7.8

10.3

10.710.8

10.9

12.5

20.7

0 5 10 15 20 25

England


Poland

Qatar

Bahrain

Sweden

Pakistan, Karachi

Thailand, Lamphun

Kuwait

Oman


Saudi Arabia

Norway

Part003.indd 65 15-04-2008 10:43:23 AM

66

** References:

1 United States Cancer Statistics. 2004 Incidence and Mortality, 2007 http://www.cdc.gov/cancer/npcr/npcrpdfs/US_Cancer_Statistics_2004_Incidence_and_Mortality.pdf 2 Office for National Statistics, Cancer Statistics registrations: Registrations of cancer diagnosed in 2004 England. Series MB1 no. 35. 2007, National Statistics: London. http://www.statistics.gov.uk/downloads/theme_health/MB1_35/MB1_No%2035_2004.pdf 3 Cancer Incidence in Sweden http://www.socialstyrelsen.se/NR/rdonlyres/A23BCC9E-23B5-4747-AAA9-23BB9CDF4B75/4753/20054291.pdf 4 Karachi Cancer Registry and Cancer Control in Pakistan http://www.thaigraphic.com/apocp/download/Volume5/Vol5_No1/Yasmin%20Bhurgri.pdf 5 Atlas of Cancer in India http://www.canceratlasindia.org/chapter4_1.htm 6 Cancer in Norway 2004. Cancer Registry of Norway. Institute of Population-based Cancer Research 7 Cancer Incidence in Lamphun, Thailand. Volume I, 1998-2002 8 The Five-Year Cancer Incidence. Gulf Center for Cancer Registration. 1998-2002 Report. 2006 9 Descriptive epidemiology Group, IARC. Globocan, 2002, Available from: (http://www.dep.iarc.fr/) 10 Cancer in Poland in 2004. The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology. Warszawa 2006.

Part003.indd 66 15-04-2008 10:43:23 AM

PART IVCANCER AMONG NON-SAUDIS

2004

Part004.indd 67 15-04-2008 10:51:33 AM

Part004.indd 68 15-04-2008 10:51:33 AM

69

Between January and December 2004, a total of 1,987 cancer cases were reported among the Non-Saudi population. Forty three in situ cases were excluded from the analysis. As a result, the total number of cases analyzed were 1944 out of this 1066(54.8%) were males and 878 (45.2%) were females. The male to female ratio was 121:100. Taking into consideration the population structure of non-Saudis and the fact that cancer is primarily a disease of the elderly, the pattern of cancer had

some significant differences. Those over 60 years represented only 1.8 % and the 20 to 54 age-group represented 72.4% of non-Saudi population. During 2004, approximately 5.8% of all cancers occurred before the age of 15, 28 % occurred between the ages 15 to 40 years, 54.6% were between the ages 41-64, and 12% occured after the age of 64. The median age at diagnosis was 49 years in males (range 0-96 years) and 45 years in females (range 0-98 years).

Table 4.1 Ten Most common Cancers among non-Saudis, 2004

Table 4.2 Distribution of Cancer Cases among Different Nationalities in Order of Relative Frequency

Cancer Among Non-Saudi Population 2004

Cancer All %

Breast 333 17.1%

Colo-rectal 198 10.2%

NHL 121 6.2%

Skin 117 6.0%

Leukemia 106 5.5%

Thyroid 72 3.7%

Stomach 67 3.4%

Bladder 64 3.3%

Lung 63 3.2%

Prostate 60 3.1%

Nationality Male % Female % Total Yemen 209 10.5% 159 8.0% 368 Egypt 117 5.9% 77 3.9% 194 Sudan 109 5.5% 75 3.8% 184 Philippines 60 3.0% 78 3.9% 138 Pakistan 76 3.8% 48 2.4% 124 India 69 3.5% 30 1.5% 99 Syrian Arab Republic 51 2.6% 38 1.9% 89 Bangladesh 72 3.6% 9 0.5% 81 Gaza Strip (Palestine) 39 2.0% 39 2.0% 78 Indonesia 6 0.3% 58 2.9% 64 Jordan 30 1.5% 26 1.3% 56 Bahrain 13 0.7% 38 1.9% 51 United Kingdom 30 1.5% 13 0.7% 43 United States of America 30 1.5% 11 0.6% 41 Kuwait 8 0.4% 8 0.4% 16 Qatar 5 0.3% 3 0.2% 8 Iraq 4 0.2% 2 0.1% 6 Oman 3 0.2% 0 0.0% 3 United Arab Emirates 1 0.1% 1 0.1% 2 Other Nationalities 160 8.1% 182 9.2% 342 Total 1092 55.0% 895 45.0% 1987

Part004.indd 69 15-04-2008 10:51:34 AM

70

Figure 4.2 Age-Specific Incidence Rate (AIR) for All Cancers among non-Saudis in Saudi Arabia, 2004

Figure 4.1 Ten Most Common Cancer among non-Saudis, 2004

126

87

84

72

60

56

54

51

45

32

11.8%

8.2%

7.9%

6.8%

5.6%

5.3%

5.1%

4.8%

4.2%

3.0%

Colo-rectal

Other Skin

NHL

Leukemia

Prostate

Bladder

Stomach

Lung

Liver

Hodgkin disease

Male Female

Breast

Colo-rectal

Thyroid

Cervix Uteri

Ovary

NHL

Corpus Uteri

Leukemia

Other Skin

Hodgkin disease

323

72

47

45

37

37

34

34

30

17

36.8%

8.2%

5.4%

5.1%

4.2%

4.2%

3.9%

3.9%

3.4%

1.9%

1065 878

0

100

200

300

400

500

600

700

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

Age Groups

male female

AIR

(per

100

,000

)

Part004.indd 70 15-04-2008 10:51:35 AM

PART VTABLES

Part005.indd 71 15-04-2008 10:52:28 AM

72

ICD

(10)

SITE

Tot.

UN

K0-

45-

910

-14

15-1

920

-24

25-2

930

-34

35-3

940

-44

45-4

950

-54

55-5

960

-64

65-6

970

-74

75+

%C

00Li

p8

00

00

00

00

00

01

20

11

3

0.

2 C

01-C

02To

ngue

310

00

00

01

21

04

33

66

32

0.9

C03

-C06

Mou

th35

00

00

11

01

03

13

14

26

12

1.

0 C

07-C

08Sa

livar

y G

land

s11

00

01

01

02

20

00

10

12

1

0.

3 C

9To

nsil

20

00

00

00

00

00

00

10

10

0.1

C10

Oth

er o

roph

aryn

x2

00

00

00

00

00

00

00

00

2

0.

1 C

11N

asop

hary

nx10

00

01

36

41

46

1313

149

109

25

2.9

C12

-C13

Hyp

opha

rynx

60

00

01

00

00

01

20

20

00

0.2

C14

Phar

ynx

unsp

ec.

40

00

00

00

01

10

10

01

00

0.1

C15

Oes

opha

gus

500

00

00

00

10

00

24

56

626

1.4

C16

Stom

ach

141

10

00

00

14

55

49

1227

1813

42

4.

1 C

17Sm

all i

ntes

tine

210

00

01

00

11

23

42

23

02

0.6

C18

Col

on19

00

00

00

24

511

1625

1513

3121

2126

5.5

C19

-C20

Rec

tum

176

00

00

20

15

108

1417

2824

2321

23

5.

1 C

21An

us18

00

00

00

00

00

52

15

11

3

0.

5 C

22Li

ver

231

05

00

12

13

25

1017

2132

4534

53

6.

6 C

23-C

24G

all b

ladd

er e

tc.

240

00

00

00

00

20

41

61

28

0.7

C25

Panc

reas

710

00

00

01

23

35

57

1215

810

2.0

C30

-C31

Nos

e, s

inus

es, e

tc.

100

00

10

01

01

10

01

02

12

0.3

C32

Lary

nx49

00

00

00

00

10

66

310

96

8

1.

4 C

33-C

34Tr

ache

a, B

ronc

hus,

Lun

g23

30

20

02

10

44

1115

2623

4524

3145

6.7

C37

-C38

Oth

er T

hora

cic

Org

ans

120

20

00

20

01

00

20

21

02

0.3

C40

-C41

Bone

630

25

1420

123

31

10

01

00

01

1.8

C43

Mel

anom

a of

Ski

n13

00

00

00

00

00

10

05

02

5

0.

4 C

44O

ther

Ski

n13

60

00

01

11

63

105

214

1122

2238

3.9

C45

Mes

othe

liom

a6

00

00

00

00

01

00

01

11

2

0.

2 C

46Ka

posi

sar

com

a25

00

00

00

14

01

33

21

44

2

0.

7 C

47; C

49C

onne

ctiv

e, S

oft T

issu

e57

04

13

48

63

66

31

14

03

4

1.

6 C

50Br

east

150

00

00

00

12

13

50

20

10

0.4

C60

Peni

s3

00

00

00

00

00

00

20

01

0

0.

1 C

61Pr

osta

te21

40

00

00

01

01

04

814

2936

4477

6.2

C62

Test

is44

02

11

48

62

74

52

11

00

0

1.

3 C

63O

ther

mal

e ge

nita

l3

01

00

00

00

00

00

01

10

0

0.

1 C

64Ki

dney

122

08

31

02

44

59

139

1310

168

17

3.

5 C

65R

enal

pel

vis

80

00

00

00

00

00

21

11

12

0.2

C66

Ure

ter

20

00

00

00

00

00

10

01

00

0.1

C67

Blad

der

160

00

10

00

01

46

1313

823

2523

43

4.

6 C

68O

ther

urin

ary

orga

ns1

00

00

00

00

00

00

01

00

0

0.

0 C

69Ey

e19

06

00

10

10

10

02

21

21

2

0.

5 C

70-C

72Br

ain,

Ner

vous

Sys

tem

147

025

1711

53

57

1010

58

69

98

9

4.

2 C

73Th

yroi

d87

00

00

15

109

129

82

47

96

5

2.

5 C

74Ad

rena

l gla

nd5

03

10

00

10

00

00

00

00

0

0.

1 C

75O

ther

End

ocrin

e3

00

10

10

10

00

00

00

00

0

0.

1 C

81H

odgk

in D

isea

se16

60

1220

1827

2111

1110

710

25

52

41

4.8

C82

-C85

; C96

Non

Hod

gkin

lym

phom

a33

20

919

1523

1617

1928

1621

1711

3329

2237

9.5

C88

Imm

unop

rolif

erat

ive

dis.

10

00

00

00

00

00

00

10

00

0.0

C90

Mul

tiple

Mye

lom

a37

00

00

00

01

05

31

36

83

7

1.

1 C

91Ly

mph

oid

Leuk

emia

128

036

1214

129

43

52

25

34

36

8

3.

7 C

92-C

94M

yelo

id L

euke

mia

102

114

011

99

93

65

43

14

94

10

2.

9 C

95Le

ukem

ia u

nspe

c.11

03

04

10

00

01

11

00

00

0

0.

3 O

ther

Oth

er &

uns

peci

fied

143

04

10

11

41

53

1113

1219

1913

36

4.

1 A

llA

ll Si

tes

3478

213

883

9712

410

896

112

155

167

221

233

236

403

386

336

581

100

All

but C

44A

ll si

tes

but C

4433

422

138

8397

123

107

9510

615

215

721

623

122

239

236

431

454

396

.09

Tabl

e 5.

1.1

Age

Dis

trib

utio

n of

Can

cer

Cas

es a

mon

g Sa

udi M

ales

, 200

4

Part005.indd 72 15-04-2008 10:52:29 AM

73

Tabl

e 5.

1.2

Age

Dis

trib

utio

n of

Can

cer

Cas

es a

mon

g Sa

udi F

emal

es, 2

004

ICD

10SI

TETo

t U

NK

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

+%

C

00Li

p6

00

00

00

00

00

10

22

10

00.

2C

01-C

02To

ngue

300

00

01

03

02

10

51

72

53

0.9

C03

-C06

Mou

th22

00

00

01

11

03

02

24

42

20.

6C

07-C

08S

aliv

ary

Gla

nds

100

00

00

00

10

02

20

12

20

0.3

C9

Tons

il1

00

00

00

00

00

01

00

00

00.

0C

10O

ther

oro

phar

ynx

20

00

00

00

00

00

00

02

00

0.1

C11

Nas

opha

rynx

450

00

11

04

33

79

24

62

21

1.3

C12

-C13

Hyp

opha

rynx

160

00

00

01

10

23

32

31

00

0.5

C14

Pha

rynx

uns

pec.

30

00

00

00

00

10

00

02

00

0.1

C15

Oes

opha

gus

510

00

00

01

03

44

13

96

911

1.5

C16

Sto

mac

h70

00

00

11

60

37

45

37

1110

122.

0C

17S

mal

l int

estin

e13

00

00

00

00

11

20

30

30

30.

4C

18C

olon

173

00

00

00

27

1513

2315

1824

1917

205.

0C

19-C

20R

ectu

m10

80

00

02

30

29

1011

127

1510

1215

3.1

C21

Anu

s4

00

00

01

01

00

00

00

10

10.

1C

22Li

ver

930

20

20

10

03

26

126

209

1515

2.7

C23

-C24

Gal

l bla

dder

etc

.51

00

00

00

01

25

64

76

66

81.

5C

25P

ancr

eas

280

00

00

00

00

12

51

72

64

0.8

C30

-C31

Nos

e, s

inus

es, e

tc.

60

00

11

01

00

01

20

00

00

0.2

C32

Lary

nx5

00

00

00

00

00

00

00

20

30.

1C

33-C

34Tr

ache

a, B

ronc

hus,

Lun

g63

00

00

13

10

11

55

1013

76

101.

8C

37-C

38O

ther

Tho

raci

c O

rgan

s10

00

00

01

01

01

01

21

21

00.

3C

40-C

41B

one

380

25

89

40

21

03

40

00

00

1.1

C43

Mel

anom

a of

Ski

n12

00

00

10

11

01

00

21

11

30.

3C

44O

ther

Ski

n12

51

10

03

33

37

62

412

1621

1924

3.6

C45

Mes

othe

liom

a4

00

00

00

00

00

12

10

00

00.

1C

46K

apos

i sar

com

a6

00

00

00

10

10

20

01

00

10.

2C

47; C

49C

onne

ctiv

e, S

oft T

issu

e70

012

34

31

86

33

47

16

60

32.

0C

50B

reas

t78

30

00

02

1026

7110

413

012

094

7670

2323

3422

.4C

51V

ulva

110

10

01

01

02

00

00

22

11

0.3

C52

Vag

ina

30

20

00

00

00

00

00

01

00

0.1

C53

Cer

vix

Ute

ri89

01

00

00

25

1412

1117

86

66

12.

5C

54C

orpu

s U

teri

117

00

00

10

13

310

154

1422

1812

143.

4C

55U

teru

s U

nspe

c.9

00

00

00

00

01

02

40

10

10.

3C

56O

vary

.10

80

01

52

36

58

913

109

129

610

3.1

C57

Oth

er F

emal

e G

enita

l9

00

00

00

00

02

10

21

01

20.

3C

58P

lace

nta

50

00

00

21

10

00

10

00

00

0.1

C64

Kid

ney

760

211

00

10

23

45

56

1110

70

2.2

C65

Ren

al p

elvi

s0

00

00

00

00

00

00

00

00

00.

0C

66U

rete

r2

00

00

00

00

10

00

10

00

00.

1C

67B

ladd

er41

00

00

10

00

22

63

58

34

71.

2C

68O

ther

urin

ary

orga

ns1

00

00

00

00

00

00

00

00

10.

0C

69E

ye18

012

00

00

00

00

00

11

20

20.

5C

70-C

72B

rain

, Ner

vous

Sys

tem

100

014

176

89

35

64

13

43

86

32.

9C

73Th

yroi

d32

80

02

622

3728

4545

3720

2415

229

511

9.4

C74

Adr

enal

gla

nd16

012

10

00

10

02

00

00

00

00.

5C

75O

ther

End

ocrin

e2

00

10

00

01

00

00

00

00

00.

1C

81H

odgk

in D

isea

se98

03

214

2422

55

53

20

23

32

32.

8C

82-C

85; C

96N

on H

odgk

in ly

mph

oma

224

19

65

911

910

1312

1422

2023

2016

246.

4C

88Im

mun

opro

lifer

ativ

e di

s.0

00

00

00

00

00

00

00

00

00.

0C

90M

ultip

le M

yelo

ma

210

00

00

00

01

02

32

41

53

0.6

C91

Lym

phoi

d Le

ukem

ia81

034

148

62

12

10

01

41

14

22.

3C

92-C

94M

yelo

id L

euke

mia

106

06

59

98

78

109

88

65

13

43.

0C

95Le

ukem

ia u

nspe

c.7

02

30

00

00

01

10

00

00

00.

2O

ther

Oth

er &

uns

peci

fied

171

11

10

11

15

1311

1613

1718

2618

284.

9A

llA

ll A

ges

Tota

l34

91

3

135

62

69

109

125

125

198

285

318

326

304

283

361

266

232

290

100

N

ot C

44A

ll si

tes

but C

4433

662

134

6269

106

122

122

195

278

312

324

300

271

345

245

213

266

96

Part005.indd 73 15-04-2008 10:52:30 AM

74

Tabl

e 5.

1.3

Can

cer

Inci

denc

e C

ases

am

ong

Saud

i Mal

es b

y A

ge G

roup

(pe

r 10

0,00

0), 2

004

ICD

10

SITE

Tot

UN

K0-

45-

910

-14

15-1

920

-24

25-2

930

-34

35-3

940

-44

45-4

950

-54

55-5

960

-64

65-6

970

-74

75+

Cru

de

Rat

eA

SR

Wor

ldC

00Li

p8

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.4

1.4

0.0

1.0

1.3

2.6

0.1

0.2

C01

-C02

Tong

ue31

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.4

0.2

0.0

1.3

1.3

2.0

4.7

5.8

3.9

1.7

0.4

0.7

C03

-C06

Mou

th35

0.0

0.0

0.0

0.0

0.1

0.1

0.0

0.2

0.0

0.7

0.3

1.3

0.7

3.2

1.9

7.7

10.4

0.4

0.7

C07

-C08

Sal

ivar

y G

land

s11

0.0

0.0

0.0

0.1

0.0

0.1

0.0

0.4

0.4

0.0

0.0

0.0

0.7

0.0

1.0

2.6

0.9

0.1

0.2

C9

Tons

il2

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.8

0.0

1.3

0.0

0.0

0.1

C10

Oth

er o

roph

aryn

x2

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.7

0.0

0.0

C11

Nas

opha

rynx

100

0.0

0.0

0.1

0.3

0.6

0.5

0.1

0.7

1.2

3.1

4.1

6.3

6.1

7.9

8.7

2.6

4.3

1.2

2.0

C12

-C13

Hyp

opha

rynx

60.

00.

00.

00.

00.

10.

00.

00.

00.

00.

00.

30.

90.

01.

60.

00.

00.

00.

10.

1C

14P

hary

nx u

nspe

c.4

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.2

0.0

0.4

0.0

0.0

1.0

0.0

0.0

0.0

0.1

C15

Oes

opha

gus

500.

00.

00.

00.

00.

00.

00.

00.

20.

00.

00.

00.

92.

73.

95.

87.

722

.40.

61.

1C

16S

tom

ach

141

1.0

0.0

0.0

0.0

0.0

0.0

0.1

0.7

1.0

1.2

1.3

4.0

8.2

21.3

17.4

16.8

36.2

1.7

3.2

C17

Sm

all i

ntes

tine

210.

00.

00.

00.

00.

10.

00.

00.

20.

20.

51.

01.

81.

41.

62.

90.

01.

70.

30.

4C

18C

olon

190

0.0

0.0

0.0

0.0

0.0

0.3

0.6

0.9

2.2

3.9

8.0

6.7

8.9

24.4

20.3

27.1

22.4

2.3

4.2

C19

-C20

Rec

tum

176

0.0

0.0

0.0

0.0

0.2

0.0

0.1

0.9

2.0

1.9

4.5

7.6

19.1

18.9

22.2

27.1

19.8

2.1

4.1

C21

Anu

s18

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.6

0.9

0.7

3.9

1.0

1.3

2.6

0.2

0.4

C22

Live

r23

10.

00.

50.

00.

00.

10.

30.

10.

50.

41.

23.

27.

614

.325

.243

.543

.945

.72.

85.

5C

23-C

24G

all b

ladd

er e

tc.

240.

00.

00.

00.

00.

00.

00.

00.

00.

00.

50.

01.

80.

74.

71.

02.

66.

90.

30.

6C

25P

ancr

eas

710.

00.

00.

00.

00.

00.

00.

10.

40.

60.

71.

62.

24.

89.

514

.510

.38.

60.

91.

7C

30-C

31N

ose,

sin

uses

, etc

.10

0.0

0.0

0.0

0.1

0.0

0.0

0.1

0.0

0.2

0.2

0.0

0.0

0.7

0.0

1.9

1.3

1.7

0.1

0.2

C32

Lary

nx49

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.0

1.9

2.7

2.0

7.9

8.7

7.7

6.9

0.6

1.2

C33

-C34

Trac

hea,

Bro

nchu

s, L

ung

233

0.0

0.2

0.0

0.0

0.2

0.1

0.0

0.7

0.8

2.7

4.8

11.7

15.7

35.5

23.2

40.0

38.8

2.8

5.5

C37

-C38

Oth

er T

hora

cic

Org

ans

120.

00.

20.

00.

00.

00.

30.

00.

00.

20.

00.

00.

90.

01.

61.

00.

01.

70.

10.

2C

40-C

41B

one

630.

00.

20.

41.

32.

11.

60.

40.

50.

20.

20.

00.

00.

70.

00.

00.

00.

90.

80.

6C

43M

elan

oma

of S

kin

130.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

30.

00.

03.

90.

02.

64.

30.

20.

3C

44O

ther

Ski

n13

60.

00.

00.

00.

00.

10.

10.

11.

10.

62.

41.

60.

99.

68.

721

.328

.432

.81.

63.

0C

45M

esot

helio

ma

60.

00.

00.

00.

00.

00.

00.

00.

00.

00.

20.

00.

00.

00.

81.

01.

31.

70.

10.

1C

46K

apos

i sar

com

a25

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.7

0.0

0.2

1.0

1.3

1.4

0.8

3.9

5.2

1.7

0.3

0.5

C47

; C49

Con

nect

ive,

Sof

t Tis

sue

570.

00.

40.

10.

30.

41.

10.

80.

51.

21.

51.

00.

40.

73.

20.

03.

93.

50.

70.

8C

50B

reas

t15

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.4

0.2

1.0

2.2

0.0

1.6

0.0

1.3

0.0

0.2

0.3

C60

Pen

is3

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.4

0.0

0.0

1.3

0.0

0.0

0.1

C61

Pro

stat

e21

40.

00.

00.

00.

00.

00.

00.

10.

00.

20.

01.

33.

69.

622

.934

.856

.866

.42.

65.

1C

62Te

stis

440.

00.

20.

10.

10.

41.

10.

80.

41.

41.

01.

60.

90.

70.

80.

00.

00.

00.

50.

6C

63O

ther

mal

e ge

nita

l3

0.0

0.1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.8

1.0

0.0

0.0

0.0

0.1

C64

Kid

ney

122

0.0

0.7

0.3

0.1

0.0

0.3

0.6

0.7

1.0

2.2

4.1

4.0

8.9

7.9

15.5

10.3

14.7

1.5

2.5

C65

Ren

al p

elvi

s8

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.9

0.7

0.8

1.0

1.3

1.7

0.1

0.2

C66

Ure

ter

20.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

40.

00.

01.

00.

00.

00.

00.

1C

67B

ladd

er16

00.

00.

00.

10.

00.

00.

00.

00.

20.

81.

54.

15.

85.

518

.124

.229

.737

.11.

93.

7C

68O

ther

urin

ary

orga

ns1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.8

0.0

0.0

0.0

0.0

0.0

C69

Eye

190.

00.

60.

00.

00.

10.

00.

10.

00.

20.

00.

00.

91.

40.

81.

91.

31.

70.

20.

3C

70-C

72B

rain

, Ner

vous

Sys

tem

147

0.0

2.3

1.5

1.0

0.5

0.4

0.7

1.2

2.0

2.4

1.6

3.6

4.1

7.1

8.7

10.3

7.8

1.8

2.3

C73

Thyr

oid

870.

00.

00.

00.

00.

10.

71.

41.

62.

42.

22.

50.

92.

75.

58.

77.

74.

31.

01.

6C

74A

dren

al g

land

50.

00.

30.

10.

00.

00.

00.

10.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

10.

1C

75O

ther

End

ocrin

e3

0.0

0.0

0.1

0.0

0.1

0.0

0.1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C81

Hod

gkin

Dis

ease

166

0.0

1.1

1.8

1.7

2.8

2.8

1.5

1.9

2.0

1.7

3.2

0.9

3.4

3.9

1.9

5.2

0.9

2.0

2.1

C82

-C85

; C96

Non

Hod

gkin

lym

phom

a33

20.

00.

81.

71.

42.

42.

12.

33.

35.

73.

96.

77.

67.

526

.028

.028

.431

.94.

05.

9C

88Im

mun

opro

lifer

ativ

e di

s.1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.8

0.0

0.0

0.0

0.0

0.0

C90

Mul

tiple

Mye

lom

a37

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.0

1.2

1.0

0.4

2.0

4.7

7.7

3.9

6.0

0.4

0.9

C91

Lym

phoi

d Le

ukem

ia12

80.

03.

41.

11.

31.

31.

20.

60.

51.

00.

50.

62.

22.

03.

22.

97.

76.

91.

51.

7C

92-C

94M

yelo

id L

euke

mia

102

1.0

1.3

0.0

1.0

0.9

1.2

1.2

0.5

1.2

1.2

1.3

1.3

0.7

3.2

8.7

5.2

8.6

1.2

1.6

C95

Leuk

emia

uns

pec.

110.

00.

30.

00.

40.

10.

00.

00.

00.

00.

20.

30.

40.

00.

00.

00.

00.

00.

10.

1O

ther

Oth

er &

uns

peci

fied

143

0.0

0.4

0.1

0.0

0.1

0.1

0.6

0.2

1.0

0.7

3.5

5.8

8.2

15.0

18.4

16.8

31.1

1.7

3.2

All

All

Age

s To

tal

3478

2.0

13.0

7.5

9.1

12.8

14.4

12.8

19.9

31.1

40.2

70.6

103.

816

1.3

317.

937

3.4

433.

850

1.0

41.6

70.2

Not

C44

All

site

s bu

t C44

3342

2.0

13.0

7.5

9.1

12.7

14.3

12.7

18.8

30.5

37.8

69.0

102.

915

1.7

309.

235

2.1

405.

446

8.2

40.0

67.2

Part005.indd 74 15-04-2008 10:52:32 AM

75

Tabl

e 5.

1.4

Can

cer

Inci

denc

e C

ases

am

ong

Saud

i Fem

ales

by

Age

Gro

up (

per

100,

000)

, 200

4

ICD

10

SITE

Tot

UN

K0-

45-

910

-14

15-1

920

-24

25-2

930

-34

35-3

940

-44

45-4

950

-54

55-5

960

-64

65-6

970

-74

75+

Cru

de

Rat

eA

SR

Wor

ldC

00Li

p6

00

00

00

00

00

0.4

01.

31.

51

00

0.1

0.2

C01

-C02

Tong

ue30

00

00

0.1

00.

40

0.4

0.3

02.

50.

75.

22

5.9

3.2

0.4

0.7

C03

-C06

Mou

th22

00

00

00.

10.

10.

20

0.8

01

1.3

33.

92.

42.

10.

30.

5C

07-C

08S

aliv

ary

Gla

nds

100

00

00

00

0.2

00

0.7

10

0.7

22.

40

0.1

0.2

C9

Tons

il1

00

00

00

00

00

00.

50

00

00

00

C10

Oth

er o

roph

aryn

x2

00

00

00

00

00

00

00

20

00

0.1

C11

Nas

opha

rynx

450

00

0.1

0.1

00.

60.

50.

61.

93.

21

2.6

4.5

22.

41.

10.

50.

9C

12-C

13H

ypop

hary

nx16

00

00

00

0.1

0.2

00.

51.

11.

51.

32.

21

00

0.2

0.4

C14

Pha

rynx

uns

pec.

30

00

00

00

00

0.3

00

00

20

00

0.1

C15

Oes

opha

gus

510

00

00

00.

10

0.6

1.1

1.4

0.5

26.

75.

910

.611

.80.

61.

2C

16S

tom

ach

700

00

00.

10.

10.

90

0.6

1.9

1.4

2.5

25.

210

.811

.812

.80.

81.

6C

17S

mal

l int

estin

e13

00

00

00

00

0.2

0.3

0.7

02

03

03.

20.

20.

3C

18C

olon

173

00

00

00

0.3

1.2

33.

58.

37.

511

.717

.818

.720

21.4

2.1

3.9

C19

-C20

Rec

tum

108

00

00

0.2

0.4

00.

31.

82.

74

64.

611

.19.

914

.116

1.3

2.4

C21

Anu

s4

00

00

00.

10

0.2

00

00

00

10

1.1

00.

1C

22Li

ver

930

0.2

00.

20

0.1

00

0.6

0.5

2.2

63.

914

.98.

917

.616

1.1

2.2

C23

-C24

Gal

l bla

dder

etc

.51

00

00

00

00.

20.

41.

32.

22

4.6

4.5

5.9

7.1

8.5

0.6

1.2

C25

Pan

crea

s28

00

00

00

00

00.

30.

72.

50.

75.

22

7.1

4.3

0.3

0.7

C30

-C31

Nos

e, s

inus

es, e

tc.

60

00

0.1

0.1

00.

10

00

0.4

10

00

00

0.1

0.1

C32

Lary

nx5

00

00

00

00

00

00

00

20

3.2

0.1

0.1

C33

-C34

Trac

hea,

Bro

nchu

s, L

ung

630

00

00.

10.

40.

10

0.2

0.3

1.8

2.5

6.5

9.7

6.9

7.1

10.7

0.8

1.5

C37

-C38

Oth

er T

hora

cic

Org

ans

100

00

00

0.1

00.

20

0.3

00.

51.

30.

72

1.2

00.

10.

2C

40-C

41B

one

380

0.2

0.4

0.7

10.

50

0.3

0.2

01.

12

00

00

00.

50.

5C

43M

elan

oma

of S

kin

120

00

00.

10

0.1

0.2

00.

30

01.

30.

71

1.2

3.2

0.1

0.2

C44

Oth

er S

kin

125

10.

10

00.

30.

40.

40.

51.

41.

60.

72

7.8

11.9

20.7

22.3

25.6

1.5

2.9

C45

Mes

othe

liom

a4

00

00

00

00

00

0.4

10.

70

00

00

0.1

C46

Kap

osi s

arco

ma

60

00

00

00.

10

0.2

00.

70

00.

70

01.

10.

10.

1C

47; C

49C

onne

ctiv

e, S

oft T

issu

e70

01.

10.

30.

30.

30.

11.

11

0.6

0.8

1.4

3.5

0.7

4.5

5.9

03.

20.

81.

2C

50B

reas

t78

30

00

00.

21.

33.

712

.320

.834

.843

.247

49.5

5222

.727

36.3

9.5

15.4

C51

Vul

va11

00.

10

00.

10

0.1

00.

40

00

01.

52

1.2

1.1

0.1

0.2

C52

Vag

ina

30

0.2

00

00

00

00

00

00

10

00

0.1

C53

Cer

vix

Ute

ri89

00.

10

00

00.

30.

92.

83.

24

8.5

5.2

4.5

5.9

7.1

1.1

1.1

1.8

C54

Cor

pus

Ute

ri11

70

00

00.

10

0.1

0.5

0.6

2.7

5.4

29.

116

.317

.714

.115

1.4

2.8

C55

Ute

rus

Uns

pec.

90

00

00

00

00

0.3

01

2.6

01

01.

10.

10.

2C

56O

vary

.10

80

00.

10.

40.

20.

40.

90.

91.

62.

44.

75

5.9

8.9

8.9

7.1

10.7

1.3

2.2

C57

Oth

er F

emal

e G

enita

l9

00

00

00

00

00.

50.

40

1.3

0.7

01.

22.

10.

10.

2C

58P

lace

nta

50

00

00

0.3

0.1

0.2

00

00.

50

00

00

0.1

0.1

C64

Kid

ney

760

20.

10

00.

10

0.3

0.6

1.1

1.8

2.5

3.9

8.2

9.9

8.2

00.

91.

6C

65R

enal

pel

vis

00

00

00

00

00

00

00

00

00

00

C66

Ure

ter

20

00

00

00

00.

20

00

0.7

00

00

00

C67

Bla

dder

410

00

00.

10

00

0.4

0.5

2.2

1.5

3.3

5.9

34.

77.

50.

51

C68

Oth

er u

rinar

y or

gans

10

00

00

00

00

00

00

00

01.

10

0C

69E

ye18

01.

10

00

00

00

00

00.

70.

72

02.

10.

20.

3C

70-C

72B

rain

, Ner

vous

Sys

tem

100

01.

31.

50.

50.

91.

10.

40.

91.

21.

10.

41.

52.

62.

27.

97.

13.

21.

21.

5C

73Th

yroi

d32

80

00.

20.

52.

34.

74

7.8

99.

97.

212

9.8

16.3

8.9

5.9

11.8

45.

3C

74A

dren

al g

land

160

1.1

0.1

00

00.

10

00.

50

00

00

00

0.2

0.2

C75

Oth

er E

ndoc

rine

20

00.

10

00

00.

20

00

00

00

00

00

C81

Hod

gkin

Dis

ease

980

0.3

0.2

1.2

2.6

2.8

0.7

0.9

10.

80.

70

1.3

2.2

32.

43.

21.

21.

2C

82-C

85; C

96N

on H

odgk

in ly

mph

oma

224

10.

90.

50.

41

1.4

1.3

1.7

2.6

3.2

511

1317

.119

.718

.825

.62.

74.

5C

88Im

mun

opro

lifer

ativ

e di

s.0

00

00

00

00

00

00

00

00

00

0C

90M

ultip

le M

yelo

ma

210

00

00

00

00.

20

0.7

1.5

1.3

31

5.9

3.2

0.3

0.5

C91

Lym

phoi

d Le

ukem

ia81

03.

21.

30.

70.

60.

30.

10.

30.

20

00.

52.

60.

71

4.7

2.1

11

C92

-C94

Mye

loid

Leu

kem

ia10

60

0.6

0.4

0.8

11

11.

42

2.4

2.9

43.

93.

71

3.5

4.3

1.3

1.6

C95

Leuk

emia

uns

pec.

70

0.2

0.3

00

00

00

0.3

0.4

00

00

00

0.1

0.1

Oth

erO

ther

& u

nspe

cifie

d17

11

0.1

0.1

00.

10.

10.

10.

92.

62.

95.

86.

511

.113

.425

.621

.229

.92.

13.

9A

llA

ll A

ges

Tota

l34

913

12.8

5.6

5.9

11.6

15.8

17.3

34.4

5785

.311

7.6

152

184.

826

826

2.7

273.

330

9.9

42.1

69.3

Not

C44

All

site

s bu

t C44

3366

212

.75.

65.

911

.315

.416

.933

.955

.683

.711

6.9

150

177

256.

124

225

128

4.3

40.6

66.4

Part005.indd 75 15-04-2008 10:52:35 AM

76

Tabl

e 5.

2.1

Num

ber,

Rel

ativ

e Fr

eque

ncie

s, A

ge S

tand

ardi

zed

and

Cru

de R

ates

for

All

Can

cer

Cas

es A

mon

g Sa

udi M

ales

by

Site

and

Adm

inis

trat

ive

Reg

ion,

200

4

ICD

(10t

h)A

LL S

ITES

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

Tot.

%

Cru

deA

SRC

00Li

p0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C01

-C02

Tong

ue2

0.77

0.3

0.5

46.

92.

63.

54

3.8

0.8

1.3

C03

-C06

Mou

th3

1.2

0.4

0.6

11.

70.

70.

510

9.4

2.1

3.1

C07

-C08

Saliv

ary

Gla

nds

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

9To

nsil

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

10O

ther

oro

phar

ynx

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

11N

asop

hary

nx9

3.5

1.3

2.3

23.

41.

32.

30

0.0

0.0

0.0

C12

-C13

Hyp

opha

rynx

10.

40.

10.

30

0.0

0.0

0.0

00.

00.

00.

0C

14Ph

aryn

x un

spec

.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C15

Oes

opha

gus

62.

30.

91.

00

0.0

0.0

0.0

21.

90.

40.

7C

16St

omac

h11

4.2

1.6

2.5

11.

70.

70.

97

6.6

1.4

2.6

C17

Smal

l int

estin

e3

1.2

0.4

0.8

00.

00.

00.

01

0.9

0.2

0.3

C18

Col

on12

4.6

1.7

2.9

46.

92.

63.

25

4.7

1.0

1.5

C19

-C20

Rec

tum

135.

01.

92.

92

3.4

1.3

1.7

76.

61.

41.

8C

21An

us2

0.8

0.3

0.4

00.

00.

00.

00

0.0

0.0

0.0

C22

Live

r12

4.6

1.7

2.7

35.

22.

02.

56

5.7

1.2

2.0

C23

-C24

Gal

l bla

dder

etc

.2

0.8

0.3

0.4

11.

70.

70.

50

0.0

0.0

0.0

C25

Panc

reas

41.

50.

61.

11

1.7

0.7

0.9

10.

90.

20.

2C

30-C

31N

ose,

sin

uses

, etc

.2

0.8

0.3

0.4

11.

70.

70.

40

0.0

0.0

0.0

C32

Lary

nx1

0.4

0.1

0.1

00.

00.

00.

03

2.8

0.6

0.8

C33

-C34

Trac

hea,

Bro

nchu

s, L

ung

31.

20.

40.

65

8.6

3.3

5.6

10.

90.

20.

4C

37-C

38O

ther

Tho

raci

c O

rgan

s0

0.0

0.0

0.0

00.

00.

00.

01

0.9

0.2

0.3

C40

-C41

Bone

62.

30.

90.

73

5.2

2.0

1.6

21.

90.

40.

3C

43M

elan

oma

of S

kin

20.

80.

30.

30

0.0

0.0

0.0

21.

90.

40.

7C

44O

ther

Ski

n22

8.5

3.1

4.0

23.

41.

31.

34

3.8

0.8

1.1

C45

Mes

othe

liom

a0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C46

Kapo

si s

arco

ma

93.

51.

31.

90

0.0

0.0

0.0

32.

80.

60.

9C

47; C

49C

onne

ctiv

e, S

oft T

issu

e4

1.5

0.6

0.7

00.

00.

00.

02

1.9

0.4

0.7

C50

Brea

st0

0.0

0.0

0.0

11.

70.

70.

80

0.0

0.0

0.0

C60

Peni

s0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C61

Pros

tate

218.

13.

04.

15

8.6

3.3

3.2

76.

61.

42.

6C

62Te

stis

20.

80.

30.

31

1.7

0.7

0.7

00.

00.

00.

0C

63O

ther

mal

e ge

nita

l1

0.4

0.1

0.2

00.

00.

00.

00

0.0

0.0

0.0

C64

Kidn

ey8

3.1

1.1

1.5

23.

41.

31.

71

0.9

0.2

0.3

C65

Ren

al p

elvi

s0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C66

Ure

ter

00.

00.

00.

00

0.0

0.0

0.0

10.

90.

20.

3C

67Bl

adde

r13

5.0

1.9

2.9

23.

41.

30.

95

4.7

1.0

1.7

C68

Oth

er u

rinar

y or

gans

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

69Ey

e5

1.9

0.7

0.8

00.

00.

00.

00

0.0

0.0

0.0

C70

-C72

Brai

n, N

ervo

us S

yste

m8

3.1

1.1

1.2

23.

41.

31.

73

2.8

0.6

0.4

C73

Thyr

oid

51.

90.

70.

90

0.0

0.0

0.0

10.

90.

20.

2C

74Ad

rena

l gla

nd0

0.0

0.0

0.0

11.

70.

70.

60

0.0

0.0

0.0

C75

Oth

er E

ndoc

rine

00.

00.

00.

01

1.7

0.7

0.5

00.

00.

00.

0C

81H

odgk

in D

isea

se9

3.5

1.3

1.1

23.

41.

32.

03

2.8

0.6

0.7

C82

-C85

; C96

Non

Hod

gkin

lym

phom

a23

8.9

3.3

4.0

35.

22.

03.

211

10.4

2.3

2.7

C88

Imm

unop

rolif

erat

ive

dis.

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

90M

ultip

le M

yelo

ma

41.

50.

61.

01

1.7

0.7

1.3

21.

90.

40.

9C

91Ly

mph

oid

Leuk

emia

155.

82.

12.

14

6.9

2.6

2.2

32.

80.

60.

5C

92-C

94M

yelo

id L

euke

mia

83.

11.

11.

11

1.7

0.7

0.6

54.

71.

01.

4C

95Le

ukem

ia u

nspe

c.0

0.0

0.0

0.0

11.

70.

70.

40

0.0

0.0

0.0

Oth

erO

ther

& u

nspe

cifie

d8

3.1

1.1

1.5

11.

70.

71.

03

2.8

0.6

0.7

All

All

Site

s

259

100.

036

.949

.858

100.

038

.645

.710

610

0.0

21.4

31.1

All

but C

44A

ll Si

tes

but C

4423

791

.533

.845

.856

96.6

37.3

44.4

102

96.2

20.6

30.0

Asi

r B

aha

Jaza

n

Part005.indd 76 15-04-2008 10:52:38 AM

77

Tabl

e 5.

2.1

cont

inue

d ...

......

ICD

(10t

h)A

LL S

ITES

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

Tot.

%

Cru

deA

SRC

00Li

p0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C01

-C02

Tong

ue1

0.5

0.2

0.2

00.

00.

00.

01

0.6

0.2

0.6

C03

-C06

Mou

th1

0.5

0.2

0.2

00.

00.

00.

00

0.0

0.0

0.0

C07

-C08

Saliv

ary

Gla

nds

00.

00.

00.

00

0.0

0.0

0.0

21.

20.

50.

7C

9To

nsil

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

10O

ther

oro

phar

ynx

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

11N

asop

hary

nx6

3.1

1.1

1.9

33.

91.

41.

65

3.1

1.2

1.9

C12

-C13

Hyp

opha

rynx

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

14Ph

aryn

x un

spec

.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C15

Oes

opha

gus

10.

50.

20.

50

0.0

0.0

0.0

63.

71.

52.

1C

16St

omac

h10

5.1

1.8

3.7

22.

60.

91.

09

5.5

2.2

3.6

C17

Smal

l int

estin

e0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C18

Col

on15

7.7

2.6

5.9

33.

91.

41.

79

5.5

2.2

3.4

C19

-C20

Rec

tum

105.

11.

83.

87

9.1

3.2

4.2

116.

72.

74.

8C

21An

us0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C22

Live

r16

8.2

2.8

4.8

911

.74.

16.

77

4.3

1.7

3.2

C23

-C24

Gal

l bla

dder

etc

.2

1.0

0.4

0.6

11.

30.

50.

82

1.2

0.5

0.6

C25

Panc

reas

21.

00.

40.

54

5.2

1.8

2.2

31.

80.

71.

3C

30-C

31N

ose,

sin

uses

, etc

.1

0.5

0.2

0.2

00.

00.

00.

00

0.0

0.0

0.0

C32

Lary

nx4

2.0

0.7

1.3

22.

60.

91.

20

0.0

0.0

0.0

C33

-C34

Trac

hea,

Bro

nchu

s, L

ung

126.

12.

13.

74

5.2

1.8

2.9

53.

11.

22.

1C

37-C

38O

ther

Tho

raci

c O

rgan

s1

0.5

0.2

0.3

11.

30.

50.

81

0.6

0.2

0.2

C40

-C41

Bone

63.

11.

10.

91

1.3

0.5

0.3

21.

20.

50.

4C

43M

elan

oma

of S

kin

00.

00.

00.

01

1.3

0.5

0.8

10.

60.

20.

3C

44O

ther

Ski

n4

2.0

0.7

1.3

33.

91.

42.

27

4.3

1.7

3.0

C45

Mes

othe

liom

a0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C46

Kapo

si s

arco

ma

00.

00.

00.

01

1.3

0.5

0.8

10.

60.

20.

6C

47; C

49C

onne

ctiv

e, S

oft T

issu

e2

1.0

0.4

0.3

11.

30.

50.

42

1.2

0.5

0.6

C50

Brea

st1

0.5

0.2

0.3

00.

00.

00.

00

0.0

0.0

0.0

C60

Peni

s0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C61

Pros

tate

115.

61.

93.

31

1.3

0.5

0.7

116.

72.

74.

7C

62Te

stis

21.

00.

40.

61

1.3

0.5

0.5

10.

60.

20.

4C

63O

ther

mal

e ge

nita

l0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C64

Kidn

ey4

2.0

0.7

1.5

22.

60.

91.

65

3.1

1.2

1.8

C65

Ren

al p

elvi

s3

1.5

0.5

1.1

00.

00.

00.

00

0.0

0.0

0.0

C66

Ure

ter

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

67Bl

adde

r13

6.6

2.3

4.6

45.

21.

82.

04

2.5

1.0

1.7

C68

Oth

er u

rinar

y or

gans

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

69Ey

e1

0.5

0.2

0.4

00.

00.

00.

01

0.6

0.2

0.6

C70

-C72

Brai

n, N

ervo

us S

yste

m14

7.1

2.5

2.6

45.

21.

81.

85

3.1

1.2

1.4

C73

Thyr

oid

00.

00.

00.

05

6.5

2.3

3.7

63.

71.

52.

4C

74Ad

rena

l gla

nd0

0.0

0.0

0.0

11.

30.

50.

40

0.0

0.0

0.0

C75

Oth

er E

ndoc

rine

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

81H

odgk

in D

isea

se11

5.6

1.9

2.1

56.

52.

32.

610

6.1

2.5

2.5

C82

-C85

; C96

Non

Hod

gkin

lym

phom

a20

10.2

3.5

4.6

56.

52.

32.

619

11.7

4.7

5.4

C88

Imm

unop

rolif

erat

ive

dis.

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

90M

ultip

le M

yelo

ma

21.

00.

40.

81

1.3

0.5

0.6

10.

60.

20.

4C

91Ly

mph

oid

Leuk

emia

52.

60.

90.

70

0.0

0.0

0.0

74.

31.

72.

1C

92-C

94M

yelo

id L

euke

mia

73.

61.

21.

30

0.0

0.0

0.0

106.

12.

53.

1C

95Le

ukem

ia u

nspe

c.1

0.5

0.2

0.1

00.

00.

00.

00

0.0

0.0

0.0

Oth

erO

ther

& u

nspe

cifie

d7

3.6

1.2

1.7

56.

52.

33.

29

5.5

2.2

4.2

All

All

Site

s

196

100.

034

.955

.877

100.

035

.647

.316

310

0.0

39.7

60.1

All

but C

44A

ll Si

tes

but C

4419

298

.034

.254

.574

96.1

34.2

45.1

156

95.7

38.0

57.1

Mad

inah

H

ail

Qas

sim

Part005.indd 77 15-04-2008 10:52:40 AM

78

Tabl

e 5.

2.1

cont

inue

d ...

......

ICD

(10t

h)A

LL S

ITES

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

C00

Lip

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C01

-C02

Tong

ue2

3.4

1.2

3.1

00.

00.

00.

00

0.0

0.0

0.0

26.

11.

73.

6C

03-C

06M

outh

11.

70.

61.

60

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C07

-C08

Saliv

ary

Gla

nds

00.

00.

00.

00

0.0

0.0

0.0

10.

90.

30.

30

0.0

0.0

0.0

C9

Tons

il0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

10O

ther

oro

phar

ynx

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C11

Nas

opha

rynx

11.

70.

60.

53

5.5

1.9

2.7

10.

90.

30.

81

3.0

0.8

1.8

C12

-C13

Hyp

opha

rynx

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C14

Phar

ynx

unsp

ec.

00.

00.

00.

01

1.8

0.6

0.7

00.

00.

00.

00

0.0

0.0

0.0

C15

Oes

opha

gus

23.

41.

22.

81

1.8

0.6

1.9

32.

61.

02.

70

0.0

0.0

0.0

C16

Stom

ach

23.

41.

21.

91

1.8

0.6

1.2

21.

80.

71.

51

3.0

0.8

2.2

C17

Smal

l int

estin

e0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

13.

00.

80.

8C

18C

olon

11.

70.

61.

25

9.1

3.2

6.1

54.

41.

64.

72

6.1

1.7

3.9

C19

-C20

Rec

tum

11.

70.

61.

70

0.0

0.0

0.0

65.

32.

05.

53

9.1

2.5

6.9

C21

Anus

00.

00.

00.

00

0.0

0.0

0.0

10.

90.

31.

21

3.0

0.8

2.2

C22

Live

r1

1.7

0.6

0.5

11.

80.

60.

610

8.8

3.3

10.1

00.

00.

00.

0C

23-C

24G

all b

ladd

er, e

tc.

00.

00.

00.

00

0.0

0.0

0.0

21.

80.

72.

01

3.0

0.8

2.5

C25

Panc

reas

11.

70.

61.

72

3.6

1.3

3.4

00.

00.

00.

00

0.0

0.0

0.0

C30

-C31

Nos

e, s

inus

es, e

tc.

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C32

Lary

nx1

1.7

0.6

1.5

23.

61.

33.

63

2.6

1.0

3.2

00.

00.

00.

0C

33-C

34Tr

ache

a, B

ronc

hus,

Lun

g2

3.4

1.2

1.7

47.

32.

65.

38

7.0

2.6

7.4

00.

00.

00.

0C

37-C

38O

ther

Tho

raci

c O

rgan

s0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

40-C

41Bo

ne2

3.4

1.2

1.0

11.

80.

60.

52

1.8

0.7

1.0

00.

00.

00.

0C

43M

elan

oma

of S

kin

00.

00.

00.

00

0.0

0.0

0.0

10.

90.

30.

80

0.0

0.0

0.0

C44

Oth

er S

kin

712

.14.

07.

53

5.5

1.9

2.7

54.

41.

64.

11

3.0

0.8

1.8

C45

Mes

othe

liom

a0

0.0

0.0

0.0

00.

00.

00.

01

0.9

0.3

1.0

13.

00.

81.

6C

46Ka

posi

sar

com

a0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

47; C

49C

onne

ctiv

e, S

oft T

issu

e0

0.0

0.0

0.0

11.

80.

60.

54

3.5

1.3

2.2

00.

00.

00.

0C

50Br

east

00.

00.

00.

00

0.0

0.0

0.0

10.

90.

31.

20

0.0

0.0

0.0

C60

Peni

s0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

13.

00.

81.

9C

61Pr

osta

te0

0.0

0.0

0.0

11.

80.

61.

43

2.6

1.0

2.6

13.

00.

82.

0C

62Te

stis

23.

41.

21.

11

1.8

0.6

0.7

00.

00.

00.

00

0.0

0.0

0.0

C63

Oth

er m

ale

geni

tal

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

01

3.0

0.8

2.5

C64

Kidn

ey3

5.2

1.7

2.9

35.

51.

93.

14

3.5

1.3

2.8

00.

00.

00.

0C

65R

enal

pel

vis

00.

00.

00.

00

0.0

0.0

0.0

10.

90.

31.

20

0.0

0.0

0.0

C66

Ure

ter

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C67

Blad

der

23.

41.

22.

44

7.3

2.6

6.0

119.

63.

68.

91

3.0

0.8

2.5

C68

Oth

er u

rinar

y or

gans

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C69

Eye

00.

00.

00.

00

0.0

0.0

0.0

10.

90.

30.

31

3.0

0.8

0.7

C70

-C72

Brai

n, N

ervo

us S

yste

m1

1.7

0.6

0.5

23.

61.

31.

06

5.3

2.0

3.0

13.

00.

82.

2C

73Th

yroi

d1

1.7

0.6

0.9

47.

32.

66.

72

1.8

0.7

1.0

00.

00.

00.

0C

74Ad

rena

l gla

nd0

0.0

0.0

0.0

11.

80.

60.

60

0.0

0.0

0.0

00.

00.

00.

0C

75O

ther

End

ocrin

e0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

81H

odgk

in D

isea

se5

8.6

2.9

3.3

11.

80.

60.

47

6.1

2.3

3.8

515

.24.

23.

8C

82-C

85; C

96N

on H

odgk

in ly

mph

oma

915

.55.

27.

47

12.7

4.5

6.2

76.

12.

32.

61

3.0

0.8

0.5

C88

Imm

unop

rolif

erat

ive

dis.

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C90

Mul

tiple

Mye

lom

a3

5.2

1.7

4.1

00.

00.

00.

01

0.9

0.3

1.2

13.

00.

82.

2C

91Ly

mph

oid

Leuk

emia

23.

41.

21.

63

5.5

1.9

2.6

54.

41.

63.

61

3.0

0.8

1.7

C92

-C94

Mye

loid

Leu

kem

ia3

5.2

1.7

3.3

00.

00.

00.

04

3.5

1.3

1.3

26.

11.

71.

4C

95Le

ukem

ia u

nspe

c.1

1.7

0.6

1.2

00.

00.

00.

01

0.9

0.3

0.3

00.

00.

00.

0O

ther

Oth

er &

uns

peci

fied

23.

41.

22.

13

5.5

1.9

3.1

54.

41.

62.

83

9.1

2.5

5.7

All

All

Site

s

5810

0.0

34.0

57.5

5510

0.0

34.9

61.0

114

100.

037

.285

.133

100.

027

.154

.4A

ll bu

t C44

All

Site

s bu

t C44

5187

.930

.050

.052

94.5

33.0

58.3

109

95.6

35.6

81.0

3297

.026

.352

.6

Naj

ran

Jouf

Ta

buk

Nor

ther

n

Part005.indd 78 15-04-2008 10:52:42 AM

79

Tabl

e 5.

2.1

cont

inue

d ...

......

ICD

(10t

h)A

LL S

ITES

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

Tot.

%

Cru

deA

SRC

00Li

p2

0.2

0.1

0.2

40.

50.

20.

42

0.4

0.2

0.4

C01

-C02

Tong

ue6

0.7

0.3

0.8

40.

50.

20.

44

0.7

0.3

0.3

C03

-C06

Mou

th6

0.7

0.3

0.5

101.

20.

60.

83

0.5

0.2

0.6

C07

-C08

Saliv

ary

Gla

nds

20.

20.

10.

24

0.5

0.2

0.3

20.

40.

20.

1C

9To

nsil

00.

00.

00.

02

0.2

0.1

0.2

00.

00.

00.

0C

10O

ther

oro

phar

ynx

00.

00.

00.

02

0.2

0.1

0.2

00.

00.

00.

0C

11N

asop

hary

nx27

3.0

1.4

2.3

242.

81.

31.

816

2.8

1.2

2.8

C12

-C13

Hyp

opha

rynx

00.

00.

00.

02

0.2

0.1

0.3

30.

50.

20.

4C

14Ph

aryn

x un

spec

.0

0.0

0.0

0.0

20.

20.

10.

21

0.2

0.1

0.2

C15

Oes

opha

gus

131.

50.

71.

69

1.0

0.5

0.8

71.

20.

51.

6C

16St

omac

h34

3.8

1.8

4.0

424.

82.

33.

917

3.0

1.3

3.4

C17

Smal

l int

estin

e7

0.8

0.4

0.7

30.

30.

20.

25

0.9

0.4

1.1

C18

Col

on43

4.8

2.3

4.3

596.

83.

35.

524

4.2

1.8

4.6

C19

-C20

Rec

tum

444.

92.

35.

340

4.6

2.2

3.8

305.

32.

36.

0C

21An

us3

0.3

0.2

0.4

50.

60.

30.

46

1.1

0.5

1.1

C22

Live

r99

11.1

5.2

12.4

424.

82.

34.

323

4.1

1.8

4.0

C23

-C24

Gal

l bla

dder

, etc

.3

0.3

0.2

0.3

80.

90.

40.

92

0.4

0.2

0.4

C25

Panc

reas

182.

00.

92.

225

2.9

1.4

2.5

101.

80.

81.

9C

30-C

31N

ose,

sin

uses

, etc

.1

0.1

0.1

0.0

30.

30.

20.

32

0.4

0.2

0.4

C32

Lary

nx8

0.9

0.4

1.0

151.

70.

81.

69

1.6

0.7

2.0

C33

-C34

Trac

hea,

Bro

nchu

s, L

ung

465.

22.

45.

380

9.2

4.4

8.2

5710

.14.

311

.2C

37-C

38O

ther

Tho

raci

c O

rgan

s3

0.3

0.2

0.2

20.

20.

10.

23

0.5

0.2

0.5

C40

-C41

Bone

131.

50.

70.

513

1.5

0.7

0.7

111.

90.

80.

7C

43M

elan

oma

of S

kin

40.

40.

20.

51

0.1

0.1

0.1

10.

20.

10.

3C

44O

ther

Ski

n30

3.4

1.6

3.6

273.

11.

52.

616

2.8

1.2

2.6

C45

Mes

othe

liom

a0

0.0

0.0

0.0

20.

20.

10.

22

0.4

0.2

0.3

C46

Kapo

si s

arco

ma

40.

40.

20.

45

0.6

0.3

0.4

20.

40.

20.

4C

47; C

49C

onne

ctiv

e, S

oft T

issu

e11

1.2

0.6

0.6

172.

00.

91.

212

2.1

0.9

0.9

C50

Brea

st6

0.7

0.3

0.6

20.

20.

10.

24

0.7

0.3

0.4

C60

Peni

s2

0.2

0.1

0.3

00.

00.

00.

00

0.0

0.0

0.0

C61

Pros

tate

525.

82.

76.

758

6.7

3.2

5.7

437.

63.

39.

3C

62Te

stis

101.

10.

50.

514

1.6

0.8

0.8

101.

80.

80.

8C

63O

ther

mal

e ge

nita

l1

0.1

0.1

0.0

00.

00.

00.

00

0.0

0.0

0.0

C64

Kidn

ey30

3.4

1.6

2.7

404.

62.

23.

719

3.4

1.4

2.9

C65

Ren

al p

elvi

s1

0.1

0.1

0.1

20.

20.

10.

21

0.2

0.1

0.2

C66

Ure

ter

00.

00.

00.

01

0.1

0.1

0.1

00.

00.

00.

0C

67Bl

adde

r34

3.8

1.8

3.7

445.

12.

44.

423

4.1

1.8

4.7

C68

Oth

er u

rinar

y or

gans

10.

10.

10.

10

0.0

0.0

0.0

00.

00.

00.

0C

69Ey

e4

0.4

0.2

0.4

30.

30.

20.

33

0.5

0.2

0.3

C70

-C72

Brai

n, N

ervo

us S

yste

m48

5.4

2.5

3.5

273.

11.

51.

824

4.2

1.8

3.9

C73

Thyr

oid

273.

01.

42.

214

1.6

0.8

1.0

223.

91.

72.

6C

74Ad

rena

l gla

nd2

0.2

0.1

0.1

00.

00.

00.

00

0.0

0.0

0.0

C75

Oth

er E

ndoc

rine

10.

10.

10.

00

0.0

0.0

0.0

10.

20.

10.

1C

81H

odgk

in D

isea

se39

4.4

2.0

2.0

354.

01.

92.

234

6.0

2.6

2.6

C82

-C85

; C96

Non

Hod

gkin

lym

phom

a87

9.7

4.6

8.0

869.

94.

87.

054

9.5

4.1

6.8

C88

Imm

unop

rolif

erat

ive

dis.

10.

10.

10.

10

0.0

0.0

0.0

00.

00.

00.

0C

90M

ultip

le M

yelo

ma

80.

90.

40.

99

1.0

0.5

0.8

40.

70.

30.

9C

91Ly

mph

oid

Leuk

aem

ia40

4.5

2.1

2.4

293.

31.

61.

714

2.5

1.1

1.7

C92

-C94

Mye

loid

Leu

kaem

ia28

3.1

1.5

2.3

161.

80.

91.

218

3.2

1.4

1.6

C95

Leuk

aem

ia u

nspe

c.2

0.2

0.1

0.1

30.

30.

20.

22

0.4

0.2

0.2

Oth

erO

ther

& u

nspe

cifie

d42

4.7

2.2

5.2

333.

81.

83.

220

3.5

1.5

3.4

All

All

Site

s

893

100.

047

.289

.286

810

0.0

48.0

76.9

566

100.

043

.590

.6A

ll bu

t C44

All

Site

s bu

t C44

863

96.6

45.6

85.6

841

96.9

46.5

74.3

550

97.2

42.3

88.0

Riy

adh

M

akka

h

East

ern

Prov

ince

Part005.indd 79 15-04-2008 10:52:43 AM

80

Tabl

e 5.

2.2

Num

ber,

Rel

ativ

e Fr

eque

ncie

s, A

ge S

tand

ardi

zed

and

Cru

de R

ates

for A

ll C

ance

r C

ases

Am

ong

Saud

i Fem

ales

by

Site

and

Reg

ion,

200

4

ICD

(10t

h)A

LL S

ITES

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

Tot.

%

Cru

deA

SRC

00Li

p0

0.0

0.0

0.0

00.

00.

00.

03

2.8

0.6

1.2

C01

-C02

Tong

ue2

0.8

0.3

0.5

22.

71.

12.

010

9.2

2.0

3.3

C03

-C06

Mou

th2

0.8

0.3

0.3

11.

40.

60.

56

5.5

1.2

2.0

C07

-C08

Saliv

ary

Gla

nds

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

9To

nsil

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

10O

ther

oro

phar

ynx

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

11N

asop

hary

nx4

1.7

0.5

0.9

00.

00.

00.

03

2.8

0.6

0.8

C12

-C13

Hyp

opha

rynx

31.

20.

40.

80

0.0

0.0

0.0

10.

90.

20.

2C

14Ph

aryn

x un

spec

.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C15

Oes

opha

gus

31.

20.

40.

42

2.7

1.1

1.7

10.

90.

20.

2C

16St

omac

h11

4.5

1.5

2.5

34.

11.

72.

02

1.8

0.4

0.5

C17

Smal

l int

estin

e0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C18

Col

on19

7.9

2.6

4.1

34.

11.

72.

03

2.8

0.6

1.0

C19

-C20

Rec

tum

166.

62.

23.

60

0.0

0.0

0.0

10.

90.

20.

2C

21An

us0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C22

Live

r8

3.3

1.1

1.8

11.

40.

60.

63

2.8

0.6

1.0

C23

-C24

Gal

l bla

dder

, etc

.4

1.7

0.5

1.0

00.

00.

00.

02

1.8

0.4

0.7

C25

Panc

reas

20.

80.

30.

31

1.4

0.6

0.7

00.

00.

00.

0C

30-C

31N

ose,

sin

uses

, etc

.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C32

Lary

nx0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C33

-C34

Trac

hea,

Bro

nchu

s, L

ung

31.

20.

40.

50

0.0

0.0

0.0

10.

90.

20.

4C

37-C

38O

ther

Tho

raci

c O

rgan

s0

0.0

0.0

0.0

11.

40.

60.

60

0.0

0.0

0.0

C40

-C41

Bone

20.

80.

30.

20

0.0

0.0

0.0

10.

90.

20.

1C

43M

elan

oma

of S

kin

10.

40.

10.

11

1.4

0.6

0.7

00.

00.

00.

0C

44O

ther

Ski

n11

4.5

1.5

2.0

34.

11.

72.

08

7.3

1.6

2.4

C45

Mes

othe

liom

a0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C46

Kapo

si s

arco

ma

10.

40.

10.

10

0.0

0.0

0.0

00.

00.

00.

0C

47; C

49C

onne

ctiv

e, S

oft T

issu

e3

1.2

0.4

0.4

00.

00.

00.

01

0.9

0.2

0.1

C51

Fem

ale

Brea

st27

11.2

3.7

5.7

1520

.58.

511

.320

18.3

3.9

6.3

C52

Vulv

a2

0.8

0.3

0.4

11.

40.

60.

60

0.0

0.0

0.0

C53

Vagi

na0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C54

Cer

vix

Ute

ri3

1.2

0.4

0.7

34.

11.

72.

62

1.8

0.4

0.6

C55

Cor

pus

Ute

ri10

4.1

1.4

2.5

34.

11.

72.

81

0.9

0.2

0.3

C56

Ute

rus

Uns

pec.

10.

40.

10.

30

0.0

0.0

0.0

00.

00.

00.

0C

57O

vary

.3

1.2

0.4

0.5

34.

11.

72.

94

3.7

0.8

1.3

C58

Oth

er F

emal

e G

enita

l0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C64

Plac

enta

00.

00.

00.

01

1.4

0.6

1.0

21.

80.

40.

3C

64Ki

dney

52.

10.

70.

91

1.4

0.6

0.6

10.

90.

20.

2C

65R

enal

pel

vis

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

66U

rete

r0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C67

Blad

der

62.

50.

81.

51

1.4

0.6

1.0

43.

70.

81.

4C

68O

ther

urin

ary

orga

ns0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C69

Eye

20.

80.

30.

40

0.0

0.0

0.0

00.

00.

00.

0C

70-C

72Br

ain,

Ner

vous

Sys

tem

41.

70.

50.

52

2.7

1.1

1.3

21.

80.

40.

3C

73Th

yroi

d25

10.3

3.4

4.9

56.

82.

83.

48

7.3

1.6

2.3

C74

Adre

nal g

land

10.

40.

10.

11

1.4

0.6

0.6

10.

90.

20.

2C

75O

ther

End

ocrin

e0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C81

Hod

gkin

Dis

ease

72.

90.

91.

01

1.4

0.6

0.4

10.

90.

20.

2C

82-C

85; C

96N

on H

odgk

in ly

mph

oma

197.

92.

63.

58

11.0

4.6

4.5

98.

31.

82.

7C

88Im

mun

opro

lifer

ativ

e di

s.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C90

Mul

tiple

Mye

lom

a1

0.4

0.1

0.3

00.

00.

00.

01

0.9

0.2

0.3

C91

Lym

phoi

d Le

ukem

ia6

2.5

0.8

0.8

11.

40.

60.

61

0.9

0.2

0.1

C92

-C94

Mye

loid

Leu

kem

ia5

2.1

0.7

0.8

22.

71.

11.

33

2.8

0.6

0.6

C95

Leuk

emia

uns

pec.

31.

20.

40.

40

0.0

0.0

0.0

00.

00.

00.

0O

ther

Oth

er &

uns

peci

fied

177.

02.

33.

67

9.6

4.0

4.3

32.

80.

60.

8A

llA

ll Si

tes

24

210

0.0

32.8

48.3

7310

0.0

41.7

52.0

109

100.

021

.732

.0A

ll bu

t C44

All

Site

s bu

t C44

231

95.5

31.3

46.3

7095

.940

.050

.010

192

.720

.129

.6

Asi

r

Bah

a

Jaza

n

Part005.indd 80 15-04-2008 10:52:45 AM

81

Tabl

e 5.

2.2

cont

inue

d ...

......

ICD

(10t

h)A

LL S

ITES

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

Tot.

%

Cru

deA

SRC

00Li

p1

0.5

0.2

0.4

00.

00.

00.

00

0.0

0.0

0.0

C01

-C02

Tong

ue0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C03

-C06

Mou

th2

0.9

0.3

0.7

00.

00.

00.

00

0.0

0.0

0.0

C07

-C08

Saliv

ary

Gla

nds

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

9To

nsil

10.

50.

20.

30

0.0

0.0

0.0

00.

00.

00.

0C

10O

ther

oro

phar

ynx

00.

00.

00.

00

0.0

0.0

0.0

10.

70.

20.

6C

11N

asop

hary

nx4

1.9

0.7

1.2

00.

00.

00.

04

3.0

1.0

1.7

C12

-C13

Hyp

opha

rynx

10.

50.

20.

30

0.0

0.0

0.0

32.

20.

71.

6C

14Ph

aryn

x un

spec

.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C15

Oes

opha

gus

115.

21.

94.

00

0.0

0.0

0.0

43.

01.

01.

8C

16St

omac

h9

4.2

1.6

2.9

00.

00.

00.

04

3.0

1.0

1.7

C17

Smal

l int

estin

e1

0.5

0.2

0.4

00.

00.

00.

01

0.7

0.2

0.5

C18

Col

on10

4.7

1.7

3.1

34.

51.

32.

05

3.7

1.2

2.6

C19

-C20

Rec

tum

41.

90.

71.

43

4.5

1.3

1.6

53.

71.

22.

1C

21An

us0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C22

Live

r8

3.8

1.4

2.6

00.

00.

00.

01

0.7

0.2

0.5

C23

-C24

Gal

l bla

dder

, etc

.0

0.0

0.0

0.0

00.

00.

00.

03

2.2

0.7

1.1

C25

Panc

reas

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

30-C

31N

ose,

sin

uses

, etc

.0

0.0

0.0

0.0

00.

00.

00.

01

0.7

0.2

0.2

C32

Lary

nx0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C33

-C34

Trac

hea,

Bro

nchu

s, L

ung

41.

90.

71.

40

0.0

0.0

0.0

10.

70.

20.

4C

37-C

38O

ther

Tho

raci

c O

rgan

s0

0.0

0.0

0.0

11.

50.

40.

41

0.7

0.2

0.3

C40

-C41

Bone

20.

90.

30.

33

4.5

1.3

1.5

21.

50.

50.

4C

43M

elan

oma

of S

kin

10.

50.

20.

40

0.0

0.0

0.0

21.

50.

50.

7C

44O

ther

Ski

n8

3.8

1.4

2.1

23.

00.

91.

57

5.2

1.7

3.2

C45

Mes

othe

liom

a0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C46

Kapo

si s

arco

ma

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

47; C

49C

onne

ctiv

e, S

oft T

issu

e6

2.8

1.0

1.4

23.

00.

91.

32

1.5

0.5

0.8

C51

Fem

ale

Brea

st36

17.0

6.2

10.6

1420

.96.

09.

034

25.4

8.3

12.6

C52

Vulv

a0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C53

Vagi

na0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C54

Cer

vix

Ute

ri9

4.2

1.6

3.4

23.

00.

91.

52

1.5

0.5

0.9

C55

Cor

pus

Ute

ri9

4.2

1.6

3.2

23.

00.

91.

31

0.7

0.2

0.5

C56

Ute

rus

Uns

pec.

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

57O

vary

.7

3.3

1.2

1.9

23.

00.

91.

53

2.2

0.7

1.1

C58

Oth

er F

emal

e G

enita

l0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C64

Plac

enta

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

64Ki

dney

41.

90.

71.

21

1.5

0.4

0.4

32.

20.

71.

6C

65R

enal

pel

vis

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

66U

rete

r0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C67

Blad

der

10.

50.

20.

41

1.5

0.4

0.6

10.

70.

20.

5C

68O

ther

urin

ary

orga

ns0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C69

Eye

10.

50.

20.

10

0.0

0.0

0.0

10.

70.

20.

6C

70-C

72Br

ain,

Ner

vous

Sys

tem

115.

21.

92.

46

9.0

2.6

2.0

32.

20.

70.

8C

73Th

yroi

d9

4.2

1.6

1.8

69.

02.

63.

012

9.0

2.9

3.4

C74

Adre

nal g

land

31.

40.

50.

50

0.0

0.0

0.0

00.

00.

00.

0C

75O

ther

End

ocrin

e1

0.5

0.2

0.2

00.

00.

00.

00

0.0

0.0

0.0

C81

Hod

gkin

Dis

ease

104.

71.

71.

72

3.0

0.9

0.6

10.

70.

20.

3C

82-C

85; C

96N

on H

odgk

in ly

mph

oma

146.

62.

44.

25

7.5

2.2

2.2

118.

22.

73.

1C

88Im

mun

opro

lifer

ativ

e di

s.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C90

Mul

tiple

Mye

lom

a1

0.5

0.2

0.3

00.

00.

00.

01

0.7

0.2

0.4

C91

Lym

phoi

d Le

ukem

ia6

2.8

1.0

0.8

23.

00.

90.

73

2.2

0.7

0.9

C92

-C94

Mye

loid

Leu

kem

ia8

3.8

1.4

1.6

34.

51.

32.

49

6.7

2.2

3.0

C95

Leuk

emia

uns

pec.

00.

00.

00.

00

0.0

0.0

0.0

21.

50.

50.

4O

ther

Oth

er &

uns

peci

fied

94.

21.

62.

77

10.4

3.0

4.9

00.

00.

00.

0A

llA

ll Si

tes

21

210

0.0

36.9

59.9

6710

0.0

29.1

38.4

134

100.

032

.150

.3A

ll bu

t C44

All

Site

s bu

t C44

204

96.2

35.5

57.8

6597

.028

.236

.912

794

.830

.447

.1

Mad

inah

H

ail

Q

assi

m

Part005.indd 81 15-04-2008 10:52:47 AM

82

Tabl

e 5.

2.2

cont

inue

d ...

......

ICD

(10t

h)A

LL S

ITES

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

C00

Lip

00.

00.

00.

01

1.8

0.6

1.7

00.

00.

00.

00

0.0

0.0

0.0

C01

-C02

Tong

ue1

2.7

0.6

1.5

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

03-C

06M

outh

12.

70.

60.

90

0.0

0.0

0.0

11.

00.

30.

61

1.0

0.3

0.6

C07

-C08

Saliv

ary

Gla

nds

00.

00.

00.

02

3.6

1.3

3.3

00.

00.

00.

00

0.0

0.0

0.0

C9

Tons

il0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

10O

ther

oro

phar

ynx

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C11

Nas

opha

rynx

00.

00.

00.

01

1.8

0.6

1.5

11.

00.

30.

91

1.0

0.3

0.9

C12

-C13

Hyp

opha

rynx

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C14

Phar

ynx

unsp

ec.

12.

70.

61.

70

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C15

Oes

opha

gus

00.

00.

00.

00

0.0

0.0

0.0

55.

11.

73.

75

5.1

1.7

3.7

C16

Stom

ach

12.

70.

60.

51

1.8

0.6

1.7

55.

11.

75.

05

5.1

1.7

5.0

C17

Smal

l int

estin

e0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

18C

olon

12.

70.

60.

70

0.0

0.0

0.0

66.

12.

15.

26

6.1

2.1

5.2

C19

-C20

Rec

tum

00.

00.

00.

01

1.8

0.6

1.5

11.

00.

30.

91

1.0

0.3

0.9

C21

Anus

12.

70.

60.

40

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C22

Live

r0

0.0

0.0

0.0

00.

00.

00.

01

1.0

0.3

0.9

11.

00.

30.

9C

23-C

24G

all b

ladd

er e

tc3

8.1

1.7

3.1

23.

61.

32.

90

0.0

0.0

0.0

00.

00.

00.

0C

25Pa

ncre

as0

0.0

0.0

0.0

00.

00.

00.

01

1.0

0.3

0.9

11.

00.

30.

9C

30-C

31N

ose,

sin

uses

, etc

.1

2.7

0.6

1.4

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

32La

rynx

00.

00.

00.

01

1.8

0.6

1.7

00.

00.

00.

00

0.0

0.0

0.0

C33

-C34

Trac

hea,

Bro

nchu

s, L

ung

00.

00.

00.

02

3.6

1.3

3.0

00.

00.

00.

00

0.0

0.0

0.0

C37

-C38

Oth

er T

hora

cic

Org

ans

00.

00.

00.

00

0.0

0.0

0.0

11.

00.

30.

91

1.0

0.3

0.9

C40

-C41

Bone

12.

70.

60.

40

0.0

0.0

0.0

11.

00.

30.

21

1.0

0.3

0.2

C43

Mel

anom

a of

Ski

n0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

44O

ther

Ski

n2

5.4

1.1

2.0

35.

51.

94.

71

1.0

0.3

0.4

11.

00.

30.

4C

45M

esot

helio

ma

00.

00.

00.

00

0.0

0.0

0.0

11.

00.

30.

91

1.0

0.3

0.9

C46

Kapo

si s

arco

ma

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C47

; C49

Con

nect

ive,

Sof

t Tis

sue

38.

11.

72.

51

1.8

0.6

1.7

33.

01.

02.

13

3.0

1.0

2.1

C51

Fem

ale

Brea

st2

5.4

1.1

2.2

1629

.110

.417

.518

18.2

6.2

11.7

1818

.26.

211

.7C

52Vu

lva

00.

00.

00.

01

1.8

0.6

1.6

00.

00.

00.

00

0.0

0.0

0.0

C53

Vagi

na0

0.0

0.0

0.0

00.

00.

00.

01

1.0

0.3

0.3

11.

00.

30.

3C

54C

ervi

x U

teri

00.

00.

00.

00

0.0

0.0

0.0

22.

00.

70.

82

2.0

0.7

0.8

C55

Cor

pus

Ute

ri0

0.0

0.0

0.0

35.

51.

94.

04

4.0

1.4

3.1

44.

01.

43.

1C

56U

teru

s U

nspe

c.0

0.0

0.0

0.0

11.

80.

61.

50

0.0

0.0

0.0

00.

00.

00.

0C

57O

vary

.1

2.7

0.6

1.0

11.

80.

61.

54

4.0

1.4

3.7

44.

01.

43.

7C

58O

ther

Fem

ale

Gen

ital

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C64

Plac

enta

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C64

Kidn

ey1

2.7

0.6

0.7

11.

80.

61.

73

3.0

1.0

1.5

33.

01.

01.

5C

65R

enal

pel

vis

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C66

Ure

ter

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C67

Blad

der

00.

00.

00.

00

0.0

0.0

0.0

22.

00.

72.

02

2.0

0.7

2.0

C68

Oth

er u

rinar

y or

gans

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C69

Eye

00.

00.

00.

00

0.0

0.0

0.0

11.

00.

30.

31

1.0

0.3

0.3

C70

-C72

Brai

n, N

ervo

us S

yste

m1

2.7

0.6

0.4

23.

61.

31.

68

8.1

2.8

4.8

88.

12.

84.

8C

73Th

yroi

d4

10.8

2.3

2.9

23.

61.

32.

24

4.0

1.4

2.2

44.

01.

42.

2C

74Ad

rena

l gla

nd2

5.4

1.1

0.9

00.

00.

00.

01

1.0

0.3

0.3

11.

00.

30.

3C

75O

ther

End

ocrin

e0

0.0

0.0

0.0

00.

00.

00.

01

1.0

0.3

0.2

11.

00.

30.

2C

81H

odgk

in D

isea

se2

5.4

1.1

1.1

23.

61.

30.

93

3.0

1.0

0.8

33.

01.

00.

8C

82-C

85; C

96N

on H

odgk

in ly

mph

oma

12.

70.

61.

43

5.5

1.9

3.9

66.

12.

13.

46

6.1

2.1

3.4

C88

Imm

unop

rolif

erat

ive

dis.

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C90

Mul

tiple

Mye

lom

a0

0.0

0.0

0.0

11.

80.

61.

71

1.0

0.3

0.9

11.

00.

30.

9C

91Ly

mph

oid

Leuk

emia

12.

70.

60.

44

7.3

2.6

3.9

44.

01.

41.

14

4.0

1.4

1.1

C92

-C94

Mye

loid

Leu

kem

ia4

10.8

2.3

3.5

11.

80.

60.

54

4.0

1.4

2.0

44.

01.

42.

0C

95Le

ukem

ia u

nspe

c.1

2.7

0.6

1.3

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0O

ther

Oth

er &

uns

peci

fied

12.

70.

60.

72

3.6

1.3

2.8

44.

01.

43.

04

4.0

1.4

3.0

All

All

Site

s

3710

021

.431

.655

100

3569

9910

033

.664

.799

100

33.6

64.7

All

but C

44A

ll Si

tes

but C

4435

94.6

20.3

29.6

5294

.533

.164

.398

99.0

33.3

64.3

9899

.033

.364

.3

Naj

ran

Jo

uf

Tabu

k

Nor

ther

n R

egio

n

Part005.indd 82 15-04-2008 10:52:49 AM

83

Tabl

e 5.

2.2

cont

inue

d ...

......

ICD

(10t

h)A

LL S

ITES

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

Tot.

%

Cru

de

ASR

C00

Lip

00.

00.

00.

01

0.1

0.1

0.1

00.

00.

00.

0C

01-C

02To

ngue

40.

40.

20.

58

1.0

0.4

0.6

30.

50.

20.

5C

03-C

06M

outh

40.

40.

20.

63

0.4

0.2

0.3

10.

20.

10.

2C

07-C

08Sa

livar

y G

land

s3

0.3

0.2

0.3

20.

20.

10.

22

0.3

0.2

0.4

C9

Tons

il0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C10

Oth

er o

roph

aryn

x0

0.0

0.0

0.0

10.

10.

10.

10

0.0

0.0

0.0

C11

Nas

opha

rynx

141.

50.

81.

27

0.8

0.4

0.6

61.

00.

51.

0C

12-C

13H

ypop

hary

nx5

0.5

0.3

0.5

00.

00.

00.

03

0.5

0.2

0.7

C14

Phar

ynx

unsp

ec.

00.

00.

00.

00

0.0

0.0

0.0

20.

30.

20.

3C

15O

esop

hagu

s11

1.2

0.6

1.6

111.

30.

60.

93

0.5

0.2

0.5

C16

Stom

ach

131.

40.

71.

511

1.3

0.6

1.1

101.

70.

81.

7C

17Sm

all i

ntes

tine

40.

40.

20.

55

0.6

0.3

0.5

20.

30.

20.

3C

18C

olon

515.

42.

86.

139

4.7

2.2

3.8

315.

12.

54.

9C

19-C

20R

ectu

m31

3.3

1.7

3.5

182.

21.

01.

725

4.1

2.0

4.1

C21

Anus

20.

20.

10.

20

0.0

0.0

0.0

10.

20.

10.

2C

22Li

ver

373.

92.

04.

917

2.0

0.9

1.6

152.

51.

23.

1C

23-C

24G

all b

ladd

er e

tc.

192.

01.

02.

411

1.3

0.6

1.1

50.

80.

40.

9C

25Pa

ncre

as13

1.4

0.7

1.7

70.

80.

40.

84

0.7

0.3

0.7

C30

-C31

Nos

e, s

inus

es, e

tc.

00.

00.

00.

02

0.2

0.1

0.1

10.

20.

10.

2C

32La

rynx

30.

30.

20.

40

0.0

0.0

0.0

00.

00.

00.

0C

33-C

34Tr

ache

a, B

ronc

hus,

Lun

g9

0.9

0.5

0.9

232.

71.

32.

520

3.3

1.6

4.0

C37

-C38

Oth

er T

hora

cic

Org

ans

20.

20.

10.

31

0.1

0.1

0.1

30.

50.

20.

7C

40-C

41Bo

ne12

1.3

0.7

0.7

60.

70.

30.

37

1.2

0.6

0.5

C43

Mel

anom

a of

Ski

n3

0.3

0.2

0.4

20.

20.

10.

22

0.3

0.2

0.3

C44

Oth

er S

kin

262.

71.

43.

231

3.7

1.7

3.2

183.

01.

43.

1C

45M

esot

helio

ma

20.

20.

10.

21

0.1

0.1

0.1

00.

00.

00.

0C

46Ka

posi

sar

com

a3

0.3

0.2

0.3

10.

10.

10.

11

0.2

0.1

0.2

C47

; C49

Con

nect

ive,

Sof

t Tis

sue

202.

11.

11.

412

1.4

0.7

1.1

152.

51.

21.

6C

51Fe

mal

e Br

east

202

21.3

11.1

19.4

227

27.1

12.7

19.1

159

26.3

12.7

22.6

C52

Vulv

a3

0.3

0.2

0.4

20.

20.

10.

12

0.3

0.2

0.3

C53

Vagi

na0

0.0

0.0

0.0

10.

10.

10.

11

0.2

0.1

0.1

C54

Cer

vix

Ute

ri15

1.6

0.8

1.5

283.

31.

62.

419

3.1

1.5

2.5

C55

Cor

pus

Ute

ri31

3.3

1.7

3.9

273.

21.

52.

625

4.1

2.0

5.0

C56

Ute

rus

Uns

pec.

20.

20.

10.

25

0.6

0.3

0.5

00.

00.

00.

0C

57O

vary

.35

3.7

1.9

3.4

293.

51.

62.

415

2.5

1.2

2.7

C58

Oth

er F

emal

e G

enita

l4

0.4

0.2

0.5

40.

50.

20.

31

0.2

0.1

0.2

C64

Plac

enta

10.

10.

10.

01

0.1

0.1

0.1

00.

00.

00.

0C

64Ki

dney

242.

51.

32.

411

1.3

0.6

1.0

162.

61.

32.

5C

65R

enal

pel

vis

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

66U

rete

r0

0.0

0.0

0.0

00.

00.

00.

01

0.2

0.1

0.1

C67

Blad

der

70.

70.

40.

811

1.3

0.6

1.1

30.

50.

20.

5C

68O

ther

urin

ary

orga

ns0

0.0

0.0

0.0

00.

00.

00.

01

0.2

0.1

0.2

C69

Eye

50.

50.

30.

36

0.7

0.3

0.5

20.

30.

20.

3C

70-C

72Br

ain,

Ner

vous

Sys

tem

212.

21.

11.

424

2.9

1.3

1.8

162.

61.

31.

8C

73Th

yroi

d12

613

.36.

99.

969

8.2

3.8

4.5

498.

13.

95.

4C

74Ad

rena

l gla

nd2

0.2

0.1

0.1

30.

40.

20.

22

0.3

0.2

0.2

C75

Oth

er E

ndoc

rine

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

81H

odgk

in D

isea

se27

2.8

1.5

1.7

182.

21.

00.

921

3.5

1.7

2.0

C82

-C85

; C96

Non

Hod

gkin

lym

phom

a52

5.5

2.8

5.6

698.

23.

86.

226

4.3

2.1

4.2

C88

Imm

unop

rolif

erat

ive

dis.

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

90M

ultip

le M

yelo

ma

50.

50.

30.

63

0.4

0.2

0.3

71.

20.

61.

4C

91Ly

mph

oid

Leuk

aem

ia23

2.4

1.3

1.4

161.

90.

91.

012

2.0

1.0

0.9

C92

-C94

Mye

loid

Leu

kaem

ia25

2.6

1.4

1.9

172.

00.

91.

324

4.0

1.9

2.5

C95

Leuk

aem

ia u

nspe

c.0

0.0

0.0

0.0

00.

00.

00.

01

0.2

0.1

0.1

Oth

erO

ther

& u

nspe

cifie

d48

5.1

2.6

5.6

465.

52.

64.

522

3.6

1.8

4.1

All

All

Site

s

949

100.

052

.194

.383

710

0.0

46.8

72.0

605

100.

048

.889

.7A

ll bu

t C44

All

Site

s bu

t C44

923

97.3

50.7

91.1

806

96.3

45.1

68.8

587

97.0

47.4

86.6

Riy

adh

M

akka

h

East

ern

Prov

ince

Part005.indd 83 15-04-2008 10:52:51 AM

84

Tabl

e 5.

3.1

Age

Dis

trib

utio

n of

Can

cer

Cas

es a

mon

g no

n-Sa

udi M

ales

, 200

4

ICD

(10)

SITE

Tot.

UN

K0-

45-

910

-14

15-1

920

-24

25-2

930

-34

35-3

940

-44

45-4

950

-54

55-5

960

-64

65-6

970

-74

75+

%C

00Li

p2

00

00

00

00

00

10

00

10

00.

2C

01-C

02To

ngue

90

00

00

00

10

32

20

10

00

0.8

C03

-C06

Mou

th5

00

00

00

00

10

10

01

01

10.

5C

07-C

08S

aliv

ary

Gla

nds

40

00

00

00

03

10

00

00

00

0.4

C9

Tons

il4

00

00

00

00

11

01

00

10

00.

4C

10O

ther

oro

phar

ynx

00

00

00

00

00

00

00

00

00

0.0

C11

Nas

opha

rynx

230

00

02

31

03

34

42

10

00

2.2

C12

-C13

Hyp

opha

rynx

20

00

00

00

00

01

10

00

00

0.2

C14

Pha

rynx

uns

pec.

00

00

00

00

00

00

00

00

00

0.0

C15

Oes

opha

gus

170

00

00

00

00

15

53

10

11

1.6

C16

Sto

mac

h54

00

00

01

22

67

310

68

45

05.

1C

17S

mal

l int

estin

e7

00

00

00

10

01

22

00

00

10.

7C

18C

olon

790

00

00

10

58

87

1511

137

31

7.4

C19

-C20

Rec

tum

470

00

00

23

35

108

34

51

12

4.4

C21

Anu

s6

00

00

01

01

11

02

00

00

00.

6C

22Li

ver

450

10

10

02

03

37

79

24

33

4.2

C23

-C24

Gal

l bla

dder

etc

.16

00

00

00

01

12

11

33

12

11.

5C

25P

ancr

eas

150

00

00

00

00

20

24

22

21

1.4

C30

-C31

Nos

e, s

inus

es, e

tc.

60

00

00

01

01

02

20

00

00

0.6

C32

Lary

nx19

00

00

00

00

13

13

34

22

01.

8C

33-C

34Tr

ache

a, B

ronc

hus,

Lun

g51

00

00

00

11

22

69

89

72

44.

8C

37-C

38O

ther

Tho

raci

c O

rgan

s3

00

00

00

00

01

01

00

00

10.

3C

40-C

41B

one

70

00

02

10

12

00

01

00

00

0.7

C43

Mel

anom

a of

Ski

n5

00

00

00

00

10

20

10

10

00.

5C

44O

ther

Ski

n87

11

10

00

25

811

914

188

33

38.

2C

45M

esot

helio

ma

30

00

00

00

00

00

10

10

01

0.3

C46

Kap

osi s

arco

ma

40

10

00

00

00

10

01

00

01

0.4

C47

; C49

Con

nect

ive,

Sof

t Tis

sue

260

42

11

02

21

45

30

01

00

2.4

C50

Bre

ast

100

00

00

00

01

13

22

10

00

0.9

C60

Pen

is0

00

00

00

00

00

00

00

00

00.

0C

61P

rost

ate

600

00

00

00

00

12

68

166

912

5.6

C62

Test

is22

00

01

03

36

43

20

00

00

02.

1C

63O

ther

mal

e ge

nita

l0

00

00

00

00

00

00

00

00

00.

0C

64K

idne

y24

03

00

00

02

06

52

51

00

02.

3C

65R

enal

pel

vis

10

00

00

00

00

00

00

10

00

0.1

C66

Ure

ter

00

00

00

00

00

00

00

00

00

0.0

C67

Bla

dder

560

00

00

00

02

45

139

97

34

5.3

C68

Oth

er u

rinar

y or

gans

10

00

00

00

00

00

00

10

00

0.1

C69

Eye

80

20

01

00

11

01

20

00

00

0.8

C70

-C72

Bra

in, N

ervo

us S

yste

m31

05

31

21

11

22

52

41

00

12.

9C

73Th

yroi

d25

00

10

11

20

65

34

11

00

02.

3C

74A

dren

al g

land

00

00

00

00

00

00

00

00

00

0.0

C75

Oth

er E

ndoc

rine

00

00

00

00

00

00

00

00

00

0.0

C81

Hod

gkin

Dis

ease

320

22

13

22

47

25

02

00

00

3.0

C82

-C85

; C96

Non

Hod

gkin

lym

phom

a84

14

33

43

117

614

78

54

12

17.

9C

88Im

mun

opro

lifer

ativ

e di

s.0

00

00

00

00

00

00

00

00

00.

0C

90M

ultip

le M

yelo

ma

80

00

00

00

00

01

32

02

00

0.8

C91

Lym

phoi

d Le

ukem

ia33

05

54

56

11

00

22

10

01

03.

1C

92-C

94M

yelo

id L

euke

mia

320

20

23

16

03

84

10

10

10

3.0

C95

Leuk

emia

uns

pec.

70

01

00

00

00

20

10

11

10

0.7

Oth

erO

ther

& u

nspe

cifie

d85

01

01

02

28

214

148

117

86

18.

0A

llA

ll Si

tes

1065

231

1815

2428

4352

8212

712

614

212

410

360

4840

100

All

but C

44A

ll si

tes

but C

4497

81

3017

1524

2841

4774

116

117

128

106

9557

4537

91.8

31

Part005.indd 84 15-04-2008 10:52:53 AM

85

Tabl

e 5.

3.2

Age

Dis

trib

utio

n of

Can

cer

Cas

es a

mon

g no

n-Sa

udi F

emal

es, 2

004

ICD

10SI

TETo

t U

NK

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

+%

C

00Li

p2

00

00

00

00

01

00

01

00

00.

2C

01-C

02To

n gue

50

00

00

00

02

01

00

10

10

0.6

C03

-C06

Mou

th0

00

00

00

00

00

00

00

00

00.

0C

07-C

08S

aliv

ary

Gla

nds

20

00

00

00

00

10

10

00

00

0.2

C9

Tons

il1

00

00

00

00

00

01

00

00

00.

1C

10O

ther

oro

phar

ynx

10

00

00

00

00

00

01

00

00

0.1

C11

Nas

opha

r ynx

100

00

00

20

21

11

10

11

00

1.1

C12

-C13

Hyp

opha

r ynx

10

00

00

00

00

01

00

00

00

0.1

C14

Pha

r ynx

uns

pec.

00

00

00

00

00

00

00

00

00

0.0

C15

Oes

opha

gus

80

00

00

00

01

11

10

12

01

0.9

C16

Sto

mac

h13

00

00

00

10

12

21

10

23

01.

5C

17S

mal

l int

estin

e2

00

00

00

00

00

11

00

00

00.

2C

18C

olon

460

00

00

02

45

69

55

53

02

5.2

C19

-C20

Rec

tum

260

00

01

11

34

22

52

21

11

3.0

C21

Anu

s5

00

00

01

00

01

10

00

10

10.

6C

22Li

ver

120

00

00

01

00

01

51

12

01

1.4

C23

-C24

Gal

l bla

dder

etc

.10

00

00

00

00

03

02

11

30

01.

1C

25P

ancr

eas

50

00

00

00

10

00

11

01

01

0.6

C30

-C31

Nos

e, s

inus

es, e

tc.

10

00

00

00

00

00

10

00

00

0.1

C32

Lar y

nx1

00

00

00

00

00

00

00

10

00.

1C

33-C

34Tr

ache

a, B

ronc

hus,

Lun

g12

00

00

01

11

10

13

11

11

01.

4C

37-C

38O

ther

Tho

raci

c O

r gan

s1

00

00

00

00

00

01

00

00

00.

1C

40-C

41B

one

80

11

21

10

00

20

00

00

00

0.9

C43

Mel

anom

a of

Ski

n8

00

00

01

00

10

11

02

11

00.

9C

44O

ther

Ski

n30

00

00

00

11

22

36

55

11

33.

4C

45M

esot

helio

ma

00

00

00

00

00

00

00

00

00

0.0

C46

Kap

osi s

arco

ma

00

00

00

00

00

00

00

00

00

0.0

C47

; C49

Con

nect

ive,

Sof

t Tis

sue

70

00

01

01

01

12

01

00

00

0.8

C50

Bre

ast

323

00

00

12

1723

4568

6338

2322

86

736

.8C

51V

ulva

00

00

00

00

00

00

00

00

00

0.0

C52

Va g

ina

10

00

00

00

00

00

00

10

00

0.1

C53

Cer

vix

Ute

ri45

00

00

10

26

84

56

05

34

15.

1C

54C

orpu

s U

teri

340

00

00

00

01

67

09

45

20

3.9

C55

Ute

rus

Uns

pec.

60

00

00

00

00

02

12

10

00

0.7

C56

Ova

r y.

370

00

00

24

15

54

60

45

10

4.2

C57

Oth

er F

emal

e G

enita

l0

00

00

00

00

00

00

00

00

00.

0C

58P

lace

nta

30

00

00

11

00

10

00

00

00

0.3

C64

Kid

ney

110

21

00

03

30

00

20

00

00

1.3

C65

Ren

al p

elvi

s0

00

00

00

00

00

00

00

00

00.

0C

66U

rete

r1

00

00

00

00

00

00

00

10

00.

1C

67B

ladd

er8

00

00

00

00

10

01

20

12

10.

9C

68O

ther

urin

ary

orga

ns0

00

00

00

00

00

00

00

00

00.

0C

69E

ye2

00

00

00

00

00

01

00

00

10.

2C

70-C

72B

rain

, Ner

vous

Sys

tem

140

13

21

10

00

23

00

01

00

1.6

C73

Thyr

oid

470

00

00

25

611

85

52

20

10

5.4

C74

Adr

enal

gla

nd3

01

01

00

00

01

00

00

00

00.

3C

75O

ther

End

ocrin

e1

00

00

10

00

00

00

00

00

00.

1C

81H

odgk

in D

isea

se17

00

22

15

21

11

11

00

00

01.

9C

82-C

85; C

96N

on H

odgk

in ly

mph

oma

370

01

13

22

53

32

50

44

11

4.2

C88

Imm

unop

rolif

erat

ive

dis.

10

00

00

00

00

00

00

10

00

0.1

C90

Mul

tiple

Mye

lom

a8

00

00

00

00

10

01

21

12

00.

9C

91L y

mph

oid

Leuk

emia

190

83

11

21

00

00

12

00

00

2.2

C92

-C94

Mye

loid

Leu

kem

ia15

00

11

21

22

02

20

10

01

01.

7C

95Le

ukem

ia u

nspe

c.0

00

00

00

00

00

00

00

00

00.

0O

ther

Oth

er &

uns

peci

fied

281

20

01

11

33

34

40

10

40

3.2

All

All

Age

s To

tal

878

115

1210

1526

4862

9812

712

510

862

6749

3221

100.

0N

ot C

44A

ll si

tes

but C

4484

81

1512

1015

2647

6196

125

122

102

5762

4831

1896

.6

Part005.indd 85 15-04-2008 10:52:54 AM

86

Tabl

e 5.

3.3

Inci

denc

e R

ates

for

Can

cer

Cas

es a

mon

g no

n-Sa

udi M

ales

by

Age

Gro

up (

per

100,

000)

, 200

4

ICD

10

SITE

Tot

UN

K0-

45-

910

-14

15-1

920

-24

25-2

930

-34

35-3

940

-44

45-4

950

-54

55-5

960

-64

65-6

970

-74

75+

Cru

de

Rat

eA

SR

Wor

ldC

00Li

p2

00

00

00

00

00

0.3

00

06

00

00.

2C

01-C

02To

ngue

90

00

00

00

0.1

00.

60.

61

02.

50

00

0.2

0.2

C03

-C06

Mou

th5

00

00

00

00

0.1

00.

30

02.

50

10.1

11.1

0.1

0.6

C07

-C08

Sal

ivar

y G

land

s4

00

00

00

00

0.4

0.2

00

00

00

00.

10

C9

Tons

il4

00

00

00

00

0.1

0.2

00.

50

06

00

0.1

0.2

C10

Oth

er o

roph

aryn

x0

00

00

00

00

00

00

00

00

00

0C

11N

asop

hary

nx23

00

00

1.3

10.

20

0.4

0.6

1.2

2.1

2.4

2.5

00

00.

50.

6C

12-C

13H

ypop

hary

nx2

00

00

00

00

00

0.3

0.5

00

00

00

0C

14P

hary

nx u

nspe

c.0

00

00

00

00

00

00

00

00

00

0C

15O

esop

hagu

s17

00

00

00

00

00.

21.

52.

63.

52.

50

10.1

11.1

0.4

0.9

C16

Sto

mac

h54

00

00

00.

30.

30.

30.

91.

40.

95.

27.

120

.223

.950

.70

1.3

3.3

C17

Sm

all i

ntes

tine

70

00

00

00.

20

00.

20.

61

00

00

11.1

0.2

0.3

C18

Col

on79

00

00

00.

30

0.7

1.2

1.6

2.1

7.8

12.9

32.8

41.9

30.4

11.1

1.8

4.7

C19

-C20

Rec

tum

470

00

00

0.7

0.5

0.4

0.7

1.9

2.4

1.6

4.7

12.6

610

.122

.21.

12

C21

Anu

s6

00

00

00.

30

0.1

0.1

0.2

01

00

00

00.

10.

1C

22Li

ver

450

0.4

00.

60

00.

30

0.4

0.6

2.1

3.6

10.6

523

.930

.433

.31.

13.

1C

23-C

24G

all b

ladd

er e

ct.

160

00

00

00

0.1

0.1

0.4

0.3

0.5

3.5

7.6

620

.311

.10.

41.

3C

25P

ancr

eas

150

00

00

00

00

0.4

01

4.7

512

20.3

11.1

0.4

1.5

C30

-C31

Nos

e, s

inus

es, e

tc.

60

00

00

00.

20

0.1

00.

61

00

00

00.

10.

1C

32La

rynx

190

00

00

00

00.

10.

60.

31.

63.

510

.112

20.3

00.

41.

4C

33-C

34Tr

ache

a, B

ronc

hus,

Lun

g51

00

00

00

0.2

0.1

0.3

0.4

1.8

4.7

9.4

22.7

41.9

20.3

44.4

1.2

4.2

C37

-C38

Oth

er T

hora

cic

Org

ans

30

00

00

00

00

0.2

00.

50

00

011

.10.

10.

3C

40-C

41B

one

70

00

01.

30.

30

0.1

0.3

00

01.

20

00

00.

20.

2C

43M

elan

oma

of S

kin

50

00

00

00

00.

10

0.6

01.

20

60

00.

10.

3C

44O

ther

Ski

n87

10.

40.

50

00

0.3

0.7

1.2

2.1

2.7

7.2

21.2

20.2

1830

.433

.32

4.4

C45

Mes

othe

liom

a3

00

00

00

00

00

00.

50

2.5

00

11.1

0.1

0.3

C46

Kap

osi s

arco

ma

40

0.4

00

00

00

00.

20

01.

20

00

11.1

0.1

0.3

C47

; C49

Con

nect

ive,

Sof

t Tis

sue

260

1.8

10.

60.

70

0.3

0.3

0.1

0.8

1.5

1.6

00

60

00.

60.

9C

50B

reas

t10

00

00

00

00

0.1

0.2

0.9

12.

42.

50

00

0.2

0.3

C60

Pen

is0

00

00

00

00

00

00

00

00

00

0C

61P

rost

ate

600

00

00

00

00

0.2

0.6

3.1

9.4

40.4

35.9

91.3

133.

31.

47.

8C

62Te

stis

220

00

0.6

01

0.5

0.8

0.6

0.6

0.6

00

00

00

0.5

0.3

C63

Oth

er m

ale

geni

tal

00

00

00

00

00

00

00

00

00

00

C64

Kid

ney

240

1.3

00

00

00.

30

1.2

1.5

15.

92.

50

00

0.6

0.7

C65

Ren

al p

elvi

s1

00

00

00

00

00

00

02.

50

00

00.

1C

66U

rete

r0

00

00

00

00

00

00

00

00

00

0C

67B

ladd

er56

00

00

00

00

0.3

0.8

1.5

6.7

10.6

22.7

41.9

30.4

44.4

1.3

4.6

C68

Oth

er u

rinar

y or

gans

10

00

00

00

00

00

00

2.5

00

00

0.1

C69

Eye

80

0.9

00

0.7

00

0.1

0.1

00.

31

00

00

00.

20.

3C

70-C

72B

rain

, Ner

vous

Sys

tem

310

2.2

1.4

0.6

1.3

0.3

0.2

0.1

0.3

0.4

1.5

14.

72.

50

011

.10.

71.

3C

73Th

yroi

d25

00

0.5

00.

70.

30.

30

0.9

10.

92.

11.

22.

50

00

0.6

0.6

C74

Adr

enal

gla

nd0

00

00

00

00

00

00

00

00

00

0C

75O

ther

End

ocrin

e0

00

00

00

00

00

00

00

00

00

0C

81H

odgk

in D

isea

se32

00.

91

0.6

20.

70.

30.

61

0.4

1.5

02.

40

00

00.

70.

8C

82-C

85; C

96N

on H

odgk

in ly

mph

oma

841

1.8

1.4

1.7

2.7

11.

81

0.9

2.7

2.1

4.1

5.9

10.1

620

.311

.12

3.1

C88

Imm

unop

rolif

erat

ive

dis.

00

00

00

00

00

00

00

00

00

00

C90

Mul

tiple

Mye

lom

a8

00

00

00

00

00

0.3

1.6

2.4

012

00

0.2

0.5

C91

Lym

phoi

d Le

ukem

ia33

02.

22.

42.

33.

32

0.2

0.1

00

0.6

11.

20

010

.10

0.8

1.5

C92

-C94

Mye

loid

Leu

kem

ia32

00.

90

1.1

20.

31

00.

41.

61.

20.

50

2.5

010

.10

0.7

1C

95Le

ukem

ia u

nspe

c.7

00

0.5

00

00

00

0.4

00.

50

2.5

610

.10

0.2

0.6

Oth

erO

ther

& u

nspe

cifie

d85

00.

40

0.6

00.

70.

31.

10.

32.

74.

14.

112

.917

.747

.960

.911

.12

5A

llA

ll A

ges

Tota

l10

652.

014

.09.

08.

016

.09.

07.

07.

012

.025

.037

.073

.014

6.0

260.

035

9.0

487.

044

4.0

24.9

60.3

Not

C44

All

site

s bu

t C44

978

1.0

13.0

8.0

8.0

16.0

9.0

7.0

7.0

11.0

23.0

35.0

66.0

125.

024

0.0

341.

045

7.0

411.

022

.955

.9

Part005.indd 86 15-04-2008 10:52:57 AM

87

Tabl

e 5.

3.4

Inci

denc

e R

ates

for

Can

cer

Cas

es a

mon

g no

n-Sa

udi F

emal

es b

y A

ge G

roup

(pe

r 10

0,00

0), 2

004

ICD

10SI

TETo

t U

NK

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

+C

rude

R

ate

ASR

W

orld

C00

Lip

20

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.8

0.0

0.0

0.0

6.7

0.0

0.0

0.0

0.1

0.3

C01

-C02

Ton g

ue5

00.

00.

00.

00.

00.

00.

00.

01.

00.

01.

40.

00.

06.

70.

015

.60.

00.

30.

7C

03-C

06M

outh

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

00

C07

-C08

Sal

ivar

y G

land

s2

00.

00.

00.

00.

00.

00.

00.

00.

00.

80.

02.

30.

00.

00.

00.

00.

00.

10.

2C

9To

nsil

10

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.3

0.0

0.0

0.0

0.0

0.0

0.1

0.1

C10

Oth

er o

roph

aryn

x1

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

04.

60.

00.

00.

00.

00.

10.

2C

11N

asop

har y

nx10

00.

00.

00.

00.

01.

20.

00.

70.

50.

81.

42.

30.

06.

712

.70.

00.

00.

51.

1C

12-C

13H

ypop

har y

nx1

00.

00.

00.

00.

00.

00.

00.

00.

00.

01.

40.

00.

00.

00.

00.

00.

00.

10.

1C

14P

har y

nx u

nspe

c.0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00

0C

15O

esop

hagu

s8

00.

00.

00.

00.

00.

00.

00.

00.

50.

81.

42.

30.

06.

725

.40.

013

.80.

41.

6C

16S

tom

ach

130

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.5

1.6

2.7

2.3

4.6

0.0

25.4

46.9

0.0

0.7

2.3

C17

Sm

all i

ntes

tine

20

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.4

2.3

0.0

0.0

0.0

0.0

0.0

0.1

0.2

C18

Col

on46

00.

00.

00.

00.

00.

00.

81.

52.

64.

912

.311

.523

.133

.338

.20.

027

.62.

45.

9C

19-C

20R

ectu

m26

00.

00.

00.

00.

70.

60.

41.

12.

11.

62.

711

.59.

213

.312

.715

.613

.81.

43

C21

Anu

s5

00.

00.

00.

00.

00.

60.

00.

00.

00.

81.

40.

00.

00.

012

.70.

013

.80.

30.

8C

22Li

ver

120

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.0

0.0

1.4

11.5

4.6

6.7

25.4

0.0

13.8

0.6

2.2

C23

-C24

Gal

l bla

dder

ect

.10

00.

00.

00.

00.

00.

00.

00.

00.

02.

50.

04.

64.

66.

738

.20.

00.

00.

52

C25

Pan

crea

s5

00.

00.

00.

00.

00.

00.

00.

40.

00.

00.

02.

34.

60.

012

.70.

013

.80.

31

C30

-C31

Nos

e, s

inus

es, e

tc.

10

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.3

0.0

0.0

0.0

0.0

0.0

0.1

0.1

C32

Lar y

nx1

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

012

.70.

00.

00.

10.

4C

33-C

34Tr

ache

a, B

ronc

hus,

Lun

g12

00.

00.

00.

00.

00.

60.

40.

40.

50.

01.

46.

94.

66.

712

.715

.60.

00.

61.

7C

37-C

38O

ther

Tho

raci

c O

r gan

s1

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

02.

30.

00.

00.

00.

00.

00.

10.

1C

40-C

41B

one

80

0.5

0.5

1.2

0.7

0.6

0.0

0.0

0.0

1.6

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.4

0.4

C43

Mel

anom

a of

Ski

n8

00.

00.

00.

00.

00.

60.

00.

00.

50.

01.

42.

30.

013

.312

.715

.60.

00.

41.

5C

44O

ther

Ski

n30

00.

00.

00.

00.

00.

00.

40.

41.

01.

64.

113

.823

.133

.312

.715

.641

.41.

64.

9C

45M

esot

helio

ma

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C46

Kap

osi s

arco

ma

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C47

; C49

Con

nect

ive,

Sof

t Tis

sue

70

0.0

0.0

0.0

0.7

0.0

0.4

0.0

0.5

0.8

2.7

0.0

4.6

0.0

0.0

0.0

0.0

0.4

0.5

C50

Bre

ast

323

00.

00.

00.

00.

71.

27.

18.

523

.655

.786

.487

.110

6.0

146.

610

1.8

93.8

96.6

17.1

32.5

C51

Vul

va0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00

0C

52V

a gin

a1

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

06.

70.

00.

00.

00.

10.

3C

53C

ervi

x U

teri

450

0.0

0.0

0.0

0.7

0.0

0.8

2.2

4.2

3.3

6.9

13.8

0.0

33.3

38.2

62.6

13.8

2.4

5.8

C54

Cor

pus

Ute

ri34

00.

00.

00.

00.

00.

00.

00.

00.

54.

99.

60.

041

.526

.763

.631

.30.

01.

86.

2C

55U

teru

s U

nspe

c.6

00.

00.

00.

00.

00.

00.

00.

00.

00.

02.

72.

39.

26.

70.

00.

00.

00.

30.

9C

56O

var y

.37

00.

00.

00.

00.

01.

21.

70.

42.

64.

15.

513

.80.

026

.763

.615

.60.

02

5C

57O

ther

Fem

ale

Gen

ital

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

00

C58

Pla

cent

a3

00.

00.

00.

00.

00.

60.

40.

00.

00.

80.

00.

00.

00.

00.

00.

00.

00.

20.

1C

64K

idne

y11

00.

90.

50.

00.

00.

01.

21.

10.

00.

00.

04.

60.

00.

00.

00.

00.

00.

60.

6C

65R

enal

pel

vis

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C66

Ure

ter

10

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

12.7

0.0

0.0

0.1

0.4

C67

Bla

dder

80

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.5

0.0

0.0

2.3

9.2

0.0

12.7

31.3

13.8

0.4

1.8

C68

Oth

er u

rinar

y or

gans

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C69

Eye

20

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.3

0.0

0.0

0.0

0.0

13.8

0.1

0.4

C70

-C72

Bra

in, N

ervo

us S

yste

m14

00.

51.

51.

20.

70.

60.

00.

00.

01.

64.

10.

00.

00.

012

.70.

00.

00.

71.

2C

73Th

yroi

d47

00.

00.

00.

00.

01.

22.

12.

25.

86.

56.

911

.59.

213

.30.

015

.60.

02.

53.

3C

74A

dren

al g

land

30

0.5

0.0

0.6

0.0

0.0

0.0

0.0

0.0

0.8

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.2

C75

Oth

er E

ndoc

rine

10

0.0

0.0

0.0

0.7

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.1

C81

Hod

gkin

Dis

ease

170

0.0

1.0

1.2

0.7

3.1

0.8

0.4

0.5

0.8

1.4

2.3

0.0

0.0

0.0

0.0

0.0

0.9

0.9

C82

-C85

; C96

Non

Hod

gkin

lym

phom

a37

00.

00.

50.

62.

11.

20.

81.

81.

62.

52.

711

.50.

026

.750

.915

.613

.82

4.7

C88

Imm

unop

rolif

erat

ive

dis.

10

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

6.7

0.0

0.0

0.0

0.1

0.3

C90

Mul

tiple

Mye

lom

a8

00.

00.

00.

00.

00.

00.

00.

00.

50.

00.

02.

39.

26.

712

.731

.30.

00.

41.

8C

91L y

mph

oid

Leuk

emia

190

3.7

1.5

0.6

0.7

1.2

0.4

0.0

0.0

0.0

0.0

2.3

9.2

0.0

0.0

0.0

0.0

11.

3C

92-C

94M

yelo

id L

euke

mia

150

0.0

0.5

0.6

1.4

0.6

0.8

0.7

0.0

1.6

2.7

0.0

4.6

0.0

0.0

15.6

0.0

0.8

1.2

C95

Leuk

emia

uns

pec.

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

00

Oth

erO

ther

& u

nspe

cifie

d28

10.

90.

00.

00.

70.

60.

41.

11.

62.

55.

59.

20.

06.

70.

062

.60.

01.

53

All

All

Age

s To

tal

878

17.

06.

06.

011

.016

.020

.023

.051

.010

4.0

171.

024

8.0

286.

044

7.0

623.

050

0.0

290.

046

.610

3.1

Not

C44

All

site

s bu

t C44

848

17.

06.

06.

011

.016

.020

.022

.050

.010

2.0

167.

023

4.0

263.

041

3.0

611.

048

5.0

248.

045

.098

.2

Part005.indd 87 15-04-2008 10:53:13 AM

88

Part005.indd 88 15-04-2008 10:53:14 AM

PART VIAPPENDICES

Part006.indd 89 15-04-2008 11:26:06 AM

90

Abha Private Hospital Majaridah General HospitalArmed Forces Hospital South Maternity & Children's Hospital Ahad Rafidah General Hospital Namas General HospitalAhli Hospital King Abdullah Bin Abdul AzizAsir Central Hospital Sarat Obeidah General HospitalAsir Hospital NOS Saudi German Hospital (Abha) Bashayer Hospital Thaleeth General HospitalDhahran Al Janoob Unknown Asir HospitalKhamys Mishayt Civil Hospital ZaferKing Fahd Armed Forces HospitalKing Faisal Military HospitalMahael General Hospital

Baha Hospital NOS MandaqBaljurashi General Hospital Physical Therapy CenterKing Fahd Hospital Unknown Baha Hospital

Al Ahsa Hospital (Hofuf) King Fahd Hospital (Hofuf)Al Mana General Hospital (Dammam) King Fahd Hospital in the Eastern ProvinceAl Mana General Hospital (Khobar) King Fahd MilitaryAl Mana General Hospital (Hofuf) King Khalid General Hospital Al Mana General Hospital (Jubail) Luluatt International HospitalArabian Oil Company Hospital Maternity & Children's Hospital ARAMCO Clinic Mousa Hospital (Hofuf) Armed Forces Hospital (Hafr Baten) Mouwasat Hospital Astoon Hospital (Thomairy) (Dammam) Mouwasat Dispensary Dammam Central Hospital NaireiaDammam National Dispensary Noor Khan Hospital (Hafr Batin)Dhahran Medical Center Prince Saud Bin Jalawi HospitalDossary Hospital QaisumaDr Fakhry & Mouhawis Qatif Central HospitalEastern Province Hospital Qatif General HospitalFanateer Hospital Rowdha Dispensary Hofuf Polyclinic Saad Specialist Medical CenterImam Abdu Rahman Bin Fahd Salama Hospital Jubail Hospital Tadawy General Hospital Jufer Hospital Thukhair DispensaryKing Abdul Aziz Air Base Hospital Unknown Eastern Province HospitalKing Abdul Aziz Navy Hospital Zamil HospitalKing Abdul Aziz National hospital

Hail General Hospital Baqa HospitalKing Khaled General Hospital, Hail Unknown Hail HospitalRashid Hospital

Asir Region

Baha Region

Eastern Province

Hail Region

Part006.indd 90 15-04-2008 11:26:06 AM

91

Jazan General King Fahd Specialist Hospital

Jazan Hospital NOS Samtah General Hospital

King Fahd Central Hospital Unknown Jazan Hospital

Prince Abdul Rahman Sudairi Hospital Tabarjal General HospitalQurayyat General Hospital Unknown Jouf HospitalSkaka General Hospital

Al Dar Hospital Mouwasat Hospital

Ansar Hospital Ohoud Hospital

Badr General Hospital Psychaitric Hospital

Dr. Hamed Al Ahmadi Hospital Tariq Bin Laden Hospital

Hanakyah Hospital Ula General (Prince Abdullah Bin Abdul Aziz)

Khaybar General Hospital Unknown Madinah Hospital

King Fahd Hospital Yanboa General Hospital

Madinah National Hospital Zahra Private Hospital

Mahad Hospital Zen Laboratory

Maternity & Children's Hospital

Meeqat Hospital

Abdrahman Qari Center King Fahad Armed Forces Hospital

Abuzinada Hospital King Fahad General Hospital

Ahmed Hassan Fetahi Hospital King Fahad Air Base Hospital

Ajiyad General Hospital King Faisal (Taif)

Al Abraj Laboratory King Faisal Al Sheshah Hospital

Alawi Tunsi & Bros Hospital King Faisal Specialist Hospital & Research Centre

Amen Hospital King Hospital

Bakhsh Hospital Makkah Hospital NOS

Bugshan General Hospital Maternity & Children's Hospital

Children & Maternity Hospital Mustaqbal (Dhagastani)

Dar Shifa Saudi Nahda National Hospital

Dr. Erfan & Bagedo Hospital New Jeddah Clinic

Dr. Ghassan Pharaon Noor Specialist Hospital

Dr. Khalid Idriss Quen Hospital

Dr. Siddiqa Maternity Qunfudah General Hospital

Dr. Solaiman Fakeeh Hospital Rabegh General Hospital

El Maghraby Eye Hospital Rafie Hospital

Eye Hospital (JD) Royal Commission Medical Center

Hada Military Hospital Salamah Hospital

Jazan Region

Jouf Region

Madinah Region

Makkah Region

Part006.indd 91 15-04-2008 11:26:07 AM

92

Hai Al Jamea Saudi German Hospital, Jeddah

Hamra Hospital Saudi Hospital

Hera General Hospital Saudia Airlines Medical Services

Jedaani Hospital Sheffaa Hospital

Jeddah General Taif Chest Hospital

King Abdul Aziz Hospital (Taif) Taif Children's Hospital

King Abdul Aziz Al Zaher Thagher Hospital

King Abdul Aziz Hospital & Oncology Center Umm Al Qura Poly Clinic

King Abdul Aziz Medical City United Doctors

King Abdul Aziz University Hospital Yanboa General Hospital

Armed Forces Hospital Najran Najran General Hospital

Armed Forces Hospital Sharoura Sharourah General Hospital

Chest and Fever Center Unknown Najran HospitalKing Khaled General Hospital

Arar Central Hospital Rafha General Hospital

Bukairiya General Hospital Midhnab General Hospital

Buraidah Central Hospital Onaizah General Hospital

King Fahd Specialist Hospital Rass General Hospital

King Saud Hospital (Onaizah)

Maternity and Children Hospital

Riyadh-Al Kharj Armed forces Hospital King Khaled General (Majma'a)

Afif General King Khaled International Hospital

Aflaj General Hospital King Khaled University Hospital

Al Amal Clinic Mamlaka (Kingdom) Hospital

Al Borg Laboratory Maternity and Children's Hospital

Armed Forces Wadi Dawasir Mobarak Hospital

Bustan Clinic Mouwasat Riyadh

Chest Diseases Center Muzahamiyah General

College of Dentistry Nukhba Medical Center

Consulting Clinic Obeid Hospital

Dallah Hospital Olaya Medical Center

Dawadmi General Hospital Prince Salman Bin Abdul Aziz Hospital

Dr Abdul Rahman Al Mishari Hospital Quwayiyah Hospital

Dr. Al Moagel's Polyclinic Riyadh Care Hospital (Social Insurance Hospital)

Dr Al Mofarreh Polyclinic Riyadh Hospital (NOS)

Dr. Fahd Al Shedoukhy Riyadh Medical Complex

Dr Suliman Al Habib Medical Center Saati Medical Center

Makkah Region continued …..

Najran Region

Northern Region

Qassim Region

Riyadh Region

Part006.indd 92 15-04-2008 11:26:07 AM

93

Elaj Laboratory Saudi German Hospital (Riyadh)

Eman General Hospital Saudi Medical Services

Faleh International hospital Security Forces

Green Crescent Hospital Shaqra Hospital

Hammadi Hospital Sharif Poly Clinic

Hotta Bani Tammim Hospital Specialized Medical Center

Howtat Sudair Sports Medicine

Huraymila General Hospital Sulail

Jafel International Hospital Thadeq General Hospital

Kharj Hospital Unknown Riyadh hospital

King Abdul Aziz Medical City Usrah Hospital

King Abdul Aziz University Hospital Wadi Al Dawasser

King Fahad Medical City Watani (Riyadh National hospital)

King Faisal Specialist Hospital & Research Centre Yamamah Hospital

King Khaled Eye Specialist Hospital Zulfi general Hospital

King Khaled General Hospital

Dhuba Hospital North West Armed Forces Hospital

Haql General Hospital Prince Fahad Bin Sultan Hospital

King Abdul Aziz Military Hospital Tabuk Civil Hospital

King Fahad Hospital Umm Lujj General Hospital King Khalid General Hospital Unknown Tabuk HospitalMaternity and Children's Hospital Wajh General Hospital

Bahrain Pakistan

Bangladesh Philippines

Canada Samoa, America

France Sudan

Germany Sweden

Hong Kong (SARC) Syrian Arab republic

India Thailand

Jordan Tunisia

Kuwait United Arab Emirates

Lebanon United Kingdom

Libyan Arab Republic United States of America

Malaysia Western Sahara

Netherlands Yemen

Niger

Nigeria

International Hospitals in the Following Countries

Tabuk Region

Riyadh Region continued…

Part006.indd 93 15-04-2008 11:26:07 AM

94

SCR Main Office MBC 64 PO Box 3354, Riyadh 11211 Saudi Arabia Tel: 01-442-3929 Fax: 01-442-3941 Website: www.kfshrc.edu.sa/NCR/ Email: [email protected] [email protected]

Chairman: Dep. Chairman: Admin. Director: Registrar:

Epidemiologist: Data Manager:

Shouki Bazarbashi, MD Nasser Al Hamdan, MD Haya Al Eid, BDS, DFE, CTR Mohamed Hayder, CTR

Haya Al Eid, BDS, DFE, CTR Suad O. Arteh, MA

Armed Forces Hospitals Riyadh Military Hospital PO Box 7897, Riyadh 11159 Tel: 01-477-7714 x 6747 Fax: 01-477-6743 x 6743

Director:

Rizq Allah Assiri, MD

Central Region King Khalid University Hospital PO Box 2925, Riyadh 11461 Tel: 01-467-9488/2398 Fax: 01-467-9487

Director:

Dahish Ajarim, MD

Eastern Region King Fahd Hospital of the University PO Box 40004, Al Khobar 31952 Tel: 03-896-6741 Fax: 03-869-6741

Director:

Prof. Hassan Al Iddrissi, MD

King Abdulaziz University Hospital Faculty of Medicine & Allied Science PO Box 80215, Jeddah 21589 Tel: 02-624-0000 x 18244/18253 Fax: 02-617-1412

Director:

Prof. Mohamoud Shaheen Al Ahwal, MD

King Faisal Specialist Hospital & Research Center MBC-64 PO Box 3354, Riyadh 11211 Tel: 01-442-3938, 464 -7272 x 24541

Directors:

Shouki Bazarbashi, MD Ali Al-Zahrani, MD, PhD

Part006.indd 94 15-04-2008 11:26:07 AM

95

Madinah & Northern Region King Fahad Hospital Madinah Al Monawarah Tel: 04-486-1500 x 3760 Fax: 04-836-0951

Director:

Ahmed Tarawa, MD

National Guard Hospitals King Abdulaziz Medical City (KKNGH) PO Box 9515, Jeddah 21423 Tel: 02-624-0000 x 4085/4086 Fax: 02-624-0000 x 7242

Director:

Abdulwahab Andejani, MD

Security Forces Hospital PO Box 3643, Riyadh 11481 Tel: 01-477-4480 x 1193 Fax: 01-476-4757, 01-477-4480 x 3184

Director:

Abdulaziz Saleh Aba Hussein, MD

Southern Region King Khalid University PO Box 641, Abha Tel: 07-224-0711 / 224 -7800 x 118 Fax: 07-224-0964 / 224 -7570

Director:

Hassan Trabulsi, MD

Western Region King Abdulaziz Hosp. & Oncology Center PO Box 31467, Jeddah 21497 Tel: 02-637-5555 x 2283/2200 Fax: 02-637-9811

Director:

Hasnah Al Ghamdi, MD

Edward De Vol, PhD Hadir Meir, MD Susan E. Young, CCHRA©, CTR

Director Director Administrative Director

January 2001 - April 2006 January 2001 - August 2005 March 2003 -May 2006

Part006.indd 95 15-04-2008 11:26:07 AM

96

Request for data from the Saudi Cancer Registry All requests should be submitted to the attention of the Chairman of Directors, National Cancer Registry,

MCB 64, P.O. Box 3354, Riyadh 11211, Saudi Arabia, Fax: +966 1 442 3941

Name : Date Submitted : Department : Hospital : Telephone : Information Requested: (Specify Patient Population, Time Period, Year/s, Anatomic Site/Histology, Staging information, Region, etc.) Purpose of Request: (Specify Presentation at conference/meeting/publication, clinical/epidemiological study, personal information, etc.) Collaborators and Co-authors: Requesters affirmation statement: I hereby, the requester of the above data affirm that the data given to me by the NCR will be treated with utmost confidentiality in relation to patient’s identity. I also affirm that the data given to me will not be presented or published by me or any of my collaborators as an original work but rather can be cited in my presentations and/or publication with acknowledgment of the NCR.

Requesters Signature Date

For Official use only: Request : Approved Denied Chairman SCR Board of Directors Signature Date

�لسجل �لسعو�� للأ�� لصحة

�لمملكة �لعربية �لسعو�ية

Saudi Cancer RegistryMinistry of HealthKingdom of Saudi Arabia

Part006.indd 96 15-04-2008 11:26:15 AM

97

Part006.indd 97 15-04-2008 11:26:18 AM

98

Part006.indd 98 15-04-2008 11:26:24 AM

cancer incidence report 2004 - nhic.gov.sa report 2004.pdf · ** source: census 2004, central...

Documents